{"pageProps":{"id":"newsroom","content":{"id":"YskDdxAAACEAW0Sm","uid":"newsroom","url":null,"type":"page","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YskDdxAAACEAW0Sm%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-09T04:26:35+0000","last_publication_date":"2022-07-09T04:26:35+0000","slugs":["news"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"hideDefaultContactForm":null,"slices":[],"seoTitle":"News","seoDescription":"Anumana's latest news and press releases","socialImage":{},"slices1":[]}},"news":[{"id":"ZJRafBEAACYAF-Ah","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZJRafBEAACYAF-Ah%22%29+%5D%5D","tags":[],"first_publication_date":"2023-06-22T14:29:00+0000","last_publication_date":"2025-01-20T09:39:14+0000","slugs":["anumanas-ai-algorithm-for-cardiac-amyloidosis-gets-fda-breakthrough-nod"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Bioworld: Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ECG-AI detection algorithm is the fourth from the company and its partners to notch breakthrough status.","spans":[]}],"date":"2023-06-21T18:30:00+0000","image":{"dimensions":{"width":4500,"height":3000},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/3869be61-29ba-4ab1-b831-45b49d27a4ac_iStock-1199420490.jpg?auto=compress,format","id":"Y6M_YBcAACoAmMgi","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"9c7bace6-1011-414f-adb3-433995de6006","url":"https://www.bioworld.com/articles/698178-anumanas-ai-algorithm-for-cardiac-amyloidosis-gets-fda-breakthrough-nod?v=preview"},"article":[],"slices":[],"seoTitle":"Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod","seoDescription":"Bioworld: Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ECG-AI detection algorithm is the fourth from the company and its partners to notch breakthrough status.","socialImage":{}}},{"id":"ZRo9DhAAACYAxfsK","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZRo9DhAAACYAxfsK%22%29+%5D%5D","tags":["FDA"],"first_publication_date":"2023-10-02T10:45:01+0000","last_publication_date":"2025-01-20T09:39:43+0000","slugs":["anumana-receives-u.s.-fda-510k-clearance-for-ecg-ai-algorithm-to-detect-low-ejection-fraction"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Receives U.S. FDA 510(k) Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failure","spans":[{"start":0,"end":154,"type":"em"}]}],"date":"2023-10-02T10:45:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failure","spans":[{"start":0,"end":154,"type":"em"}]},{"type":"paragraph","text":"CAMBRIDGE, Mass. – Oct. 2, 2023 – Anumana, Inc., a leading AI-driven health technology and nference portfolio company working in collaboration with Mayo Clinic, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low ejection fraction (LEF) in patients at risk of heart failure.","spans":[{"start":0,"end":31,"type":"strong"},{"start":34,"end":47,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai/"}},{"start":91,"end":99,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/"}},{"start":148,"end":159,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.mayoclinic.org/"}}]},{"type":"paragraph","text":"LEF, or a weak heart pump, is a significant, at times asymptomatic, and commonly undiagnosed indicator of heart failure.1 The increasing prevalence of heart failure and its associated morbidity, mortality, rehospitalizations, and societal costs2,3 underscores the need to identify and manage patients with LEF.","spans":[{"start":120,"end":121,"type":"label","data":{"label":"superscript"}},{"start":244,"end":247,"type":"label","data":{"label":"superscript"}}]},{"type":"paragraph","text":"“Anumana’s ECG-AI LEF fills an important unmet need – the lack of an easily accessible point-of-care, noninvasive, and inexpensive tool to screen for a weak heart pump,” said Paul Friedman, M.D., chair of the Department of Cardiovascular Medicine at Mayo Clinic in Rochester, Minn. and chair of Anumana’s Board of Advisors. “It allows identification of otherwise hidden disease, for which many effective, lifesaving treatments are available – once the presence of the disease is known.”","spans":[]},{"type":"paragraph","text":"Developed in partnership with Mayo Clinic, Anumana’s ECG-AI LEF is an innovative software-as-a-medical device (SaMD) designed to screen for LEF in adults at risk for heart failure using data from a routine 12-lead electrocardiogram (ECG), a rapid and common test used in both primary and specialty care. Based on pioneering research from Mayo Clinic,4 the algorithm has been developed utilizing over 100,000 ECG and echocardiogram data pairs from unique patients and has been clinically tested in more than 25 studies involving more than 40,000 patients in the U.S. and internationally.5","spans":[{"start":350,"end":351,"type":"label","data":{"label":"superscript"}},{"start":586,"end":587,"type":"label","data":{"label":"superscript"}}]},{"type":"paragraph","text":"Anumana’s ECG-AI LEF was clinically validated in a multi-site, retrospective clinical study of 16,000 racially diverse patients, achieving its primary endpoint with an 84.5% sensitivity and 83.6% specificity.6 ECG-AI LEF achieved an AUROC7 of 0.932, demonstrating an ability to differentiate between LEF and ejection fraction (EF) >40% extremely well (a score ≥0.90 is considered excellent8) and better than most tests currently used in heart failure standard of care.9","spans":[{"start":208,"end":209,"type":"label","data":{"label":"superscript"}},{"start":238,"end":239,"type":"label","data":{"label":"superscript"}},{"start":389,"end":390,"type":"label","data":{"label":"superscript"}},{"start":468,"end":469,"type":"label","data":{"label":"superscript"}}]},{"type":"paragraph","text":"Additionally, the EAGLE study, a groundbreaking prospective, randomized, controlled clinical trial by Mayo Clinic evaluated the use of an investigational version of the algorithm in routine clinical care of 22,641 adults by 120 primary care teams from 45 clinics or hospitals, demonstrating that ECG-AI LEF implementation improved clinician’s ability to diagnosis of LEF by 31% versus standard of care without increasing the overall rate of echocardiogram usage.10","spans":[{"start":18,"end":29,"type":"hyperlink","data":{"link_type":"Web","url":"https://newsnetwork.mayoclinic.org/discussion/trial-demonstrates-early-ai-guided-detection-of-heart-disease-in-routine-practice/"}},{"start":462,"end":464,"type":"label","data":{"label":"superscript"}}]},{"type":"paragraph","text":"ECG-AI LEF is one of Anumana’s broad pipeline of algorithms, including three additional FDA breakthrough device designation algorithms (pulmonary hypertension, cardiac amyloidosis, and hyperkalemia), and is founded on more than six years of pioneering ECG-AI research and development at Mayo Clinic, including nearly 100 peer-reviewed publications to date.","spans":[{"start":136,"end":158,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c"}},{"start":160,"end":179,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.medicaldevice-network.com/news/fda-breakthrough-anumana-ecg-ai-algorithm/"}},{"start":335,"end":347,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/publications"}}]},{"type":"paragraph","text":"“Anumana was established in 2021 by nference in partnership with Mayo Clinic to unlock the electrical language of the heart through deep learning and improve disease diagnosis and patient care,” said Murali Aravamudan, co-founder and CEO of Anumana and nference. “In the short time of two years we have secured multiple FDA breakthrough device designations, entered multi-year agreements with three pharma partners, successfully established two new medical procedure codes for ECG AI technology, and now achieved our first FDA breakthrough medical device clearance. This is a significant milestone, and we are excited about the next phase of the journey, deploying our technology in the U.S. and globally to empower clinicians and enhance real-world clinical care.”","spans":[]},{"type":"paragraph","text":"Anumana is focused on driving fast-paced adoption of the new ECG-AI category, clinically developing and commercializing its novel technologies in healthcare. The newly FDA-cleared ECG-AI LEF can be easily integrated with various ECG information management systems or directly with a patient’s electronic health record via Anumana’s web-based ECG Viewer to support clinical decision-making.","spans":[]},{"type":"paragraph","text":"Anumana spearheaded the effort to bring reimbursement to ECG-AI, receiving approval for two Category III CPT® codes from the American Medical Association in 2022. These codes are now available and designed to facilitate the use, adoption, and potential reimbursement of emerging technologies in clinical workflows.","spans":[{"start":92,"end":115,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePahAAACAADoA-"}}]},{"type":"paragraph","text":"To learn more about ECG-AI LEF and schedule a demo, visit us at ECG-AI LEF.","spans":[{"start":64,"end":74,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef"}}]},{"type":"paragraph","text":"About Anumana","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in partnership with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology from an investigational resource to a clinically meaningful tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) solutions aim to detect hidden diseases using ECG-AI algorithms to enhance and improve interventional procedures through real-time AI insights.","spans":[]},{"type":"paragraph","text":"Anumana was named one of Fierce MedTech’s Fierce 15 companies for 2022. Follow Anumana at anumana.ai and on LinkedIn and Twitter.","spans":[{"start":25,"end":70,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZBhUQBAAACIAZrpK"}},{"start":108,"end":116,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d"}},{"start":121,"end":128,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83"}}]},{"type":"paragraph","text":"Dr. Friedman and Mayo Clinic have a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.","spans":[]},{"type":"paragraph","text":"References","spans":[{"start":0,"end":10,"type":"strong"}]},{"type":"paragraph","text":"1.     Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review 2020, 15:e13; https://doi.org/10.15420/ecr.2019.14.","spans":[{"start":190,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.15420/ecr.2019.14"}}]},{"type":"paragraph","text":"2.     Tsao, C.W., Aday, A.W., Almarzooq Z.I., et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation Vol. 147, No. 8; https://www.ahajournals.org/doi/10.1161/CIR.0000000000001123#d330256e1.","spans":[{"start":178,"end":248,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.ahajournals.org/doi/10.1161/CIR.0000000000001123#d330256e1"}}]},{"type":"paragraph","text":"3.     Khazanie P, Allen LA. Systematizing Heart Failure Population Health. Heart Fail Clin. 2020 Oct;16(4):457-466. Doi: 10.1016/j.hfc.2020.06.006. Epub 2020 Jul 21. PMID: 32888640; PMCID: PMC7737815; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/.","spans":[{"start":202,"end":255,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/"}}]},{"type":"paragraph","text":"4.     Attia, Z.I., Kapa, S., Lopez-Jimenez, F. et al. Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram. Nat Med 25, 70–74 (2019); https://doi.org/10.1038/s41591-018-0240-2.","spans":[{"start":187,"end":228,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.1038/s41591-018-0240-2"}}]},{"type":"paragraph","text":"5.     Anumana data on file and published studies.","spans":[]},{"type":"paragraph","text":"6.     Anumana data on file (NCT04963218).","spans":[{"start":29,"end":40,"type":"hyperlink","data":{"link_type":"Web","url":"https://classic.clinicaltrials.gov/ct2/show/NCT04963218"}}]},{"type":"paragraph","text":"7.     Area Under the Receiving Operating Characteristic curve (AUROC) is a performance metric commonly used to evaluate the ability of a model to distinguish between two classes. An AUROC of 0.5 suggests that the model is no better than random and an AUROC of 1.0 indicates a perfect classifier; https://en.wikipedia.org/wiki/Receiver_operating_characteristic.","spans":[{"start":297,"end":360,"type":"hyperlink","data":{"link_type":"Web","url":"https://en.wikipedia.org/wiki/Receiver_operating_characteristic"}}]},{"type":"paragraph","text":"8.     Muller MP, Tomlinson G, Marrie TJ, Tang P, McGeer A, Low DE, et al. Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community-acquired pneumonia? Clin Infect Dis. 40:1079–86 (2005); https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831439/.","spans":[{"start":245,"end":298,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831439/"}}]},{"type":"paragraph","text":"9.     Such as NT-proBNP, a common blood test used to help identify LEF today with an AUROC of 0.83; Koschack, J., Scherer, M., Lüers, C. et al. Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care. BMC Fam Pract 9, 14 (2008); https://doi.org/10.1186/1471-2296-9-14h.","spans":[{"start":290,"end":329,"type":"hyperlink","data":{"link_type":"Web","url":"https://bmcprimcare.biomedcentral.com/articles/10.1186/1471-2296-9-14"}}]},{"type":"paragraph","text":"10.   Yao, X., Rushlow, D.R., Inselman, J.W. et al. Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nat Med 27, 815–819 (2021); https://doi.org/10.1038/s41591-021-01335-4.","spans":[{"start":230,"end":272,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.1038/s41591-021-01335-4"}}]},{"type":"paragraph","text":"#  #  #","spans":[]},{"type":"paragraph","text":"Media Contact:","spans":[{"start":0,"end":14,"type":"strong"}]},{"type":"paragraph","text":"Sam Choinski","spans":[]},{"type":"paragraph","text":"Pazanga Health Communications for Anumana","spans":[]},{"type":"paragraph","text":"schoinski@pazangahealth.com","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:schoinski@pazangahealth.com"}}]},{"type":"paragraph","text":"(860) 301-5058","spans":[]}],"slices":[],"seoTitle":"Anumana Receives U.S. FDA 510(k) Clearance for ECG-AI Algorithm to Detect Low Ejection Fraction","seoDescription":"Based on pioneering research from Mayo Clinic, ECG-AI LEF aims to aid physicians in identifying low ejection fraction in patients at risk of heart failure","socialImage":{}}},{"id":"Zn2YRxIAACwAH2fZ","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Zn2YRxIAACwAH2fZ%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-06-27T16:52:22+0000","last_publication_date":"2025-01-20T09:40:20+0000","slugs":["data-from-anumanas-new-study-show-ai-algorithm-has-the-potential-to-detect-pulmonary-hypertension-early-using-ecg-data"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG Data","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[],"date":"2024-06-27T17:00:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass, June 27, 2024 Anumana, a leading AI-driven health technology company and portfolio company of nference, announced a new study that revealed promising results in support of further development of its investigational pulmonary hypertension (PH) algorithm. The study, “An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension,” which was published in the European Respiratory Journal, determined that the algorithm used in the study can detect PH using routine 12-lead electrocardiogram (ECG) data.","spans":[{"start":0,"end":31,"type":"strong"},{"start":31,"end":39,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":111,"end":119,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}},{"start":283,"end":368,"type":"hyperlink","data":{"link_type":"Web","url":"http://doi.org/10.1183/13993003.00192-2024","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"PH is a severe, progressive disease where delayed diagnosis is associated with a higher risk of morbidity and mortality.1-5 Despite an increasing number of available treatments for the disease, diagnostic delays – often of more than two years from symptom onset - are common, due to the non-specific symptoms at presentation.6-9  To address this challenge, Anumana, in collaboration with Mayo Clinic, Vanderbilt University Medical Center (VUMC), and Janssen Research & Development, LLC, a Johnson & Johnson company, has developed an Al algorithm designed to detect PH using routinely collected 12-lead ECG data. ","spans":[{"start":120,"end":123,"type":"label","data":{"label":"superscript"}},{"start":325,"end":328,"type":"label","data":{"label":"superscript"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"In the newly published study, a convolutional neural network developed for detecting PH was trained and validated using retrospective ECG and either right heart catheterization or echocardiogram data from 39,823 PH-likely patients and 219,404 control patients from Mayo Clinic. The algorithm used in the study was further validated on an additional 6,045 PH-likely patients and 24,256 control patients from VUMC. The algorithm demonstrated promising performance in identifying PH, achieving an area under the receiver operating characteristic curve (AUC) of 0.92 in the diagnostic test set at Mayo Clinic and 0.88 at VUMC, where AUC values range from 0 to 1.10\n","spans":[{"start":658,"end":660,"type":"label","data":{"label":"superscript"}}],"direction":"ltr"},{"type":"paragraph","text":"The PH algorithm received Breakthrough Device designation from the FDA in 2022, and Anumana is continuing to develop the PH algorithm in pursuit of FDA clearance and CE marking. Anumana has previously received FDA 510(k) clearance for its ECG-AI™ LEF algorithm, which helps clinicians detect low ejection fraction in patients at risk of heart failure.","spans":[{"start":26,"end":57,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c","target":"_blank"}},{"start":210,"end":250,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZRo9DhAAACYAxfsK","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“The promising data from our study suggest that an AI algorithm has the potential to non-invasively detect PH at an early stage using standard ECGs. This finding marks a significant step forward in the care and management of PH patients who often have a long diagnostic journey,” said Dr. Hilary DuBrock, a Mayo Clinic pulmonologist and lead author of the study. ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“These new data underscore the potential of AI algorithms to empower clinicians to uncover diseases earlier, improve patient outcomes and bring us one step closer to our mission to transform cardiac care,” said Maulik Nanavaty, CEO of Anumana. “We’re continuing to work closely with our partners to further clinically validate this much-needed algorithm, which can help clinicians worldwide get PH patients into treatment sooner to address symptoms and prolong life.” ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.\n","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana   ","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy to use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights.   ","spans":[{"start":218,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana’s lead algorithm, ECG-AI™ LEF is now available in the U.S. To learn more about how the algorithm can help clinicians identify low ejection fraction earlier and schedule a demo, visit us at ECG-AI LEF.  ","spans":[{"start":197,"end":207,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana Media Contact:","spans":[{"start":0,"end":22,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Sam Choinski","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Pazanga Health Communications","spans":[],"direction":"ltr"},{"type":"paragraph","text":"schoinski@pazangahealth.com                                    ","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:schoinski@pazangahealth.com","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"(860) 301-5058                              \n","spans":[],"direction":"ltr"},{"type":"paragraph","text":"References ","spans":[{"start":0,"end":10,"type":"strong"}],"direction":"ltr"},{"type":"o-list-item","text":"McLaughlin VV et al. .J Am Coll Cardiol 2018; 71(7):7522–763.​","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Gall H et al. J Heart Lung Transplant 2017; 36(9):9572–967. ​","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Frost AE et al. Chest 2013; 144(5):1521–1529. ​","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Nickel H et al. Eur Respir J 2012; 39(3):589–596. ​","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Vachiéry JL et al. Eur Respir Rev 2012; 21(123):40–47.","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 2011: 140(1): 19-26.","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Didden EM, Lee E, Wyckmans J, et al. Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data. Pulm Circ 2023: 13(1): e12188.","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Armstrong I, Billings C, Kiely DG, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med 2019: 19(1): 67.","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Maron BA, Humbert M. Finding pulmonary arterial hypertension-switching to offense to mitigate disease burden. JAMA cardiology 2022: 7(4): 369-370.","spans":[],"direction":"ltr"},{"type":"o-list-item","text":"Hajian-Tilaki, K. Caspian J Intern Med. 2013 Spring; 4(2): 627-635.","spans":[],"direction":"ltr"}],"slices":[],"seoTitle":"Data from Anumana’s New Study Show AI Algorithm Has the Potential to Detect Pulmonary Hypertension Early Using ECG Data","seoDescription":null,"socialImage":{}}},{"id":"ZnngEBEAACwA6Od3","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZnngEBEAACwA6Od3%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-06-25T11:00:32+0000","last_publication_date":"2025-01-20T09:40:30+0000","slugs":["anumana-and-infobionic.ai-announce-collaboration-to-advance-ai-powered-remote-cardiac-telemetry-technology-for-early-detection-of-cardiac-diseases"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases ","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[],"date":"2024-06-25T11:00:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – June 25, 2024 – Anumana, a leading AI-driven health technology company and portfolio company of nference, and InfoBionic.Ai, a digital health company specializing in remote cardiac monitoring and diagnostic solutions, today announced a joint research collaboration agreement to develop and commercialize the next generation of remote cardiac care solutions, combining Anumana’s breakthrough ECG-AI™ technology and InfoBionic.Ai’s MoMe ARC® platform. ","spans":[{"start":0,"end":16,"type":"strong"},{"start":35,"end":43,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":115,"end":123,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}},{"start":129,"end":139,"type":"hyperlink","data":{"link_type":"Web","url":"https://infobionic.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"By leveraging Anumana's ECG-AI algorithms, developed and validated in collaboration with Mayo Clinic, this initiative aims to enhance InfoBionic.Ai’s MoMe ARC Platform’s ability to detect and intervene in cardiac diseases earlier in the remote patient monitoring setting, with the potential to improve patient outcomes. Anumana and InfoBionic.Ai, both Mayo Clinic portfolio companies,1,2 will continue to work closely with Mayo Clinic under this research agreement.","spans":[{"start":384,"end":388,"type":"label","data":{"label":"superscript"}}],"direction":"ltr"},{"type":"paragraph","text":"“It is exciting to see the convergence of our pioneering work in artificial intelligence and remote patient monitoring through this new partnership between Anumana and InfoBionic.Ai,” said Peter Noseworthy, MD, chair of the Heart Rhythm Services Division of Cardiovascular Medicine at Mayo and a board director at InfoBionic.Ai. “By combining InfoBionic.Ai’s remote monitoring solutions with Anumana’s innovative ECG-AI algorithms, including the FDA-cleared algorithm for detecting low ejection fraction (LEF), we aim to equip healthcare providers with the latest cutting-edge tools to detect underlying cardiac conditions earlier, enabling timely intervention and personalized care. It’s a thrilling time for cardiology.\"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“This collaboration marks an important step in Anumana’s mission to revolutionize cardiac care by enhancing the power of ECG with AI,” said Maulik Nanavaty, CEO of Anumana. “Since the founding of Anumana, our vision has been to elevate the utility of ECG with AI across all the settings in which ECGs are used. By joining forces with InfoBionic.Ai, we are expanding our capabilities from 12 leads in clinical settings to wearable lower-lead ECGs in patients’ homes. We look forward to bringing our AI technology to meet patients and physicians where they are, ultimately benefiting both worldwide.” ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Under the agreement, InfoBionic.Ai and Anumana will develop and integrate Anumana's ECG-AI algorithms, starting with the FDA cleared ECG-AI LEF algorithm, into InfoBionic.Ai's continuous and remote cardiac monitoring platform, allowing the ability to detect LEF and other conditions through the remote monitoring of cardiac activity. The companies will also work together to validate the clinical utility of the integrated solution and seek regulatory clearance to bring this technology to market.","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana has received FDA Breakthrough Device Designation for four of its algorithms: low ejection fraction, pulmonary hypertension, cardiac amyloidosis, and hyperkalemia. Its ECG-AI platform won the 2024 MedTech Breakthrough Award for “Best New Technology Solution- Cardiology.” ECG-AI LEF, the company’s FDA-cleared AI algorithm using routine 12-lead ECG data to detect low ejection fraction (LEF), a commonly undiagnosed indicator of heart failure,3 received U.S. FDA clearance in September 2023 and is currently under review in Europe. Anumana has demonstrated that its ECG-AI technology can be adapted to lower-lead ECG devices while maintaining a high degree of performance. A version of the neural network used in Anumana’s FDA cleared ECG-AI LEF algorithm has shown the algorithm to be effective in detecting low ejection fraction using single-lead wearable ECG devices.4 ","spans":[{"start":108,"end":130,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c","target":"_blank"}},{"start":132,"end":152,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZJLQeREAACkAEMC3","target":"_blank"}},{"start":235,"end":278,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZjvhaBEAAD7InxGm","target":"_blank"}},{"start":450,"end":452,"type":"label","data":{"label":"superscript"}},{"start":461,"end":479,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZRo9DhAAACYAxfsK","target":"_blank"}},{"start":877,"end":878,"type":"label","data":{"label":"superscript"}}],"direction":"ltr"},{"type":"paragraph","text":"InfoBionic.Ai’s MoMe ARC is the first and only continuous 6-lead FDA-cleared platform leveraging leading-edge AI analysis and native business intelligence. MoMeARC is a solution that includes a 4-in-1 Gateway device that seamlessly transitions between 2-day in addition to extended Holter tests, Event and MCT modes remotely, streamlining patient monitoring time and minimizing delays.\n","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About InfoBionic.Ai ","spans":[{"start":0,"end":20,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"InfoBionic.Ai’s digital technology has transformed the efficiency and economics of cardiac remote patient monitoring. The company’s vision for its FDA-cleared third-generation platform, the MoMe ARC®, is to remove the roadblocks hindering virtual and remote diagnosis and decision-making. The Massachusetts-based team of seasoned entrepreneurs has had successful careers in healthcare, IT, medical devices, and mobile technology, and brings specific expertise in remote monitoring and cardiology.","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Visit https://infobionic.ai. ","spans":[{"start":6,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"https://c212.net/c/link/?t=0&l=en&o=4176142-1&h=2326173387&u=https%3A%2F%2Finfobionic.ai%2F&a=https%3A%2F%2Finfobionic.ai","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana  ","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy to use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights.  ","spans":[{"start":218,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":" Anumana’s lead algorithm, ECG-AI™ LEF is now available in the U.S. To learn more about how the algorithm can help clinicians identify low ejection fraction (LEF) earlier and schedule a demo, visit us at ECG-AI LEF. ","spans":[{"start":204,"end":214,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"References","spans":[{"start":0,"end":10,"type":"strong"}],"direction":"ltr"},{"type":"o-list-item","text":"https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-launches-new-technology-platform-ventures-to-revolutionize-diagnostic-medicine/","spans":[{"start":0,"end":137,"type":"hyperlink","data":{"link_type":"Web","url":"https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-launches-new-technology-platform-ventures-to-revolutionize-diagnostic-medicine/","target":"_blank"}}],"direction":"ltr"},{"type":"o-list-item","text":"https://infobionic.ai/press/infobionic-enters-know-how-agreement-mayo-clinic/","spans":[{"start":0,"end":77,"type":"hyperlink","data":{"link_type":"Web","url":"https://infobionic.ai/press/infobionic-enters-know-how-agreement-mayo-clinic/","target":"_blank"}}],"direction":"ltr"},{"type":"o-list-item","text":"Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review 2020, 15:e13; https://doi.org/10.15420/ecr.2019.14.","spans":[{"start":183,"end":219,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.15420/ecr.2019.14","target":"_blank"}}],"direction":"ltr"},{"type":"o-list-item","text":"Attia, Z.I., Harmon, D.M., Dugan, J. et al. Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction. Nat Med 28, 2497–2503 (2022). https://doi.org/10.1038/s41591-022-02053-1\n","spans":[{"start":37,"end":43,"type":"em"},{"start":132,"end":139,"type":"em"},{"start":140,"end":142,"type":"strong"},{"start":162,"end":204,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.1038/s41591-022-02053-1","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"Anumana Media Contact: ","spans":[{"start":0,"end":23,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Sam Choinski ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Pazanga ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"schoinski@pazangahealth.com                                  ","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:schoinski@pazangahealth.com","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"(860) 301-5058","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"InfoBionic.Ai Media Contact:","spans":[{"start":0,"end":28,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Karlo Jo Helms","spans":[],"direction":"ltr"},{"type":"paragraph","text":"JOTO PR™","spans":[],"direction":"ltr"},{"type":"paragraph","text":"727-777-4619","spans":[],"direction":"ltr"},{"type":"paragraph","text":"jotopr.com ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases","seoDescription":null,"socialImage":{}}},{"id":"ZTCgnhEAACEAvirh","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZTCgnhEAACEAvirh%22%29+%5D%5D","tags":["FDA"],"first_publication_date":"2023-10-19T11:00:12+0000","last_publication_date":"2025-01-20T09:39:46+0000","slugs":["anumana-appoints-maulik-nanavaty-as-ceo"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Appoints Maulik Nanavaty as CEO","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"","spans":[]}],"date":"2023-10-19T10:45:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – October 19, 2023 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, today announced that Maulik Nanavaty has joined Anumana as chief executive officer and member of the Board of Directors. Murali Aravamudan, co-founder of Anumana and nference, has transitioned to executive chairman of the Anumana Board of Directors while continuing as CEO of nference. Nanavaty will lead Anumana through a period of growth as the company begins deploying and commercializing its multi-indication ECG-AI platform technology.","spans":[{"start":0,"end":35,"type":"strong"},{"start":37,"end":50,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai/"}},{"start":124,"end":132,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/"}}]},{"type":"paragraph","text":"Nanavaty joins Anumana after 18 years at Boston Scientific, where he served as a senior executive with extensive commercial and operational medical device experience in U.S. and international markets. Most recently, Nanavaty was senior vice president and president of Neuromodulation at Boston Scientific, leading the development and commercialization of microelectronic implantable technologies and software used to treat neurological diseases and other chronic conditions. Prior to this role, he served as president of Boston Scientific Japan, and previously vice president and general manager of Interventional Cardiology, Boston Scientific Japan. Prior to Boston Scientific, Nanavaty spent 16 years in various executive positions at Baxter International. ","spans":[]},{"type":"paragraph","text":"“It is a delight to announce and welcome Maulik as the new CEO of Anumana on the heels of the recent FDA clearance of our breakthrough ECG-AI LEF device,” said Aravamudan. “Maulik’s decades of experience developing and bringing to market innovative medical products globally is exactly what is needed to build Anumana into a best-in-class multimodal cardiovascular AI enterprise. I am confident his leadership will play a pivotal role in guiding Anumana through its next phase of growth.”","spans":[]},{"type":"paragraph","text":"Anumana’s ECG-AI platform represents a breakthrough approach to ECG interpretation, enabling identification of hidden cardiovascular diseases from standard ECGs at the point of care, for which effective, lifesaving treatments may be available. The company’s lead algorithm, ECG-AI LEF, recently received FDA clearance for detecting low ejection fraction, a common undiagnosed indicator of heart failure,1 a prevalent progressive disease that affects over 6 million people in the U.S. and is associated with a significant total annual healthcare cost.2 In addition to the breakthrough ECG-AI LEF, Anumana’s expansive development pipeline includes three additional algorithms with FDA breakthrough designation. The company has multiple ongoing partnerships with leading pharmaceutical companies to further develop and commercialize algorithms in the pipeline.","spans":[{"start":274,"end":317,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZRo9DhAAACYAxfsK"}}]},{"type":"paragraph","text":"“Anumana’s mission to unlock the electrical language of the heart in order to improve patient care is incredibly inspiring, and I am grateful for the opportunity to lead its continued progress,” said Nanavaty. “The company has accomplished fast-paced disruptive innovation within just two years since its founding, in close partnership with Mayo Clinic's world-renowned cardiologists and business collaborators. Together, we will build on and accelerate this evidence-based innovative platform, bringing our unique AI-based portfolio of cardiac disease related products to market globally, with real-world evidence in transforming patient outcomes.”","spans":[]},{"type":"paragraph","text":"In addition to his role as CEO of Anumana, Nanavaty joins nference as president, Ventures. He will continue to serve as a board member of Rani Therapeutics, a publicly listed biotherapeutics company. Nanavaty earned a Ph.D. in Pharmaceutical Sciences from the University of Illinois and an M.B.A. from the University of Chicago.","spans":[]},{"type":"paragraph","text":"###","spans":[]},{"type":"paragraph","text":"About Anumana ","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never done before. The company was founded by nference and Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative AI technology applied to ECG, electrophysiology, and hemodynamics, from an investigational resource to a clinically meaningful tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) solutions aim to detect hidden diseases using ECG-AI algorithms to enhance and improve care through real-time AI insights. Anumana SaMDs are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana utilizes the nference nSights platform to design, develop, and train new algorithms, and its pipeline of algorithms have been evaluated in retrospective and prospective studies across various institutions both nationally and internationally, including nearly 100 peer-reviewed publications to date. In addition to the company’s first FDA-cleared algorithm, ECG-AI LEF, to detect low left ventricular ejection fraction, three Anumana algorithms (cardiac amyloidosis, pulmonary hypertension, and hyperkalemia) have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical validation to support additional regulatory submissions.  ","spans":[{"start":862,"end":878,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/nsights"}},{"start":1126,"end":1138,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/publications"}},{"start":1206,"end":1216,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef"}}]},{"type":"paragraph","text":"Anumana was named one of Fierce MedTech’s Fierce 15 companies for 2022. For more information, visit anumana.ai and follow Anumana on LinkedIn and X (formerly Twitter). ","spans":[{"start":25,"end":70,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZBhUQBAAACIAZrpK"}},{"start":100,"end":110,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.anumana.ai%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=anumana.ai&index=6&md5=fa195867fefb37c7ccf35a5a2184e240"}},{"start":133,"end":141,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d"}},{"start":146,"end":166,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83"}}]},{"type":"paragraph","text":"About nference  ","spans":[{"start":0,"end":15,"type":"strong"}]},{"type":"paragraph","text":"Through its powerful technology platform and software, nference is transforming healthcare by making biomedical knowledge computable. Its partnerships with major academic medical centers empower nference to synthesize decades of institutional knowledge, producing real-world evidence (RWE) in real time by converting large amounts of de-identified data into deep insights to advance discovery and development of diagnostics and therapeutics. Its proprietary AI-enabled software platform, nSights, harnesses the power of federated learning to accelerate life sciences research, development, and clinical care in significant ways, including biomarker discovery and validation, RWE generation leveraging real-world data, early disease detection, public health policy generation and validation, and more. nference is headquartered in Cambridge, Mass. Follow nference on LinkedIn and Twitter. Visit us at www.nference.com.","spans":[{"start":55,"end":63,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nference.com&esheet=53543072&newsitemid=20230822542860&lan=en-US&anchor=nference&index=2&md5=5aafb28f7c4a4043abf1ae91fb557f9e","target":"_blank"}},{"start":334,"end":352,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnference.com%2Fpublications%2FYWMH2hIAACoAzxf-%2FBuilding-a-best-in-class-de-identification-tool-for-electronic-medical-records-through-ensemble-learning21%252900081-7%3F_returnURL%3Dhttps%253A%252F%252Flinkinghub.elsevier.com%252Fretrieve%252Fpii%252FS2666389921000817%253Fshowall%253Dtrue&esheet=53543072&newsitemid=20230822542860&lan=en-US&anchor=de-identified+data&index=3&md5=059cfec8abf8140d48d4e425f3b19a4e","target":"_blank"}},{"start":866,"end":874,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnference%2F&esheet=53543072&newsitemid=20230822542860&lan=en-US&anchor=LinkedIn&index=4&md5=39d5b8e166c95901251f6005f6b9fad6","target":"_blank"}},{"start":879,"end":886,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2F_nference&esheet=53543072&newsitemid=20230822542860&lan=en-US&anchor=Twitter&index=5&md5=efec880aff291a957aaff55d3e2952e4","target":"_blank"}},{"start":900,"end":916,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnference.com%2F&esheet=53543072&newsitemid=20230822542860&lan=en-US&anchor=www.nference.com&index=6&md5=c6b7def0f300877c2c1828227e8a8c07","target":"_blank"}}]},{"type":"paragraph","text":"References","spans":[{"start":0,"end":10,"type":"strong"}]},{"type":"paragraph","text":"1.         Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review 2020, 15:e13; https://doi.org/10.15420/ecr.2019.14.","spans":[{"start":194,"end":230,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.15420/ecr.2019.14","target":"_blank"}}]},{"type":"paragraph","text":"2.         Khazanie P, Allen LA. Systematizing Heart Failure Population Health. Heart Fail Clin. 2020 Oct;16(4):457-466. doi: 10.1016/j.hfc.2020.06.006. Epub 2020 Jul 21. PMID: 32888640; PMCID: PMC7737815; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/.","spans":[{"start":206,"end":259,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/","target":"_blank"}}]}],"slices":[],"seoTitle":"Anumana Appoints Maulik Nanavaty as CEO","seoDescription":null,"socialImage":{}}},{"id":"ZTEQhREAACEAwC86","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZTEQhREAACEAwC86%22%29+%5D%5D","tags":[],"first_publication_date":"2023-10-19T11:19:36+0000","last_publication_date":"2025-01-20T09:40:46+0000","slugs":["anumana-earns-first-full-fda-clearance-for-ai-to-detect-low-ejection-fraction"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana earns first full FDA clearance for AI to detect low ejection fraction","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Fierce Biotech: Two years after its launch as a joint venture between the Mayo Clinic and Nference to develop artificial intelligence algorithms capable of pulling out new insights from routine electrocardiogram results, Anumana has earned its first 510(k) clearance from the FDA for one of those tools.","spans":[]}],"date":"2023-10-05T18:30:00+0000","image":{"dimensions":{"width":5000,"height":3000},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/e1d26b12-cdfa-4e2d-989d-26d4b5dec842_iStock-1308917364.jpg?auto=compress,format","id":"Y6M_YRcAACJwmMgm","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"054efe3f-d880-49a8-ac0b-d542fce4bac0","url":"https://www.fiercebiotech.com/medtech/anumana-earns-first-full-fda-clearance-ai-detect-low-ejection-fraction"},"article":[],"slices":[],"seoTitle":"Anumana earns first full FDA clearance for AI to detect low ejection fraction","seoDescription":"Fierce Biotech: Two years after its launch as a joint venture between the Mayo Clinic and Nference to develop artificial intelligence algorithms capable of pulling out new insights from routine electrocardiogram results, Anumana has earned its first 510(k) clearance from the FDA for one of those tools.","socialImage":{}}},{"id":"ZJRbAREAACcAF-LE","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZJRbAREAACcAF-LE%22%29+%5D%5D","tags":[],"first_publication_date":"2023-06-22T14:31:15+0000","last_publication_date":"2025-01-20T09:39:26+0000","slugs":["fda-grants-breakthrough-designation-for-new-ai-model-to-detect-cardiac-amyloidosis-in-ecg-results"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new algorithm designed to identify signs of cardiac amyloidosis in electrocardiograms (ECGs).","spans":[]}],"date":"2023-06-21T18:30:00+0000","image":{"dimensions":{"width":1357,"height":772},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a76dd04e-4aa9-416d-881c-4f7b1eea49e7_iStock-864472226.jpeg?auto=compress,format","id":"YteZkRAAACAADq4Z","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"5da6e1f9-5405-487d-8fb7-d4ffcf8263e2","url":"https://cardiovascularbusiness.com/topics/artificial-intelligence/fda-breakthrough-device-ai-cardiac-amyloidosis-ecg"},"article":[],"slices":[],"seoTitle":"FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results","seoDescription":"Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has received a breakthrough device designation from the U.S. Food and Drug Administration (FDA) for a new algorithm designed to identify signs of cardiac amyloidosis in electrocardiograms (ECGs).","socialImage":{}}},{"id":"ZWjtBBEAACMAk14K","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZWjtBBEAACMAk14K%22%29+%5D%5D","tags":[],"first_publication_date":"2023-12-01T22:04:52+0000","last_publication_date":"2025-01-20T09:41:03+0000","slugs":["jj-hired-thousands-of-data-scientists.-will-the-strategy-pay-off"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"WSJ: One project—with the Mayo Clinic and a health-technology company called Anumana based in Cambridge, Mass.—aims to speed up diagnosis of high blood pressure in the lungs, or pulmonary hypertension. It now can take two or more years to identify the life-threatening disease.","spans":[]}],"date":"2023-11-30T19:30:00+0000","image":{"dimensions":{"width":2000,"height":1333},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/2c8623dd-7db3-4929-a867-3cda24a50913_download.jpeg?auto=compress,format","id":"ZWjuDREAACAAk2Nu","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"2c3dd1d4-bfd7-4df1-9cef-a9ade42cd137","url":"https://www.wsj.com/tech/biotech/johnson-johnson-hiring-data-scientists-ai-ccbf2c07?mod=Searchresults_pos1&page=1"},"article":[],"slices":[],"seoTitle":"J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?","seoDescription":"WSJ: One project—with the Mayo Clinic and a health-technology company called Anumana based in Cambridge, Mass.—aims to speed up diagnosis of high blood pressure in the lungs, or pulmonary hypertension. It now can take two or more years to identify the life-threatening disease.","socialImage":{}}},{"id":"Z0889h4AAEsAlR35","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Z0889h4AAEsAlR35%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-12-12T12:30:48+0000","last_publication_date":"2025-01-20T09:40:02+0000","slugs":["anumana-joins-the-american-college-of-cardiology-to-advance-ai-powered-solutions-for-detecting-heart-failure"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Joins the American College of Cardiology to Advance AI-Powered Solutions for Detecting Heart Failure","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[{"type":"paragraph","text":"Anumana’s joins ACC to advance AI solutions for detecting heart failure ","spans":[{"start":0,"end":72,"type":"em"}],"direction":"ltr"}],"date":"2024-12-12T12:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – Dec. 12, 2024 – Anumana, a leading AI-driven health technology company, announced a new collaboration with the American College of Cardiology to join its Innovation Program and accelerate the detection and treatment of cardiovascular disease. ","spans":[{"start":0,"end":35,"type":"strong"},{"start":35,"end":42,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https://anumana.ai/___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6ZWQwMDozYWMwODE0MTIyZTQ0MmRlZDAxZWIxZDRmZDAzMjc2ZmZhOWE1MDdiZjViOGQ3MWZhN2Q5NDU4ODJiYmVlZjdhOnA6VDpG","target":"_blank"}},{"start":126,"end":160,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https://www.acc.org/About-ACC/Innovation%23sort=*40commonsortdate%20descending___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6MjVhZTpjMTk3MDU2OWVhOWE4MmVmZmQ5MDA1OWFlMTAwZThjNTg2NDVlYmRmMTBkZDg5ZTQwOWY2Y2Y4ZmRmZjQ3ZWU2OnA6VDpG","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"The collaboration combines Anumana’s expertise in developing AI-based Software-as-a-Medical Device (SaMD) with ACC’s mission to support and transform patient care, bridging the gap between cutting-edge research and the challenges clinicians face in detecting low ejection fraction (LEF). Anumana’s FDA-cleared ECG-AI™ LEF algorithm, which has been included in the CMS 2025 OPPS final rule, effective January 2025, analyzes standard 12-lead electrocardiogram data to identify LEF – a potential early asymptomatic key indicator of heart failure. The ACC Innovation Program and its network of cardiology experts will help Anumana optimize the integration of this algorithm into clinical workflows.","spans":[{"start":364,"end":388,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https://anumana.ai/newsroom/ZyqGmhoAAEEA4fhJ___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6NDVkMTo3ZWRjMjkyYzU4NzE4YTFhNTIzZjMwMGQzMDEzM2MzNzgxYjllMWJlYjExNjZiOTUyMDRlMjA2NzViOWFmMWM1OnA6VDpG","target":"_blank"}},{"start":498,"end":542,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https://www.ecrjournal.com/articles/asymptomatic-left-ventricle-systolic-dysfunction___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6MmM5MToyNmIxNTMzODFmNmUzZDYwMzk1N2E5NTY1NzA1ZjQyOTMxZDllMDhiYmY4NjEzZGU1Zjg5ZmEwZDA3ZGU4MGFlOnA6VDpG","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"“Joining the ACC Innovation Program provides a unique opportunity to bring Anumana’s state-of-the-art AI technology into closer alignment with clinical practice,” said Maulik Nanavaty, CEO of Anumana. “Collaborating with ACC’s industry experts and leading physicians will help us to further our commitment to developing evidence-based, AI solutions that fit into everyday practice, ultimately improving patient outcomes and addressing the evolving needs of cardiology care.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"The ACC Innovation Program is driving the digital transformation of cardiovascular care by combining research, engagement, and thought leadership. Working with industry experts and academic institutions, the program advances initiatives that improve patient outcomes. ACC aims to search for, aid, and promote the development of technologies that will enable its members to advance the care of their patients.","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“Cardiovascular disease remains the leading cause of death worldwide, underscoring the need for innovative solutions that will help physicians detect and manage heart conditions earlier,” said Ami Bhatt, ACC Chief Innovation Officer. “Anumana’s technology offers an opportunity to create a scalable and equitable approach to early disease detection. Together, we’re paving the way for more proactive heart failure management that can improve heart health and deliver tangible benefits to patients.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana ","spans":[{"start":0,"end":14,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. Anumana’s award-winning 12-lead algorithm, ECG-AI™ LEF, is now available in the U.S. To learn more about how the algorithm can help clinicians identify LEF earlier and schedule a demo, visit us at ECG-AI LEF. For more information, visit www.anumana.ai or follow us on LinkedIn and X.","spans":[{"start":883,"end":893,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https://anumana.ai/ecg-ai-lef___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6MThjZjpjNGE2YTA5ODRjZjJiNjlmYmY1ZTVmMTU0OTA3NWQ4Njc2Y2U5YjhkNDJhY2RlZGQzMTQyZjliOWJiMGYyM2MzOnA6VDpG","target":"_blank"}},{"start":923,"end":937,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___http://www.anumana.ai___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6YTIwNTpkMDEwZjA1YjE0OWNkYmFjZDliZmI5ZjIwNTVhYzY2NjZlOTg3MDNlYzlkZTBlMTFkMzQ0MWUwNDk2Nzc4YTA3OnA6VDpG","target":"_blank"}},{"start":954,"end":962,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https://www.linkedin.com/company/anumana-inc/___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6Y2I1NzpmZmQ3MmUzYTZlMzc2NGIzYzViMzExMjU0NTliZGRlMmViNzllZjVkZWVhYWJkZWM1NGRjYjc4MjNiMDAyN2M3OnA6VDpG","target":"_blank"}},{"start":967,"end":968,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https://x.com/anumanainc___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6ZDZiYzo4Y2MwYmE1MGI5YzhmOGI3MzZlNjlhZTk2MTUxNzYyYWIxMjEzNDU2OTNlOGY4YzI5ZmVkZjJhM2Q4NDk3NTY4OnA6VDpG","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About The American College of Cardiology","spans":[{"start":0,"end":40,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org or follow @ACCinTouch.","spans":[],"direction":"ltr"},{"type":"paragraph","text":"###","spans":[],"direction":"ltr"},{"type":"paragraph","text":"\n","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Media Contact","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Andrea Sampson","spans":[],"direction":"ltr"},{"type":"paragraph","text":"President/CEO, Sampson Public Relations Group","spans":[],"direction":"ltr"},{"type":"paragraph","text":"asampson@sampsonprgroup.com","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:asampson@sampsonprgroup.com","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana Joins the American College of Cardiology to Advance AI-Powered Solutions for Detecting Heart Failure","seoDescription":"Anumana’s joins ACC to advance AI solutions for detecting heart failure","socialImage":{}}},{"id":"ZzYERRkAAE0AF6ML","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZzYERRkAAE0AF6ML%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-11-14T14:08:18+0000","last_publication_date":"2025-01-20T09:40:05+0000","slugs":["anumana-to-showcase-ai-driven-cardiovascular-solutions-at-aha-and-napcrg-2024"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana to Showcase AI-Driven Cardiovascular Solutions at AHA and NAPCRG 2024","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[{"type":"paragraph","text":"Company to highlight how its ECG-AI™ algorithms enable earlier cardiovascular disease detection","spans":[{"start":0,"end":95,"type":"em"}],"direction":"ltr"}],"date":"2024-11-14T12:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – Nov. 14, 2024 – Anumana, a leading AI-driven health technology company, will showcase its leadership in AI-powered cardiovascular solutions at the American Heart Association (AHA) Scientific Sessions 2024, booth #708, in Chicago, and at the North American Primary Care Research Group (NAPCRG) Annual Meeting in Quebec City.","spans":[{"start":0,"end":35,"type":"strong"},{"start":35,"end":42,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":166,"end":223,"type":"hyperlink","data":{"link_type":"Web","url":"https://professional.heart.org/en/meetings/scientific-sessions","target":"_blank"}},{"start":260,"end":326,"type":"hyperlink","data":{"link_type":"Web","url":"https://napcrg.org/conferences/annual/annualmeeting/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"“Empowering physicians with real-time, clinically meaningful insights is at the heart of Anumana’s mission,” said Maulik Nanavaty, CEO of Anumana. “We look forward to showcasing our ECG-AI algorithm, which uses a standard 12-lead ECG to detect low ejection fraction—a key indicator of heart failure. By transforming routine tests into tools that enable earlier diagnosis and treatment, we aim to elevate standards in cardiovascular care and improve patient outcomes.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"At the conferences, Anumana will feature its FDA-cleared ECG-AI™ Low Ejection Fraction (LEF) algorithm, which is currently available in the U.S. and was recently recognized in the CMS 2025 OPPS final rule. The company will also host expert panel discussions to highlight the role of AI in clinical care.","spans":[{"start":162,"end":173,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZyqGmhoAAEEA4fhJ","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"heading4","text":"AHA Scientific Sessions","spans":[{"start":0,"end":23,"type":"hyperlink","data":{"link_type":"Web","url":"https://professional.heart.org/en/meetings/scientific-sessions","target":"_blank"}},{"start":0,"end":23,"type":"strong"}],"direction":"ltr"},{"type":"heading6","text":"Panel session: “The Future of AI in Cardiology: Trends, Expert Insights, and Panel Discussion”","spans":[{"start":0,"end":94,"type":"strong"},{"start":16,"end":93,"type":"hyperlink","data":{"link_type":"Web","url":"https://eppro01.ativ.me/appinfo.php?page=Session&project=AHA24&id=4206303&server=eppro01.ativ.me","target":"_blank"}}],"direction":"ltr"},{"type":"list-item","text":"November 17 at 12:30 p.m. CT","spans":[],"direction":"ltr"},{"type":"list-item","text":"The session will explore the latest trends of AI/ML devices in cardiology, highlighting the journey of ECG-AI LEF from its initial concept to becoming an FDA-cleared Software as a Medical Device (SaMD). Experts will discuss the opportunities, challenges, and solutions shaping the future of AI in cardiology.","spans":[],"direction":"ltr"},{"type":"list-item","text":"Speakers: Samir Awasthi, MD, PhD; Heather Alger, PhD; Ambarish Pandey, MD; Mark Stampehl, MD","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"heading6","text":"Abstract presentation: “Deep Learning Enabled Electrocardiogram Aimed to Detect Coronary Artery Disease to Predict Atherosclerotic Cardiovascular Events in the Community”","spans":[{"start":0,"end":170,"type":"strong"},{"start":24,"end":169,"type":"hyperlink","data":{"link_type":"Web","url":"https://eppro01.ativ.me/appinfo.php?page=Session&project=AHA24&id=4148033&server=eppro01.ativ.me","target":"_blank"}}],"direction":"ltr"},{"type":"list-item","text":"Presentation: November 16 at 10:20-10:25 a.m. CT","spans":[],"direction":"ltr"},{"type":"list-item","text":"Speaker: Jose R Medina-Inojosa, MD, MSc","spans":[],"direction":"ltr"},{"type":"list-item","text":"“Equity in Equations” Breakfast Symposium: November 17 at 6:30-8:00 a.m. CT","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"heading4","text":"NAPCRG Annual Meeting","spans":[{"start":0,"end":21,"type":"hyperlink","data":{"link_type":"Web","url":"https://napcrg.org/conferences/annual/annualmeeting/","target":"_blank"}},{"start":0,"end":21,"type":"strong"}],"direction":"ltr"},{"type":"heading6","text":"Workshop topic: “Primary Care is the Next Frontier for AI Disruption: Low EF ECG-AI Algorithm Development as a Case Study\"","spans":[{"start":0,"end":122,"type":"strong"},{"start":17,"end":121,"type":"hyperlink","data":{"link_type":"Web","url":"https://napcrg.org/conferences/2020/sessions/6269","target":"_blank"}}],"direction":"ltr"},{"type":"list-item","text":"November 21 at 1:45-3:15 p.m. ET","spans":[],"direction":"ltr"},{"type":"list-item","text":"The 90-minute workshop will feature experts who will explore how AI innovations can be integrated into primary care workflows. Topics will cover recent advancements in health technology tools tailored for clinical care, the current state of AI-powered ECG tools, and essential considerations for evaluating and selecting health technology tools for primary care.","spans":[],"direction":"ltr"},{"type":"list-item","text":"Speakers: Heather Alger, PhD, MPH; Rowena Dolor, MD, MHS, MHS; David Rushlow, MD, MBOE; Chris Pullins, MD","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana’s ECG-AI platform includes a suite of algorithms designed to help clinicians detect cardiovascular diseases using ECG data. In addition to its FDA-cleared ECG-AI LEF algorithm, Anumana has also received FDA Breakthrough Device Designation for its pulmonary hypertension, cardiac amyloidosis, and hyperkalemia algorithms. The company’s AI tools unlock critical insights from ECGs to enhance the detection and management of heart disease.","spans":[{"start":10,"end":25,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}},{"start":255,"end":277,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c","target":"_blank"}},{"start":279,"end":299,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZJLQeREAACkAEMC3","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana\nAnumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. Anumana’s award-winning lead algorithm, ECG-AI™ LEF, is now available in the U.S. To learn more about how the algorithm can help clinicians identify LEF earlier and schedule a demo, visit us at ECG-AI LEF. For more information, visit www.anumana.ai or follow us on LinkedIn and X.","spans":[{"start":0,"end":13,"type":"strong"},{"start":894,"end":904,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}},{"start":934,"end":948,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai","target":"_blank"}},{"start":965,"end":973,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.linkedin.com/company/anumana-inc/","target":"_blank"}},{"start":978,"end":979,"type":"hyperlink","data":{"link_type":"Web","url":"https://x.com/anumanainc","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"Media Contact\nAndrea Sampson\nPresident/CEO, Sampson Public Relations Group\nasampson@sampsonprgroup.com","spans":[{"start":0,"end":13,"type":"strong"},{"start":75,"end":102,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:asampson@sampsonprgroup.com","target":"_blank"}}],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana to Showcase AI-Driven Cardiovascular Solutions at AHA and NAPCRG 2024","seoDescription":"Company to highlight how its ECG-AI™ algorithms enable earlier cardiovascular disease detection","socialImage":{}}},{"id":"ZkJzcBEAAA40qJAR","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZkJzcBEAAA40qJAR%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-05-14T11:05:26+0000","last_publication_date":"2025-01-21T05:43:10+0000","slugs":["anumana-appoints-harry-s.-palmin-as-cfo"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Appoints Harry S. Palmin as CFO","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[],"date":"2024-05-14T12:00:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – May 14, 2024 Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry S. Palmin as chief financial officer (CFO). As a veteran in building, financing, and operating life sciences companies, Palmin brings over 25 years of experience to Anumana’s executive leadership team. In his new role, he will lead financial operations, investor relations, and corporate development activities at Anumana, and guide the company’s strategic growth. In addition to his role as CFO of Anumana, Palmin joins nference as CFO, Ventures.","spans":[{"start":0,"end":31,"type":"strong"},{"start":32,"end":39,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":112,"end":120,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Palmin's distinguished career includes tenure as CFO at Acer Therapeutics Inc., where he played a pivotal role in the company's successful acquisition by Zevra Therapeutics, Inc. His leadership was instrumental in Acer's public offering and the company’s FDA approval for OLPRUVA™, a treatment for urea cycle disorders. Prior to his role at Acer, Palmin served in multiple executive positions at Novelos Therapeutics, Inc., where he helped transform the company from conceptual stage into a leading public oncology and infectious disease development entity. ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“Harry is a highly skilled and accomplished executive with a proven track record in building successful companies in the life sciences industry,” said Maulik Nanavaty, CEO of Anumana. “I am thrilled to welcome Harry to Anumana at an exciting time for the company, where we are making tremendous progress in pipeline development and commercial traction. I look forward to partnering with him through our next phase of growth.” ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana is at the forefront of revolutionizing healthcare with its groundbreaking ECG-AITM platform that, from standard ECGs at the point of care, enables the identification of hidden cardiovascular diseases for which effective, lifesaving treatments may be available. The ECG-AI platform won the 2024 MedTech Breakthrough Award for “Best New Technology Solution- Cardiology.” ","spans":[{"start":88,"end":90,"type":"label","data":{"label":"superscript"}},{"start":333,"end":376,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZjvhaBEAAD7InxGm","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"The company’s lead algorithm, ECG-AI LEF, an FDA Breakthrough Device-designated medical device, recently received FDA clearance for detecting low ejection fraction, a common undiagnosed indicator of heart failure1 and prevalent progressive disease that affects over 6 million people in the U.S. and is associated with a significant total annual healthcare cost.2 Anumana’s expansive development pipeline also includes three additional algorithms with FDA Breakthrough Device designation (pulmonary hypertension, cardiac amyloidosis, and hyperkalemia). The company has multiple ongoing partnerships with leading pharmaceutical companies to further develop and commercialize algorithms in its pipeline.3,4 Anumana also spearheaded the effort to bring reimbursement to ECG-AI, receiving approval for two Category III CPT® codes from the American Medical Association in 2022. These codes are now available and designed to facilitate the use, adoption, and potential reimbursement of emerging technologies in clinical workflows.5","spans":[{"start":30,"end":127,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZRo9DhAAACYAxfsK","target":"_blank"}},{"start":212,"end":213,"type":"label","data":{"label":"superscript"}},{"start":361,"end":362,"type":"label","data":{"label":"superscript"}},{"start":488,"end":510,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c","target":"_blank"}},{"start":512,"end":531,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.medicaldevice-network.com/news/fda-breakthrough-anumana-ecg-ai-algorithm/","target":"_blank"}},{"start":700,"end":703,"type":"label","data":{"label":"superscript"}},{"start":801,"end":824,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePahAAACAADoA-","target":"_blank"}},{"start":1023,"end":1024,"type":"label","data":{"label":"superscript"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“Anumana is one of the most innovative companies in healthcare technology and it is an honor to be joining the organization at such a pivotal time in its growth,” said Palmin. “The progress Anumana has accomplished in just three years since its founding and the potential impact that Anumana’s AI technology platform can make on patient outcomes are inspiring. I am excited to be part of the team and the mission to use pioneering AI technology to unlock the electrical language of the heart and improve patient care.” ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Palmin earned a B.A. in economics and business and an M.A. in international economics and finance from the International Business School at Brandeis University. He also studied at the London School of Economics and the Copenhagen Business School. ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana ","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations, to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect hidden diseases using standard of care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. ","spans":[{"start":218,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana’s lead algorithm, ECG-AI™ LEF, is now available in the U.S. To learn more about how the algorithm can help clinicians identify low ejection fraction (LEF) earlier and schedule a demo, visit us at ECG-AI LEF. ","spans":[{"start":204,"end":214,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana was named one of Fierce MedTech’s Fierce 15 companies for 2022. Follow Anumana at anumana.ai and on LinkedIn and Twitter. ","spans":[{"start":25,"end":70,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZBhUQBAAACIAZrpK","target":"_blank"}},{"start":108,"end":116,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d","target":"_blank"}},{"start":121,"end":128,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About nference  ","spans":[{"start":0,"end":15,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"nference is unlocking the potential of healthcare data with AI, delivering real-world evidence, insights, and solutions informed by the most comprehensive multimodal data across all therapeutic areas. The company’s extensive de-identified, longitudinal data includes decades of clinical notes along with rich patient histories, vitals, lab tests, radiology images, digital pathology, genomics, and electrophysiology waveforms. Our federated data platform, comprising premier healthcare organizations, including Mayo Clinic, Duke Health, Banner Health, Vanderbilt University Medical Center, and Emory Healthcare, enables advanced research and custom AI model development. With unprecedented access to data from over 40 million patient journeys, our partners can accelerate target discovery, optimize clinical trial design, and enhance lifecycle management. Follow nference on LinkedIn. Visit us at www.nference.com.","spans":[{"start":897,"end":913,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"References","spans":[{"start":0,"end":10,"type":"strong"}],"direction":"ltr"},{"type":"o-list-item","text":"Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review 2020, 15:e13; https://doi.org/10.15420/ecr.2019.14.","spans":[{"start":183,"end":219,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.15420/ecr.2019.14","target":"_blank"}}],"direction":"ltr"},{"type":"o-list-item","text":"Khazanie P, Allen LA. Systematizing Heart Failure Population Health. Heart Fail Clin. 2020 Oct;16(4):457-466. doi: 10.1016/j.hfc.2020.06.006. Epub 2020 Jul 21. PMID: 32888640; PMCID: PMC7737815; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/.","spans":[{"start":195,"end":248,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/","target":"_blank"}}],"direction":"ltr"},{"type":"o-list-item","text":"Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease","spans":[{"start":0,"end":93,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/Y5otrRcAACkAg7NW","target":"_blank"}}],"direction":"ltr"},{"type":"o-list-item","text":"Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence ","spans":[{"start":0,"end":114,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePpxAAACEADoFR","target":"_blank"}}],"direction":"ltr"},{"type":"o-list-item","text":"Anumana Announces issuance of New American Medical Association CPT® Category III codes for Novel ECG AI Analysis of Cardiac Dysfunctions","spans":[{"start":0,"end":136,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePahAAACAADoA-","target":"_blank"}}],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana Appoints Harry S. Palmin as CFO","seoDescription":"Anumana Appoints Harry S. Palmin as CFO","socialImage":{}}},{"id":"ZjvhaBEAAD7InxGm","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZjvhaBEAAD7InxGm%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-05-09T13:55:50+0000","last_publication_date":"2025-01-20T09:41:07+0000","slugs":["anumanas-ecg-ai-algorithms-honored-with-2024-medtech-breakthrough-award-for-best-new-technology-solution-cardiology"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana’s ECG-AI™ Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[{"type":"paragraph","text":"Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available","spans":[{"start":0,"end":145,"type":"em"}],"direction":"ltr"}],"date":"2024-05-09T10:44:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available","spans":[{"start":0,"end":145,"type":"em"}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"CAMBRIDGE, Mass. – May 9, 2024 – Anumana, Inc., a leading AI-driven health technology company and portfolio company of nference, announced today it has received the 2024 MedTech Breakthrough Award for Best New Technology Solution in the Cardiology category. The recognition is for Anumana’s suite of artificial intelligence (AI)-based electrocardiogram (ECG) interpretation algorithms, with a spotlight on ECG-AI™ LEF, the company’s FDA cleared, breakthrough AI algorithm using routine 12-lead ECG data to detect Low Ejection Fraction (LEF).","spans":[{"start":0,"end":30,"type":"strong"},{"start":32,"end":45,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai/","target":"_blank"}},{"start":119,"end":127,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}},{"start":201,"end":229,"type":"em"}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Developed in collaboration with Mayo Clinic, Anumana’s ECG-AI LEF represents a paradigm shift in ECG interpretation. LEF, or a weak heart pump, is a significant, at times asymptomatic, and commonly undiagnosed indicator of heart failure.1 The increasing prevalence of heart failure and its associated morbidity, mortality, rehospitalizations, and societal costs2,3 underscore the need to identify and manage patients with LEF. ECG-AI LEF is an innovative software-as-a-medical device (SaMD) designed to help clinicians identify LEF in adults earlier by using data from a routine 12-lead ECG, a rapid standard of care test used across primary and specialty care settings. The AI algorithm was clinically validated in a multi-site, retrospective study of 16,000 patients, demonstrating an 84.5% sensitivity and 83.6% specificity.4 Additionally, in a randomized controlled prospective study with 22,641 adults, an investigational version of the algorithm demonstrated the ability to improve primary care clinicians’ diagnoses of LEF by +31% versus standard of care without increasing the overall rate of echocardiogram usage.5  ECG-AI LEF received U.S. FDA clearance in September 2023 and is currently under review in Europe.","spans":[{"start":237,"end":238,"type":"label","data":{"label":"superscript"}},{"start":361,"end":362,"type":"label","data":{"label":"superscript"}},{"start":363,"end":364,"type":"label","data":{"label":"superscript"}},{"start":827,"end":828,"type":"label","data":{"label":"superscript"}},{"start":1122,"end":1124,"type":"label","data":{"label":"superscript"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Beyond ECG-AI LEF, Anumana has the largest and most robust pipeline of ECG-AI algorithms in development, including three additional FDA Breakthrough Device-designated algorithms (pulmonary hypertension, cardiac amyloidosis, and hyperkalemia), founded on more than six years of pioneering ECG-AI research and development at Mayo Clinic, including nearly 100 studies to date.","spans":[{"start":179,"end":201,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c","target":"_blank"}},{"start":203,"end":222,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.medicaldevice-network.com/news/fda-breakthrough-anumana-ecg-ai-algorithm/","target":"_blank"}},{"start":357,"end":364,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/publications","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“At Anumana, we are committed to developing evidence-based AI algorithms that empower clinicians to uncover diseases earlier and improve patient outcomes,” said Maulik Nanavaty, CEO of Anumana. “We are honored to be recognized by MedTech Breakthrough for our efforts in developing and implementing our cutting edge clinically validated AI algorithms that enhance ECG interpretation. Our ECG-AI algorithm technology represents a groundbreaking shift in the utility of ECG, and we are excited to be at the forefront of improving cardiovascular care with AI technology.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"The MedTech Breakthrough Awards, organized by Tech Breakthrough, an independent, leading market intelligence organization, honors excellence in medical and health related technology, products, services, and people.\n","spans":[],"direction":"ltr"},{"type":"paragraph","text":"ECG-AI LEF is now available in the U.S. To learn more about how the algorithm can help clinicians identify LEF earlier and schedule a demo, visit us at ECG-AI LEF.","spans":[{"start":152,"end":162,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana ","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful medical-grade and easy to use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI solutions aim to detect hidden diseases using standard of care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights.","spans":[{"start":218,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana was named one of Fierce MedTech’s Fierce 15 companies for 2022. Follow Anumana at anumana.ai and on LinkedIn and Twitter.","spans":[{"start":25,"end":70,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZBhUQBAAACIAZrpK","target":"_blank"}},{"start":90,"end":100,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":108,"end":116,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d","target":"_blank"}},{"start":121,"end":128,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"References","spans":[{"start":0,"end":10,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"1.     Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review 2020, 15:e13; https://doi.org/10.15420/ecr.2019.14.","spans":[{"start":190,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.15420/ecr.2019.14","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"2.     Tsao, C.W., Aday, A.W., Almarzooq Z.I., et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation Vol. 147, No. 8; https://www.ahajournals.org/doi/10.1161/CIR.0000000000001123#d330256e1.","spans":[{"start":178,"end":248,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.ahajournals.org/doi/10.1161/CIR.0000000000001123#d330256e1","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"3.     Khazanie P, Allen LA. Systematizing Heart Failure Population Health. Heart Fail Clin. 2020 Oct;16(4):457-466. Doi: 10.1016/j.hfc.2020.06.006. Epub 2020 Jul 21. PMID: 32888640; PMCID: PMC7737815; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/.","spans":[{"start":202,"end":255,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737815/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"4.     Anumana data on file (NCT04963218).","spans":[{"start":29,"end":40,"type":"hyperlink","data":{"link_type":"Web","url":"https://classic.clinicaltrials.gov/ct2/show/NCT04963218","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"5.      Yao, X., Rushlow, D.R., Inselman, J.W. et al. Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nat Med 27, 815–819 (2021); https://doi.org/10.1038/s41591-021-01335-4.","spans":[{"start":232,"end":274,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.1038/s41591-021-01335-4","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"#  #  # ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Media Contact:","spans":[{"start":0,"end":14,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Sam Choinski","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Pazanga Health Communications for Anumana","spans":[],"direction":"ltr"},{"type":"paragraph","text":"schoinski@pazangahealth.com","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:schoinski@pazangahealth.com","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"(860) 301-5058","spans":[],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana’s ECG-AI™ Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”","seoDescription":"Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available","socialImage":{}}},{"id":"ZkuZShEAACgAwHOK","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZkuZShEAACgAwHOK%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-05-21T11:30:25+0000","last_publication_date":"2025-01-20T09:40:26+0000","slugs":["anumana-demonstrates-global-readiness-with-receipt-of-iso-13485-certification"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Demonstrates Global Readiness with Receipt of ISO 13485 Certification","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[],"date":"2024-05-21T11:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – May 21, 2024 – Anumana, a leading AI-driven health technology company and portfolio company of nference, announced today that it has received the International Organization for Standardization (ISO) 13485 certification for its Quality Management System. This certification, the quality management standard for device manufacturers, indicates that a company has developed robust policies and procedures for the development and manufacture of regulated medical devices. ","spans":[{"start":0,"end":31,"type":"strong"},{"start":33,"end":41,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai/","target":"_blank"}},{"start":114,"end":122,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana received ISO 13485 certification following an independent third-party certification firm’s rigorous assessment of its Quality Management System. With this certification, Anumana strengthens its ability to provide software-as-a-medical device (SaMD) ECG-AI™ algorithms that consistently meet customer and regulatory requirements. ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"\n“Anumana’s ISO13485 certification is a testament to our commitment to excellence in the development and manufacturing of regulated medical devices that adhere to international standards and requirements,” said David McMullin, Anumana’s chief business officer. “As a rapidly growing international medical device manufacturer, this milestone underscores our leadership in pioneering and bringing to market clinically validated and regulated ECG-AI™ algorithms as SaMDs, validates our capabilities, and enables Anumana to extend the reach of our technology to clinicians and patients worldwide.” \n","spans":[],"direction":"ltr"},{"type":"paragraph","text":"ECG-AI™ LEF, the company’s FDA-cleared, breakthrough AI algorithm using routine 12-lead ECG data to detect Low Ejection Fraction (LEF), a commonly undiagnosed indicator of heart failure,1 received U.S. FDA clearance in September 2023 and is currently under review in Europe.","spans":[{"start":186,"end":187,"type":"label","data":{"label":"superscript"}},{"start":197,"end":215,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZRo9DhAAACYAxfsK","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana ","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy to use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect hidden diseases using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. ","spans":[{"start":218,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana’s lead algorithm, ECG-AI™ LEF is now available in the U.S. To learn more about how the algorithm can help clinicians identify low ejection fraction (LEF) earlier and schedule a demo, visit us at ECG-AI LEF.","spans":[{"start":203,"end":213,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana was named one of Fierce MedTech’s Fierce 15 companies for 2022 and received the 2024 Medtech Breakthrough award for Best New Technology Solution, cardiology.  Follow Anumana at anumana.ai and on LinkedIn and Twitter. ","spans":[{"start":25,"end":70,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZBhUQBAAACIAZrpK","target":"_blank"}},{"start":88,"end":119,"type":"hyperlink","data":{"link_type":"Web","url":"https://medtechbreakthrough.com/2024-winners/","target":"_blank"}},{"start":185,"end":195,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":203,"end":211,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d","target":"_blank"}},{"start":216,"end":223,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"  ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"References ","spans":[{"start":0,"end":10,"type":"strong"}],"direction":"ltr"},{"type":"o-list-item","text":"Jaskanwal D Sara, Takumi Toya, Riad Taher, Amir Lerman, Bernard J Gersh, Nandan S Anavekar. Asymptomatic Left Ventricle Systolic Dysfunction. European Cardiology Review 2020, 15:e13; https://doi.org/10.15420/ecr.2019.14. ","spans":[{"start":183,"end":219,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.15420/ecr.2019.14","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"\nMedia Contact: \nSam Choinski \nPazanga Health Communications for Anumana\nschoinski@pazangahealth.com \n(860) 301-5058","spans":[{"start":1,"end":16,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":" ","spans":[],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana Demonstrates Global Readiness with Receipt of ISO 13485 Certification","seoDescription":null,"socialImage":{}}},{"id":"Zxh6bhoAAEgAx8NL","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Zxh6bhoAAEgAx8NL%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-10-24T11:30:42+0000","last_publication_date":"2025-01-20T09:41:13+0000","slugs":["anumana-joins-accelerating-medicines-partnership-heart-failure-program-to-advance-ecg-ai-research"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Joins Accelerating Medicines Partnership Heart Failure Program to Advance ECG-AI™ Research","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[{"type":"paragraph","text":"Program provides access to real-world data to refine AI algorithms for earlier detection of complex heart conditions","spans":[{"start":0,"end":116,"type":"em"}],"direction":"ltr"}],"date":"2024-10-24T11:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – Oct. 24, 2024 – Anumana, a leading AI-driven health technology company and portfolio company of nference, has joined the Accelerating Medicines Partnership® (AMP®) Heart Failure program. Managed by the Foundation of the National Institutes of Health (FNIH), this initiative brings together leaders in academia, industry, and government to advance critical research and improve outcomes for patients.","spans":[{"start":0,"end":35,"type":"strong"},{"start":35,"end":42,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":115,"end":123,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}},{"start":140,"end":204,"type":"hyperlink","data":{"link_type":"Web","url":"https://amphf.org/about/","target":"_blank"}},{"start":221,"end":275,"type":"hyperlink","data":{"link_type":"Web","url":"https://fnih.org/our-programs/accelerating-medicines-partnership-amp/amp-heart-failure/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"“We are honored to join leading experts in the AMP Heart Failure program to help advance the next generation of treatments,\" said Maulik Nanavaty, CEO of Anumana. \"While heart disease treatments have seen remarkable progress, heart failure deaths continue to rise. The AMP Heart Failure collaboration is poised to shift that trend. As a dedicated leader in AI-powered clinical solutions, Anumana will bring our expertise in developing and validating AI-enabled Software as Medical Device (SaMD) that identifies diseases from electrocardiogram to advance the goals of the AMP Heart Failure program. By enabling earlier diagnoses, we aim to help improve patient care by starting treatment sooner, and ultimately improving quality of life.\"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Launched in 2022 in collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health (NIH), AMP Heart Failure is a multi-year, multi-center initiative focused on understanding heart failure with preserved ejection fraction (HFpEF), a complex condition in cardiovascular health, through two parallel and interconnected components. The first component is to aggregate clinical data from over 30 existing cohorts and trials to identify subtypes of HFpEF. The second component builds upon the knowledge generated from component one by creating an extensively phenotyped new cohort of HFpEF patients. Utilizing advanced technologies, including digital measurements and AI-driven analytic methods, AMP HF aims to transform care with more precise treatment options, ultimately improving the outlook for millions of patients around the world.","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“AMP Heart Failure provides the opportunity to collaborate with partners that are using cutting-edge technologies to lower the risk of mortality in HFpEF patients and improve the quality of life,” said Tania Kamphaus, PhD, Associate Vice President, Science Partnerships, and Director of Patient Engagement at the FNIH. “Anumana will contribute key analytical tools to help deepen our understanding of HFpEF and advance our ultimate goal of developing new treatments.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Heart failure remains a leading cause of death and hospitalization globally, affecting nearly 6.7 million adults in the U.S. alone.1 As an AMP Heart Failure partner, Anumana will support the innovative program's goals, including unifying large existing real-world datasets and developing new data solutions focused on HFpEF. This expanded dataset also provides Anumana with a unique opportunity to evaluate its ECG-AI algorithms across a broader patient population. By applying its technology to this real-world data, Anumana will facilitate earlier detection of complex heart conditions and drive more personalized treatment strategies.","spans":[{"start":0,"end":13,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10864030/#:~:text=Approximately%206.7%20million%20Americans%20over,develop%20HF%20in%20their%20lifetime.","target":"_blank"}},{"start":131,"end":132,"type":"label","data":{"label":"superscript"}}],"direction":"ltr"},{"type":"paragraph","text":"ECG-AI™ LEF, Anumana’s breakthrough AI algorithm using routine 12-lead ECG data to detect Low Ejection Fraction (LEF) – a commonly underdiagnosed indicator of heart failure2 – received U.S. FDA clearance in 2023 and is currently under review in Europe. Anumana has received FDA Breakthrough Device Designation for three additional algorithms: pulmonary hypertension, cardiac amyloidosis, and hyperkalemia. The company’s algorithms have been studied in more than 75 published clinical studies, effectively identifying conditions such as low ejection fraction and other hidden heart diseases.","spans":[{"start":172,"end":173,"type":"label","data":{"label":"superscript"}},{"start":185,"end":203,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZRo9DhAAACYAxfsK","target":"_blank"}},{"start":343,"end":365,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c","target":"_blank"}},{"start":367,"end":387,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZJLQeREAACkAEMC3","target":"_blank"}},{"start":410,"end":430,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/Zn2YRxIAACwAH2fZ","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"About Anumana ","spans":[{"start":0,"end":14,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy to use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights.   ","spans":[{"start":218,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"Anumana’s award-winning lead algorithm, ECG-AI™ LEF is now available in the U.S. To learn more about how the algorithm can help clinicians identify low ejection fraction (LEF) earlier and schedule a demo, visit us at ECG-AI LEF. ","spans":[{"start":217,"end":227,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"References ","spans":[{"start":0,"end":10,"type":"strong"}],"direction":"ltr"},{"type":"o-list-item","text":"Joynt Maddox et al. Circulation. 2024; v150:n4: https://doi.org/10.1161/CIR.0000000000001256","spans":[{"start":20,"end":31,"type":"em"},{"start":48,"end":92,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.1161/CIR.0000000000001256","target":"_blank"}}],"direction":"ltr"},{"type":"o-list-item","text":"Sara et al. European Cardiology Review. 2020 Feb:e13: 10.15420/ecr.2019.14","spans":[{"start":12,"end":39,"type":"em"},{"start":54,"end":74,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.15420%2Fecr.2019.14","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Media Contact","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Andrea Sampson","spans":[],"direction":"ltr"},{"type":"paragraph","text":"President/CEO, Sampson Public Relations Group\nasampson@sampsonprgroup.com","spans":[{"start":46,"end":73,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:asampson@sampsonprgroup.com","target":"_blank"}}],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana Joins Accelerating Medicines Partnership Heart Failure Program to Advance ECG-AI™ Research","seoDescription":"Program provides access to real-world data to refine AI algorithms for earlier detection of complex heart conditions","socialImage":{}}},{"id":"ZJRZuxEAACkAF9x2","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZJRZuxEAACkAF9x2%22%29+%5D%5D","tags":[],"first_publication_date":"2023-06-22T14:28:08+0000","last_publication_date":"2025-01-20T09:39:10+0000","slugs":["fda-grants-breakthrough-designation-for-anumanas-ecg-ai-algorithm"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"FDA grants breakthrough designation for Anumana’s ECG-AI algorithm","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Medical Device Network: The US Food and Drug Administration (FDA) has granted breakthrough device designation (BDD) for the electrocardiogram-artificial intelligence (ECG-AI) algorithm by AI-driven health technology company Anumana. The algorithm is intended for the early detection of cardiac amyloidosis, an underdiagnosed cause of heart failure. Anumana has worked with the Mayo Clinic to develop the ECG-AI algorithm. The company previously signed a multi-year research agreement with Pfizer for the development of ECG-AI solutions to facilitate cardiac amyloidosis early identification.","spans":[]}],"date":"2023-06-22T18:30:00+0000","image":{"dimensions":{"width":6000,"height":4000},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/b9e7a9d8-579b-4a42-a042-b8a0fcf2b728_iStock-1371157703.jpg?auto=compress,format","id":"Y6M_YRcAACoAmMgo","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"4ea50837-092a-4149-8906-4a78d4368509","url":"https://www.medicaldevice-network.com/news/fda-breakthrough-anumana-ecg-ai-algorithm/"},"article":[],"slices":[],"seoTitle":"FDA grants breakthrough designation for Anumana’s ECG-AI algorithm","seoDescription":"Medical Device Network: The US Food and Drug Administration (FDA) has granted breakthrough device designation (BDD) for the electrocardiogram-artificial intelligence (ECG-AI) algorithm by AI-driven health technology company Anumana. The algorithm is intended for the early detection of cardiac amyloidosis, an underdiagnosed cause of heart failure. Anumana has worked with the Mayo Clinic to develop the ECG-AI algorithm. The company previously signed a multi-year research agreement with Pfizer for the development of ECG-AI solutions to facilitate cardiac amyloidosis early identification.","socialImage":{}}},{"id":"ZTElOREAACIAwJU9","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZTElOREAACIAwJU9%22%29+%5D%5D","tags":[],"first_publication_date":"2023-10-19T12:48:23+0000","last_publication_date":"2025-01-20T09:40:51+0000","slugs":["anumana-wins-fda-clearance-for-ecg-ai-algorithm"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana wins FDA clearance for ECG-AI algorithm","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Mass Device: Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.","spans":[]}],"date":"2023-10-03T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/deb3bd27-d5d3-4033-970e-c4eeb36e00a9_iStock-1273839908.jpeg?auto=compress,format","id":"Ytea4RAAACIADrQE","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"c2bf2f11-c971-40a2-99d7-f94d79495185","url":"https://www.massdevice.com/anumana-fda-clearance-ecg-ai-algorithm/"},"article":[],"slices":[],"seoTitle":"Anumana wins FDA clearance for ECG-AI algorithm","seoDescription":"Mass Device: Anumana announced that it received FDA 510(k) clearance for its AI-powered ECG-AI LEF medical device.","socialImage":{}}},{"id":"ZJRauBEAACgAF-Fa","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZJRauBEAACgAF-Fa%22%29+%5D%5D","tags":[],"first_publication_date":"2023-06-22T14:30:18+0000","last_publication_date":"2025-01-20T09:39:18+0000","slugs":["anumana-receives-u.s.-fda-breakthrough-device-designation-for-its-cardiac-amyloidosis-algorithm"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the early identification of cardiac amyloidosis, a life-threatening, rare, underdiagnosed cause of heart failure. This breakthrough device designation was granted to provide patients and healthcare providers timely access to the algorithm, subject to approval.","spans":[]}],"date":"2023-06-21T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/deb3bd27-d5d3-4033-970e-c4eeb36e00a9_iStock-1273839908.jpeg?auto=compress,format","id":"Ytea4RAAACIADrQE","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"3c26a8a5-4b3e-4ea8-a72d-ab5b93ceea10","url":"https://www.dicardiology.com/content/anumana-receives-us-fda-breakthrough-device-designation-its-cardiac-amyloidosis-algorithm"},"article":[],"slices":[],"seoTitle":"Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm","seoDescription":"DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the early identification of cardiac amyloidosis, a life-threatening, rare, underdiagnosed cause of heart failure. This breakthrough device designation was granted to provide patients and healthcare providers timely access to the algorithm, subject to approval.","socialImage":{}}},{"id":"ZJRbRBEAACYAF-QS","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZJRbRBEAACYAF-QS%22%29+%5D%5D","tags":[],"first_publication_date":"2023-06-22T14:32:34+0000","last_publication_date":"2025-01-20T09:39:31+0000","slugs":["ai-algorithm-for-detection-of-cardiac-amyloidosis-gains-fda-breakthrough-device-status"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Healio: Anumana announced it received FDA breakthrough device designation for its artificial intelligence-guided ECG algorithm for the early identification of cardiac amyloidosis.","spans":[]}],"date":"2023-06-21T18:30:00+0000","image":{"dimensions":{"width":1355,"height":774},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/085e8fa4-0b8f-4dca-93a5-204d217847e9_iStock-1290220631.jpeg?auto=compress,format","id":"YteLlhAAACIADm8P","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"9b57d6ce-a6fd-4d67-a4af-78c3ff653f56","url":"https://www.healio.com/news/cardiology/20230621/ai-algorithm-for-detection-of-cardiac-amyloidosis-gains-fda-breakthrough-device-status"},"article":[],"slices":[],"seoTitle":"AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status","seoDescription":"Healio: Anumana announced it received FDA breakthrough device designation for its artificial intelligence-guided ECG algorithm for the early identification of cardiac amyloidosis.","socialImage":{}}},{"id":"ZTEk-hEAACIAwJPz","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZTEk-hEAACIAwJPz%22%29+%5D%5D","tags":[],"first_publication_date":"2023-10-19T12:46:37+0000","last_publication_date":"2025-01-20T09:40:58+0000","slugs":["ai-powered-device-to-identify-low-lv-ejection-fraction-gains-fda-510k-clearance"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.","spans":[]}],"date":"2023-10-02T18:30:00+0000","image":{"dimensions":{"width":880,"height":582},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/6619ee72-008c-4b61-9d12-be52b5ec8368_heart-2607178_1280.jpeg?auto=compress,format","id":"Ytec3RAAACIADrz3","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"51d387c6-0ad3-485f-92e4-b6248d7066f3","url":"https://www.healio.com/news/cardiology/20231002/aipowered-device-to-identify-low-lv-ejection-fraction-gains-fda-510k-clearance"},"article":[],"slices":[],"seoTitle":"AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance","seoDescription":"Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.","socialImage":{}}},{"id":"ZJLQeREAACkAEMC3","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZJLQeREAACkAEMC3%22%29+%5D%5D","tags":[],"first_publication_date":"2023-06-21T10:31:09+0000","last_publication_date":"2025-01-20T09:39:06+0000","slugs":["anumana-receives-u.s.-fda-breakthrough-device-designation-for-its-cardiac-amyloidosis-algorithm"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosis","spans":[{"start":0,"end":164,"type":"em"}]}],"date":"2023-06-21T11:00:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosis","spans":[{"start":0,"end":164,"type":"em"}]},{"type":"paragraph","text":"CAMBRIDGE, Mass., June 21, 2023 – Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the early identification of cardiac amyloidosis, a life-threatening, rare, underdiagnosed cause of heart failure. This breakthrough device designation was granted to provide patients and healthcare providers timely access to the algorithm, subject to approval. ","spans":[{"start":0,"end":34,"type":"strong"},{"start":34,"end":46,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai"}}]},{"type":"paragraph","text":"Anumana previously announced a multi-year research agreement with Pfizer to develop ECG-AI solutions to aid in early identification of cardiac amyloidosis. The Breakthrough Device Designation recognizes the significant potential of this algorithm, and the designation is a key regulatory milestone under the agreement, providing an expedited pathway for regulatory review.1 Anumana plans to conduct a retrospective clinical validation trial and pursue De Novo classification for the algorithm as Software as a Medical Device (SaMD) and aims to gain regulatory approval for the algorithm for the detection of cardiac amyloidosis in the U.S., Europe, and Japan. ","spans":[{"start":8,"end":28,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/Y5otrRcAACkAg7NW"}},{"start":372,"end":373,"type":"hyperlink","data":{"link_type":"Web","url":"#_ftn1"}},{"start":372,"end":373,"type":"label","data":{"label":"superscript"}}]},{"type":"paragraph","text":"Cardiac amyloidosis is an underdiagnosed disease that often leads to heart failure.2 Early diagnosis is crucial to enable timely interventions that can improve outcomes.3 However, diagnosing this condition early can be challenging because of the rarity of the disease, which often presents with nonspecific signs and symptoms.4  While a standard ECG is obtained during the evaluation of these nonspecific symptoms, human interpretation of the ECG often misses subtle combinations of features that may indicate cardiac amyloidosis.5,6","spans":[{"start":83,"end":84,"type":"label","data":{"label":"superscript"}},{"start":83,"end":84,"type":"hyperlink","data":{"link_type":"Web","url":"#_ftn2"}},{"start":169,"end":170,"type":"label","data":{"label":"superscript"}},{"start":169,"end":170,"type":"hyperlink","data":{"link_type":"Web","url":"#_ftn3"}},{"start":326,"end":327,"type":"label","data":{"label":"superscript"}},{"start":326,"end":327,"type":"hyperlink","data":{"link_type":"Web","url":"#_ftn4"}},{"start":530,"end":533,"type":"label","data":{"label":"superscript"}},{"start":530,"end":531,"type":"hyperlink","data":{"link_type":"Web","url":"#_ftn5"}},{"start":532,"end":533,"type":"hyperlink","data":{"link_type":"Web","url":"#_ftn6"}}]},{"type":"paragraph","text":"Developed in collaboration with Mayo Clinic, Anumana’s ECG-AI algorithm aims to address this medical need with breakthrough technology that facilitates earlier identification of this underdiagnosed condition. Anumana is currently developing this algorithm as a SaMD, with the goal of integrating this solution into existing clinical workflows. ","spans":[]},{"type":"paragraph","text":"“The use of AI algorithms to identify subtle signals in ECGs that are imperceptible to humans stands to transform cardiovascular medicine by allowing us to detect disease early, in more easily treated stages, potentially avoiding serious consequences,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic in Rochester and Chair of Anumana’s Mayo Clinic Board of Advisors. “It is encouraging to see an algorithm that can aid in identification of cardiac amyloidosis receive Breakthrough Device Designation, as it recognizes the importance of having new tools to detect rare cardiac diseases in ways never before possible.”","spans":[]},{"type":"paragraph","text":"Anumana, a portfolio company of nference was founded in 2021 in collaboration with the Mayo Clinic Platform and has since developed a robust pipeline of FDA-ready ECG-AI algorithms. These algorithms have been validated in over 75 peer-reviewed publications - including two novel, real-world prospective studies published in Nature Medicine and The Lancet. Anumana has received four Breakthrough Device Designations from the U.S. FDA for algorithms aimed at early identification of low ejection fraction, pulmonary hypertension, hyperkalemia, and now, cardiac amyloidosis. ","spans":[{"start":323,"end":339,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.nature.com/articles/s41591-021-01335-4"}},{"start":324,"end":339,"type":"em"},{"start":343,"end":354,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01637-3/fulltext"}},{"start":344,"end":354,"type":"em"}]},{"type":"paragraph","text":"“The ubiquitous nature of the painless, non-invasive Electrophysiology tests gives ECG-AI algorithms the potential to reach a larger number of patients earlier, something clinicians have long hoped for,” said Venky Soundararajan, PhD, Co-founder, and Chief Scientific Officer of Anumana and nference. “Receiving the FDA Breakthrough Device Designation for our Cardiac Amyloidosis ECG-AI Algorithm recognizes the significant potential of this tool to detect disease early.” ","spans":[]},{"type":"paragraph","text":"","spans":[]},{"type":"paragraph","text":"About Anumana","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Anumana, a leading AI-driven health technology company, and portfolio company of nference, is leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. Anumana’s algorithms have been developed and trained on the nference nSights platform and validated in retrospective and prospective studies across various institutions both nationally and internationally. Anumana’s solutions aim to detect hidden diseases using ECG-AI algorithms and to enhance and improve interventional procedures through real-time AI insights. Currently, four Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical validation. Anumana has also received approval for two CPT® III Codes from the American Medical Association, establishing ECG-AI as a new innovative procedure. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana was named one of Fierce Medtech’s Fierce 15 companies for 2022. For more information, visit anumana.ai and follow Anumana on LinkedIn and Twitter. ","spans":[{"start":81,"end":89,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nference.com%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=nference&index=5&md5=a0f9300b3092d80a5263a979c50853a8"}},{"start":288,"end":304,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/nsights"}},{"start":1154,"end":1164,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.anumana.ai%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=anumana.ai&index=6&md5=fa195867fefb37c7ccf35a5a2184e240"}},{"start":1187,"end":1195,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d"}},{"start":1200,"end":1207,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83"}}]},{"type":"paragraph","text":" ","spans":[{"start":0,"end":1,"type":"strong"}]},{"type":"paragraph","text":"Media Contact:","spans":[{"start":0,"end":14,"type":"strong"}]},{"type":"paragraph","text":"Sam Choinski\nPazanga Health Communications for Anumana\nschoinski@pazangahealth.com\n(860) 301-5058","spans":[{"start":55,"end":82,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:schoinski@pazangahealth.com"}}]}],"slices":[],"seoTitle":"Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm","seoDescription":"Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosis","socialImage":{}}},{"id":"ZyqGmhoAAEEA4fhJ","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZyqGmhoAAEEA4fhJ%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-11-05T21:30:05+0000","last_publication_date":"2025-01-20T09:40:11+0000","slugs":["anumanas-ai-driven-low-ejection-fraction-ecg-ai-technology-recognized-in-cms-2025-opps-final-rule-expanding-access-to-advanced-cardiovascular-care"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana’s AI-Driven Low Ejection Fraction ECG-AI Technology Recognized in CMS 2025 OPPS Final Rule, Expanding Access to Advanced Cardiovascular Care","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[{"type":"paragraph","text":"Company’s ECG-AI algorithm enables earlier heart failure detection","spans":[{"start":0,"end":66,"type":"em"}],"direction":"ltr"}],"date":"2024-11-05T12:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – November 5, 2024 – Anumana, a leading artificial intelligence (AI)-driven health technology company, announced that the Centers for Medicare & Medicaid Services (CMS) has included the Company’s low ejection fraction (LEF) ECG-AI™ technology in the 2025 Hospital Outpatient Prospective Payment System (OPPS) final rule under assignment APC 5734. This approval allows outpatient settings to receive reimbursement for using Anumana’s ECG-AI service to help identify LEF in adults at risk for heart failure, aiding early detection of cardiac dysfunction.","spans":[{"start":0,"end":38,"type":"strong"},{"start":38,"end":45,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":267,"end":336,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.cms.gov/newsroom/fact-sheets/cy-2025-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center-0","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"“The new CMS reimbursement ruling reflects our efforts to bring our ECG-AI technology to broader patient populations and recognizes our ongoing leadership in AI-enabled cardiovascular care,” said Maulik Nanavaty, CEO of Anumana. “This crucial milestone will help to reduce financial barriers to adopting ECG-AI, facilitating a smooth path for its integration into routine care and ultimately improving patient outcomes in cardiovascular disease management.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana’s ECG-AI™ technology, which received Category III CPT codes (0764T and 0765T) in 2023, harnesses advanced AI technology to transform standard ECG data into a powerful diagnostic tool for cardiovascular health. By detecting subtle, clinically significant patterns in ECGs that may indicate underlying conditions, ECG-AI™ aims to assist healthcare providers in making earlier and more accurate diagnoses, leading to improved patient outcomes.","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights.   ","spans":[{"start":218,"end":226,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"Anumana has received FDA Breakthrough Device Designation for four of its ECG-AI powered algorithms, including those for low ejection fraction, pulmonary hypertension, cardiac amyloidosis, and hyperkalemia. Its award-winning lead algorithm, ECG-AI™ LEF, is now available in the U.S. and currently under review in Europe. To learn more about how the algorithm can help clinicians identify low ejection fraction (LEF) earlier and schedule a demo, visit us at ECG-AI LEF.  ","spans":[{"start":143,"end":165,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c","target":"_blank"}},{"start":167,"end":187,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZJLQeREAACkAEMC3","target":"_blank"}},{"start":456,"end":466,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"###","spans":[],"direction":"ltr"},{"type":"paragraph","text":" ","spans":[{"start":0,"end":1,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Media Contact","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Andrea Sampson","spans":[],"direction":"ltr"},{"type":"paragraph","text":"President/CEO, Sampson Public Relations Group","spans":[],"direction":"ltr"},{"type":"paragraph","text":"asampson@sampsonprgroup.com","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:asampson@sampsonprgroup.com","target":"_blank"}}],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana’s AI-Driven Low Ejection Fraction ECG-AI Technology Recognized in CMS 2025 OPPS Final Rule, Expanding Access to Advanced Cardiovascular Care","seoDescription":"Company’s ECG-AI algorithm enables earlier heart failure detection","socialImage":{}}},{"id":"ZJWk1hEAACMAmGKs","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZJWk1hEAACMAmGKs%22%29+%5D%5D","tags":[],"first_publication_date":"2023-06-23T13:58:34+0000","last_publication_date":"2025-01-20T09:39:38+0000","slugs":["anumanas-pfizer-backed-cardiac-amyloidosis-spotting-ai-algorithm-nabs-fda-breakthrough-tag"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana's Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Fierce Biotech: For the fourth time in half as many years, Anumana has earned the FDA’s breakthrough device designation for another of its artificial intelligence algorithms designed to catch hard-to-spot heart conditions in their earliest stages.","spans":[]}],"date":"2023-06-22T18:30:00+0000","image":{"dimensions":{"width":1359,"height":771},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/cb216372-203a-4332-993d-e007a78681a6_iStock-1127069581.jpeg?auto=compress,format","id":"YtehMhAAACMADtD-","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"9626f016-eed8-4f74-8d42-a32c3003b76b","url":"https://www.healio.com/news/cardiology/20230621/ai-algorithm-for-detection-of-cardiac-amyloidosis-gains-fda-breakthrough-device-status"},"article":[],"slices":[],"seoTitle":"Anumana's Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag","seoDescription":"Fierce Biotech: For the fourth time in half as many years, Anumana has earned the FDA’s breakthrough device designation for another of its artificial intelligence algorithms designed to catch hard-to-spot heart conditions in their earliest stages.","socialImage":{}}},{"id":"Y_To4BAAACUAPXZy","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y_To4BAAACUAPXZy%22%29+%5D%5D","tags":[],"first_publication_date":"2023-02-21T15:55:10+0000","last_publication_date":"2025-01-20T09:38:50+0000","slugs":["global-electrophysiology-devices-market-to-surpass-us-20069.2-million-by-2030-says-coherent-market-insights-cmi"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Global Electrophysiology Devices Market to Surpass US$ 20,069.2 Million by 2030, Says Coherent Market Insights (CMI)","spans":[]}],"published":"Features","summary":[{"type":"paragraph","text":"Coherent Market Insights: The global electrophysiology devices market is expected to exhibit a CAGR of 12.6% during the forecast period due to the increasing organic strategies such as acquisition by the key market players. For instance, in November 2022, anumana, Inc., a health technology company, announced that they had acquired NeuTrace, a medical technology company. This acquisition will help anumana, Inc., for the development of electrophysiology platform.","spans":[]}],"date":"2023-02-14T19:30:00+0000","image":{"dimensions":{"width":6000,"height":4000},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/b9e7a9d8-579b-4a42-a042-b8a0fcf2b728_iStock-1371157703.jpg?auto=compress,format","id":"Y6M_YRcAACoAmMgo","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"64ef5159-9e72-46db-9ce3-c5daf727ce89","url":"https://www.globenewswire.com/en/news-release/2023/02/14/2607732/0/en/Global-Electrophysiology-Devices-Market-to-Surpass-US-20-069-2-Million-by-2030-Says-Coherent-Market-Insights-CMI.html"},"article":[],"slices":[],"seoTitle":"Global Electrophysiology Devices Market to Surpass US$ 20,069.2 Million by 2030, Says Coherent Market Insights (CMI)","seoDescription":"Coherent Market Insights: The global electrophysiology devices market is expected to exhibit a CAGR of 12.6% during the forecast period due to the increasing organic strategies such as acquisition by the key market players. For instance, in November 2022, anumana, Inc., a health technology company, announced that they had acquired NeuTrace, a medical technology company. This acquisition will help anumana, Inc., for the development of electrophysiology platform.","socialImage":{}}},{"id":"Y5ygxBcAACgAjoPj","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5ygxBcAACgAjoPj%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-16T16:46:58+0000","last_publication_date":"2025-01-20T09:38:02+0000","slugs":["pfizer-and-anumana-boost-detection-of-cardiovascular-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Pfizer and Anumana boost detection of cardiovascular disease","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/deb3bd27-d5d3-4033-970e-c4eeb36e00a9_iStock-1273839908.jpeg?auto=compress,format","id":"Ytea4RAAACIADrQE","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"d2912977-a648-4466-9219-67e2c256246c","url":"https://www.pharmatimes.com/news/pfizer_and_anumana_boost_detection_of_cardiovascular_disease_1483097"},"article":[],"slices":[],"seoTitle":"Pfizer and Anumana boost detection of cardiovascular disease","seoDescription":"Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.","socialImage":{}}},{"id":"Y5yhCBcAACkAjoRu","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5yhCBcAACkAjoRu%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-16T16:52:50+0000","last_publication_date":"2025-01-20T09:37:54+0000","slugs":["pfizer-anumana-team-up-to-develop-ai-algorithm-for-cardiac-amyloidosis-detection"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the early detection of cardiac amyloidosis. Under the agreement, Anumana will research and pursue FDA De Novo classification for an algorithm that could find signals within electrocardiograms (ECGs) that hint at the condition. The partners also aim to gain regulatory clearance in Europe and Japan.","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/82553824-12ac-40e8-846c-2e420fd87298_iStock-1304967852.jpeg?auto=compress,format","id":"YtbpjBAAACEAC5nd","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"a7510c57-0d6c-48c5-96d2-36b2db8f2b2d","url":"https://www.mobihealthnews.com/news/pfizer-anumana-team-develop-ai-algorithm-cardiac-amyloidosis-detection"},"article":[],"slices":[],"seoTitle":"Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection","seoDescription":"Mobi Health News: Anumana, a joint venture between EHR data company nference and the Mayo Clinic, entered into a multiyear partnership with Pfizer to develop an AI-based tool for the early detection of cardiac amyloidosis. Under the agreement, Anumana will research and pursue FDA De Novo classification for an algorithm that could find signals within electrocardiograms (ECGs) that hint at the condition. The partners also aim to gain regulatory clearance in Europe and Japan.","socialImage":{}}},{"id":"Y5tTwhcAACgAiQV3","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5tTwhcAACgAiQV3%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-15T17:06:42+0000","last_publication_date":"2025-01-20T09:38:06+0000","slugs":["anumana-and-pfizer-partner-to-enable-early-detection-of-underdiagnosed-cardiovascular-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"BioSpace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm (AI-ECG) designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device (SaMD) and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe, and Japan.","spans":[]}],"date":"2022-12-15T19:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/1d8bbd56-972d-431d-aea8-c1752e772593_iStock-1211854748.jpeg?auto=compress,format","id":"YteKFRAAACEADmhe","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"306d4828-f672-4317-bf13-6289dc6b4f7f","url":"https://www.biospace.com/article/releases/anumana-and-pfizer-partner-to-enable-early-detection-of-underdiagnosed-cardiovascular-disease/?s=61"},"article":[],"slices":[],"seoTitle":"Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease","seoDescription":"BioSpace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm (AI-ECG) designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device (SaMD) and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe, and Japan.","socialImage":{}}},{"id":"YtePKxAAACAADn8c","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtePKxAAACAADn8c%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:14:21+0000","last_publication_date":"2025-01-20T09:37:51+0000","slugs":["fda-grants-breakthrough-device-designation-to-anumanas-ecg-pulmonary-hypertension-early-detection-ai-algorithm"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening disease","spans":[{"start":0,"end":196,"type":"em"}]}],"date":"2022-05-23T18:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening disease","spans":[{"start":0,"end":196,"type":"em"}]},{"type":"paragraph","text":"CAMBRIDGE, Mass., May 24, 2022 – Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to its AI-enhanced, ECG-based Pulmonary Hypertension (PH) Early Detection Algorithm. The algorithm is a precise, non-invasive screening tool that addresses an unmet need for earlier diagnosis of patients with pulmonary hypertension, which may otherwise go unnoticed until the disease has advanced, delaying treatment initiation, thereby limiting treatment efficacy and adversely impacting patient outcomes.","spans":[{"start":0,"end":17,"type":"strong"},{"start":18,"end":30,"type":"strong"},{"start":92,"end":100,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/"}}]},{"type":"paragraph","text":"FDA Breakthrough Device Designation recognizes novel innovations that demonstrate the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases and helps to accelerate the regulatory process.","spans":[]},{"type":"paragraph","text":"“Electrophysiology waveforms hold immense untapped potential for detecting diseases earlier in their natural history, particularly for conditions in which earlier diagnosis and therapeutic intervention can prolong survival and improve quality of life,” said Venky Soundararajan, PhD, co-founder and Chief Scientific Officer of Anumana and nference. “The FDA's Breakthrough Device Designation for Anumana's PH Early Detection Algorithm is one step forward for the field of ECG AI overall, and more saliently, a giant leap forward for PH patients.”","spans":[]},{"type":"paragraph","text":"PH is a progressive, life-threatening disease estimated to affect up to 0.1-1% of the global population.1,2 Due to the non-specific symptoms of the disease, such as shortness of breath, diagnostic delays are common3,4,5, often longer than a year, and have been linked with a higher mortality risk in certain patient subgroups.6,7","spans":[{"start":104,"end":107,"type":"label","data":{"label":"superscript"}},{"start":214,"end":219,"type":"label","data":{"label":"superscript"}},{"start":326,"end":329,"type":"label","data":{"label":"superscript"}}]},{"type":"paragraph","text":"Anumana’s AI-enhanced ECG algorithm is designed to easily and safely detect PH at an earlier stage, by leveraging the widespread availability of 12-lead ECGs in primary care, urgent care, and emergency room settings. The AI-enhanced ECG PH Algorithm is enabled by the nference platform, which provides insight from more than 6 million de-identified patient records, including over 8 million ECGs. It was developed through a collaboration between data scientists and physicians at Anumana, Janssen Research & Development, LLC, and Mayo Clinic. Supported by Mayo Clinic Platform, nference launched Anumana in 2021 to develop and commercialize AI-enabled algorithms.","spans":[{"start":489,"end":524,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.janssen.com/"}},{"start":530,"end":541,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.mayoclinic.org/"}},{"start":556,"end":576,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.mayoclinicplatform.org/"}}]},{"type":"paragraph","text":"If approved, the early detection algorithm will be offered as Software as a Medical Device (SaMD) that can be downloaded on a physician’s smartphone, tablet, or computer, or accessed via the Cloud through an Electronic Health Record or ECG Information Management System interface. Using a standard 12-lead ECG, the algorithm analyzes the voltage-time data and within seconds provides a prediction of likelihood of PH, reducing the time between initial symptoms and the first evaluation for PH via targeted cardiac imaging. This early detection algorithm is still in development and not yet approved for clinical use.\n \n“While therapeutic options for patients with pulmonary hypertension have evolved in recent years, we have not seen significant advancement in reducing the time from symptom onset to diagnosis – and our hypothesis was that data science could help change this,” said Najat Khan, PhD, Chief Data Science Officer and Global Head, Strategy and Operations, Janssen Research & Development, LLC. “We leveraged the power of artificial intelligence, the ingenuity of our data scientists and researchers, and deep collaboration to co-develop this AI-based innovation, with the ultimate goal of helping to improve patient outcomes and transform the trajectory of this devastating disease.”\n \n“Early diagnosis of pulmonary hypertension is paramount due to its progression and potential severity,” said Paul Friedman, M.D., chair of the Department of Cardiovascular Medicine at Mayo Clinic. “The addition of AI to a standard ECG – a painless, inexpensive, widely used test that is routinely performed – transforms the ECG into a screening tool for PH, with the opportunity to improve outcomes via early detection by guiding appropriate testing.”","spans":[{"start":970,"end":1005,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.janssen.com/"}}]},{"type":"paragraph","text":"The Pulmonary Hypertension Early Detection Algorithm is the company’s second technology to receive FDA Breakthrough Device Designation. Its low ejection fraction algorithm, developed by Mayo Clinic and licensed by Anumana, received Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Anumana has a large pipeline of novel algorithms that have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for FDA medical device approval.","spans":[{"start":425,"end":437,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/publications"}},{"start":550,"end":565,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.nature.com/articles/s41591-021-01335-4"}},{"start":550,"end":566,"type":"em"}]},{"type":"paragraph","text":"About Anumana\nAnumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic, and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs, improving outcomes, and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance. For more information, visit anumana.ai and follow Anumana on LinkedIn & Twitter.","spans":[{"start":0,"end":14,"type":"strong"},{"start":972,"end":980,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.linkedin.com/company/anumana-inc"}},{"start":983,"end":990,"type":"hyperlink","data":{"link_type":"Web","url":"https://twitter.com/anumanainc"}}]},{"type":"paragraph","text":"About nference\nThrough its powerful technology platform and software, nference is transforming health care by making biomedical knowledge computable. Its partnership with Mayo Clinic has given nference an opportunity to synthesize more than 100 years of institutional knowledge, producing real-world evidence in real time by converting large amounts of data into deep insights to advance discovery and development of diagnostics and therapeutics. nference is headquartered in Cambridge, Mass. Follow nference on LinkedIn and Twitter. Visit us at nference.com.","spans":[{"start":0,"end":14,"type":"strong"},{"start":6,"end":14,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/"}},{"start":512,"end":520,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.linkedin.com/company/nference/"}},{"start":525,"end":532,"type":"hyperlink","data":{"link_type":"Web","url":"https://twitter.com/_nference"}}]},{"type":"paragraph","text":"","spans":[]},{"type":"paragraph","text":"Media Contact","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Anumana ","spans":[]},{"type":"paragraph","text":"Andrea Sampson, Sampson Public Relations Group","spans":[]},{"type":"paragraph","text":"asampson@sampsonprgroup.com","spans":[]},{"type":"paragraph","text":"+1 562.304.0301","spans":[]},{"type":"paragraph","text":"","spans":[]},{"type":"paragraph","text":"References:","spans":[{"start":0,"end":11,"type":"strong"}]},{"type":"o-list-item","text":"Wijeratne DT, Lajkosz K, Brogly SB, et al. Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension. Circ Cardiovasc Qual Outcomes. 2018;11(2):e003973. doi:10.1161/CIRCOUTCOMES.117.003973","spans":[]},{"type":"o-list-item","text":"Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306-322. doi:10.1016/S2213-2600(15)00543-3","spans":[]},{"type":"o-list-item","text":"Armstrong I, Billings C, Kiely DG, et al. The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients. BMC Pulm Med 2019: 19: 67.","spans":[]},{"type":"o-list-item","text":"Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. Chest 2011: 140: 19-26.","spans":[]},{"type":"o-list-item","text":"Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987: 107: 216-223.","spans":[]},{"type":"o-list-item","text":"Khou V, Anderson JJ, Strange G, et al. Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry. Respirol Carlton Vic. 2020;25(8):863-871. doi:10.1111/resp.13768","spans":[]},{"type":"o-list-item","text":"Klok FA, Barco S, Konstantinides SV, et al. Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. Eur Respir J. 2018;52(6):1801687. doi:10.1183/13993003.01687-2018","spans":[]}],"slices":[],"seoTitle":"FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm","seoDescription":"Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening disease","socialImage":{}}},{"id":"YteqcBAAACEADvpY","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteqcBAAACEADvpY%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:10:43+0000","last_publication_date":"2025-01-20T09:36:12+0000","slugs":["promising-ai-clinical-use-cases-beyond-imaging"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Promising AI clinical use cases beyond imaging","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Health Evolution: Researchers in Future Healthcare Journal say that while there are claims from organizations that they’ve developed an AI solution that can “diagnose and treat a disease with equal or greater accuracy than human clinicians,” most of them are based on radiological image analysis. A survey of health care leaders found that while 58 percent are using AI in clinical practice, the most common applications are all related to imaging. ","spans":[{"start":33,"end":59,"type":"em"}]}],"date":"2021-11-09T18:30:00+0000","image":{"dimensions":{"width":1297,"height":809},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/6065a2ef-be32-416c-a0d0-47f09f11e803_iStock-1365534802.jpeg?auto=compress,format","id":"YtekgBAAACIADt_k","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"f098e82c-f1c3-412a-958c-7baaf4163f57","url":"https://www.healthevolution.com/insider/promising-ai-clinical-use-cases-beyond-imaging/"},"article":[],"slices":[],"seoTitle":"Promising AI clinical use cases beyond imaging","seoDescription":"Health Evolution: Researchers in Future Healthcare Journal say that while there are claims from organizations that they’ve developed an AI solution that can “diagnose and treat a disease with equal or greater accuracy than human clinicians,” most of them are based on radiological image analysis. A survey of health care leaders found that while 58 percent are using AI in clinical practice, the most common applications are all related to imaging.","socialImage":{}}},{"id":"Y6M9NRcAACoAmMRB","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y6M9NRcAACoAmMRB%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-21T17:08:08+0000","last_publication_date":"2025-01-20T09:38:45+0000","slugs":["ai-specialists-ink-deal-with-pfizer-to-target-cardiac-amyloidosis"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"AI specialists ink deal with Pfizer to target cardiac amyloidosis","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac amyloidosis. The groups will work to develop a new AI algorithm capable of identifying signs of cardiac amyloidosis—a significant heart issue that can lead to heart failure—in electrocardiogram (ECG) results.","spans":[]}],"date":"2022-12-20T19:30:00+0000","image":{"dimensions":{"width":1359,"height":771},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/cb216372-203a-4332-993d-e007a78681a6_iStock-1127069581.jpeg?auto=compress,format","id":"YtehMhAAACMADtD-","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"58ff5f89-c008-4387-a00f-91fc1f2b0ca9","url":"https://cardiovascularbusiness.com/topics/clinical/heart-failure/ai-specialists-ink-deal-pfizer-target-cardiac-amyloidosis"},"article":[],"slices":[],"seoTitle":"AI specialists ink deal with Pfizer to target cardiac amyloidosis","seoDescription":"Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac amyloidosis. The groups will work to develop a new AI algorithm capable of identifying signs of cardiac amyloidosis—a significant heart issue that can lead to heart failure—in electrocardiogram (ECG) results.","socialImage":{}}},{"id":"YtepGxAAACIADvRC","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtepGxAAACIADvRC%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:05:02+0000","last_publication_date":"2025-01-20T09:34:39+0000","slugs":["mayo-clinic-platform-aids-clinical-decisions"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic platform aids clinical decisions","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"IMC Newsdesk: Mayo Clinic has developed health technology to deliver clinical decision support tools, diagnostic insights and care recommendations so clinicians can make faster and more accurate diagnoses and provide continuous care to patients.","spans":[]}],"date":"2021-04-19T18:30:00+0000","image":{"dimensions":{"width":1253,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/d3cd427c-e0a0-469a-ace5-b30b3b9559e6_iStock-1253858296.jpeg?auto=compress,format","id":"YtepERAAACEADvQV","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"997e2e28-5f21-4e87-a7d4-b5ad07a79931","url":"https://www.iotm2mcouncil.org/iot-library/news/connected-health-news/mayo-clinic-platform-aids-clinical-decisions/"},"article":[],"slices":[],"seoTitle":"Mayo Clinic platform aids clinical decisions","seoDescription":"IMC Newsdesk: Mayo Clinic has developed health technology to deliver clinical decision support tools, diagnostic insights and care recommendations so clinicians can make faster and more accurate diagnoses and provide continuous care to patients.","socialImage":{}}},{"id":"Y5yorhcAAHL-jpFq","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5yorhcAAHL-jpFq%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-16T17:20:57+0000","last_publication_date":"2025-01-20T09:37:17+0000","slugs":["pfizer-to-partner-with-mayo-clinic-spinoff-on-early-cardiac-amyloidosis-detection"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition. Anumana plans to conduct a clinical trial validating the algorithm and seek de novo clearance in the U.S. It also will seek regulatory approval in Europe and Japan.","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1277,"height":822},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a0bf0dd9-77fe-4cdf-ba56-ac79c3717b49_iStock-1367729537.jpeg?auto=compress,format","id":"YteJrBAAACMADmaJ","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"d3426165-b93e-4985-b74f-c658c039c2e6","url":"https://www.medtechdive.com/news/anumana-mayo-clinic-pfizer-cardiac-amyloidosis-algorithm/638978/"},"article":[],"slices":[],"seoTitle":"Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection","seoDescription":"Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition. Anumana plans to conduct a clinical trial validating the algorithm and seek de novo clearance in the U.S. It also will seek regulatory approval in Europe and Japan.","socialImage":{}}},{"id":"ZBhUQBAAACIAZrpK","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZBhUQBAAACIAZrpK%22%29+%5D%5D","tags":[],"first_publication_date":"2023-03-20T13:48:57+0000","last_publication_date":"2025-01-20T09:39:02+0000","slugs":["anumana-named-to-fierce-medtechs-2022-fierce-15"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Named to Fierce Medtech’s 2022 Fierce 15","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac care","spans":[{"start":0,"end":93,"type":"em"}]}],"date":"2023-03-20T18:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac care","spans":[{"start":0,"end":93,"type":"em"}]},{"type":"paragraph","text":"CAMBRIDGE, Mass., March 20, 2023 – Anumana, an AI-driven health technology company and portfolio company of nference, has been named one of Fierce Medtech’s 2022 Fierce 15. This prestigious honor indicates that the two-year-old company is well-positioned to transform cardiac care by leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart.","spans":[{"start":0,"end":35,"type":"strong"},{"start":35,"end":42,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai"}},{"start":108,"end":116,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/"}},{"start":140,"end":171,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.fiercebiotech.com/medtech/fierce-medtechs-2022-fierce-15"}}]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"“We are honored to be recognized as one of the Medtech Fierce 15 companies for 2022,” said David McMullin, Chief Business Officer of Anumana. “Anumana’s goal is to decode electrical signals from the heart as never before, empowering healthcare providers to improve patient care throughout the cardiac clinical pathway. We are excited to continue developing innovative solutions to the most pressing challenges facing cardiovascular disease diagnosis, treatment, and management.” ","spans":[]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"Powered by nference’s nSights data platform, Anumana leverages ECG waveforms from the heart with deep, longitudinal electronic medical records (EMR) data at the patient level, developing state-of-the-art algorithms aimed to help physicians diagnose and treat cardiac disease earlier and more efficiently. Nference, which partners with leading healthcare systems such as Mayo Clinic and Duke Health, makes real-world data available includes multiple data modalities (clinical, molecular, and imaging). ","spans":[{"start":22,"end":43,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/nsights","target":"_blank"}}]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"Anumana’s algorithms for early detection of low ejection fraction, pulmonary hypertension, and hyperkalemia, have received Breakthrough Device Designation from the U.S. FDA. Its robust pipeline of FDA-ready algorithms has been validated with significant prospective clinical evidence in over 75 peer-reviewed publications - including two first-of-their-kind studies published in Nature Medicine and The Lancet. Anumana develops these algorithms in collaboration with the Mayo Clinic Platform and has received sponsorship from strategic pharmaceutical leaders such as Janssen,  Novartis, and Pfizer to further develop and commercialize ECG-AI algorithms.","spans":[{"start":379,"end":394,"type":"em"},{"start":379,"end":394,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.nature.com/articles/s41591-021-01335-4"}},{"start":399,"end":409,"type":"em"},{"start":399,"end":409,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01637-3/fulltext"}},{"start":471,"end":491,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.mayoclinicplatform.org/"}},{"start":567,"end":574,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePKxAAACAADn8c"}},{"start":577,"end":585,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/YtePpxAAACEADoFR"}},{"start":591,"end":597,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/Y5otrRcAACkAg7NW"}}]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"Anumana’s AI platform utilizes widely accessible screening tools and is built to seamlessly integrate into existing clinical workflows, providing clinicians with real-time insights, accelerating the time to guideline-directed medical therapy, reducing costs, and improving patient outcomes. Anumana seeks regulatory clearances for the platform as software as a medical device (SaMD) and has early milestones for reimbursement in place with two Category III CPT® codes that became effective January 1st, 2023. ","spans":[]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"Fierce Medtech’s Fierce 15, launched in 2012, is an annual special report that spotlights the most exciting startups in medtech. This year’s report features the 15 medtech startups that made the biggest splashes in 2022 and aimed to pick the players they think are “the most capable of delivering on their promises to advance the art and science of healthcare.”","spans":[]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"About Anumana","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Anumana, an AI-driven health technology company and portfolio company of nference, is leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI insights. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance. For more information, visit anumana.ai and follow Anumana on LinkedIn and Twitter.","spans":[{"start":73,"end":81,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nference.com%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=nference&index=5&md5=a0f9300b3092d80a5263a979c50853a8"}},{"start":935,"end":945,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.anumana.ai%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=anumana.ai&index=6&md5=fa195867fefb37c7ccf35a5a2184e240"}},{"start":968,"end":976,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d"}},{"start":981,"end":988,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83"}}]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"Media Contact:","spans":[{"start":0,"end":14,"type":"strong"}]},{"type":"paragraph","text":"Sam Choinski","spans":[]},{"type":"paragraph","text":"Pazanga Health Communications for Anumana","spans":[]},{"type":"paragraph","text":"schoinski@pazangahealth.com","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:schoinski@pazangahealth.com"}}]},{"type":"paragraph","text":"(860) 301-5058","spans":[]}],"slices":[],"seoTitle":"Anumana Named to Fierce Medtech’s 2022 Fierce 15","seoDescription":"AI-driven startup from nference and Mayo Clinic Platform positioned to transform cardiac care","socialImage":{}}},{"id":"YtemoBAAACEADulm","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtemoBAAACEADulm%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:54:27+0000","last_publication_date":"2025-01-20T09:32:54+0000","slugs":["mayo-clinic-launches-new-technology-platform-ventures-to-revolutionize-diagnostic-medicine"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches new technology platform ventures to revolutionize diagnostic medicine","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Mayo Clinic News Network: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide truly continuous care to patients. The Remote Diagnostics and Management Platform (RDMP) connects data with innovative new artificial intelligence (AI) algorithms and augments human decision-making within existing clinical workflows. RDMP enables \"event-driven medicine,\" providing insights in the right context, at the right time.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/b4a3c218-4795-49b1-bc73-0ccb0698564f_iStock-1298626492.jpeg?auto=compress,format","id":"YteVKBAAACMADppM","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"2d1d5890-a574-4918-a746-4884d01a87ea","url":"https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-launches-new-technology-platform-ventures-to-revolutionize-diagnostic-medicine/"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches new technology platform ventures to revolutionize diagnostic medicine","seoDescription":"Mayo Clinic News Network: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide truly continuous care to patients. The Remote Diagnostics and Management Platform (RDMP) connects data with innovative new artificial intelligence (AI) algorithms and augments human decision-making within existing clinical workflows. RDMP enables \"event-driven medicine,\" providing insights in the right context, at the right time.","socialImage":{}}},{"id":"Y3J7RxQAAN3P3raM","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y3J7RxQAAN3P3raM%22%29+%5D%5D","tags":[],"first_publication_date":"2022-11-14T17:31:59+0000","last_publication_date":"2025-01-20T09:37:47+0000","slugs":["ai-transforms-smartwatch-ecg-signals-into-a-diagnostic-tool-for-heart-failure"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"AI transforms smartwatch ECG signals into a diagnostic tool for heart failure","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Mayo Clinic News Network: Two health tech advances are at the heart of a study published in Nature Medicine: an app and backend infrastructure to let patients remotely share smartwatch ECG data with their clinicians in an easy and secure way, and the modification of a proven 12-lead ECG artificial intelligence (AI) algorithm to enable it to run on a single-lead watch ECG recording.","spans":[]}],"date":"2022-11-14T19:30:00+0000","image":{"dimensions":{"width":1253,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/67866ecc-81c7-4da0-8d57-33a0c7bdfaf5_iStock-1347259240.jpeg?auto=compress,format","id":"YteaVxAAACMADrGV","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"775bac8b-50b7-4971-a779-4913a3569a55","url":"https://www.beckershospitalreview.com/innovation/mayo-clinic-platform-portfolio-company-buys-ai-electrophysiology-startup.html"},"article":[],"slices":[],"seoTitle":"AI transforms smartwatch ECG signals into a diagnostic tool for heart failure","seoDescription":"Mayo Clinic News Network: Two health tech advances are at the heart of a study published in Nature Medicine: an app and backend infrastructure to let patients remotely share smartwatch ECG data with their clinicians in an easy and secure way, and the modification of a proven 12-lead ECG artificial intelligence (AI) algorithm to enable it to run on a single-lead watch ECG recording.","socialImage":{}}},{"id":"YtesiRAAACIADwJl","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtesiRAAACIADwJl%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:19:40+0000","last_publication_date":"2025-01-20T09:36:43+0000","slugs":["new-study-demonstrates-value-of-ai-enabled-ekg-algorithm-in-routine-practice"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"New Study Demonstrates Value of AI-Enabled EKG Algorithm in Routine Practice","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"AZO Robotics: The EAGLE—short for ECG AI-Guided Screening for Low Ejection Fraction—trial attempted to establish whether an artificial intelligence (AI) screening tool designed to spot low ejection fraction through EKG data could enhance the diagnosis of this medical disorder in regular practice. The results of the study have been published in the Nature Medicine journal.","spans":[{"start":350,"end":365,"type":"em"}]}],"date":"2021-05-06T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/e37309ce-a288-4f40-b8be-ada481ef9435_iStock-1331445923.jpeg?auto=compress,format","id":"YtesghAAACIADwJA","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"b857dcd3-a621-4643-97e6-2ecacd9a647e","url":"https://www.azorobotics.com/News.aspx?newsID=12233"},"article":[],"slices":[],"seoTitle":"New Study Demonstrates Value of AI-Enabled EKG Algorithm in Routine Practice","seoDescription":"AZO Robotics: The EAGLE—short for ECG AI-Guided Screening for Low Ejection Fraction—trial attempted to establish whether an artificial intelligence (AI) screening tool designed to spot low ejection fraction through EKG data could enhance the diagnosis of this medical disorder in regular practice. The results of the study have been published in the Nature Medicine journal.","socialImage":{}}},{"id":"YterEBAAACIADvzW","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YterEBAAACIADvzW%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:13:23+0000","last_publication_date":"2025-01-20T09:36:20+0000","slugs":["trial-demonstrates-early-ai-guided-detection-of-heart-disease-in-routine-practice"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Trial demonstrates early AI-guided detection of heart disease in routine practice","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"EurekAlert: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early stages when treatment would be most effective. The ECG AI-Guided Screening for Low Ejection Fraction, or EAGLE, trial set out to determine whether an artificial intelligence (AI) screening tool developed to detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.","spans":[{"start":539,"end":554,"type":"em"}]}],"date":"2021-04-18T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/1d8bbd56-972d-431d-aea8-c1752e772593_iStock-1211854748.jpeg?auto=compress,format","id":"YteKFRAAACEADmhe","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"4bf83dde-66b0-44f4-994a-c166850eb783","url":"https://www.eurekalert.org/news-releases/491340"},"article":[],"slices":[],"seoTitle":"Trial demonstrates early AI-guided detection of heart disease in routine practice","seoDescription":"EurekAlert: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early stages when treatment would be most effective. The ECG AI-Guided Screening for Low Ejection Fraction, or EAGLE, trial set out to determine whether an artificial intelligence (AI) screening tool developed to detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.","socialImage":{}}},{"id":"Y5ykhhcAACoAjopw","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5ykhhcAACoAjopw%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-16T17:05:08+0000","last_publication_date":"2025-01-20T09:37:58+0000","slugs":["anumana--pfizer-partner-on-amyloidosis-ai-ecg-algorithm-development"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm (AI-ECG) designed to enable the early identification of patients who may be at risk of cardiac amyloidosis.","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/1d8bbd56-972d-431d-aea8-c1752e772593_iStock-1211854748.jpeg?auto=compress,format","id":"YteKFRAAACEADmhe","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"f10c99af-949f-49bb-965a-ff3c98bb35d2","url":"https://www.mobihealthnews.com/news/pfizer-anumana-team-develop-ai-algorithm-cardiac-amyloidosis-detection"},"article":[],"slices":[],"seoTitle":"Anumana & Pfizer Partner on Amyloidosis AI-ECG Algorithm Development","seoDescription":"HIT Consultant: Anumana, an AI-driven health technology company and portfolio company of nference, today announced a multi-year agreement with Pfizer for Anumana to develop an investigational artificial intelligence electrocardiogram algorithm (AI-ECG) designed to enable the early identification of patients who may be at risk of cardiac amyloidosis.","socialImage":{}}},{"id":"Y5ypgxcAACgAjpLS","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5ypgxcAACgAjpLS%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-16T17:49:01+0000","last_publication_date":"2025-01-20T09:38:22+0000","slugs":["new-project-trains-ai-on-a-hard-to-diagnose-cardiac-issue"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"New Project Trains AI on a Hard-to-Diagnose Cardiac Issue","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Health Leaders: A start-up from the Mayo Clinic orbit is partnering with Pfizer to develop an AI-enhanced ECG that can detect cardiac amyloidosis, a progressive disease that's difficult to diagnose early.","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1355,"height":774},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/085e8fa4-0b8f-4dca-93a5-204d217847e9_iStock-1290220631.jpeg?auto=compress,format","id":"YteLlhAAACIADm8P","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"37cd2bbd-a3ed-4c47-a945-7ebab3d4f932","url":"https://www.healthleadersmedia.com/technology/new-project-trains-ai-hard-diagnose-cardiac-issue"},"article":[],"slices":[],"seoTitle":"New Project Trains AI on a Hard-to-Diagnose Cardiac Issue","seoDescription":"Health Leaders: A start-up from the Mayo Clinic orbit is partnering with Pfizer to develop an AI-enhanced ECG that can detect cardiac amyloidosis, a progressive disease that's difficult to diagnose early.","socialImage":{}}},{"id":"Yteh9hAAACMADtR6","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Yteh9hAAACMADtR6%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:34:32+0000","last_publication_date":"2025-01-20T09:32:25+0000","slugs":["mayo-clinic-launches-two-new-tech-companies"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches two new tech companies","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"JHC Online: Mayo Clinic has announced a new technology platform initiative to new clinical decision support tools, diagnostic insights, and care recommendations to help clinicians make faster and more accurate diagnoses and provide continuous care to patients.","spans":[]}],"date":"2021-11-09T18:30:00+0000","image":{"dimensions":{"width":1445,"height":725},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/c8df9b92-afa8-4e5e-90e9-5539e410b4d6_iStock-1182619271.jpeg?auto=compress,format","id":"Yteh8RAAACAADtRm","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"7f9a3b19-51a8-45fc-8122-710346982b5f","url":"https://www.jhconline.com/mayo-clinic-launches-two-new-tech-companies.html"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches two new tech companies","seoDescription":"JHC Online: Mayo Clinic has announced a new technology platform initiative to new clinical decision support tools, diagnostic insights, and care recommendations to help clinicians make faster and more accurate diagnoses and provide continuous care to patients.","socialImage":{}}},{"id":"YterbRAAACEADv2M","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YterbRAAACEADv2M%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:14:56+0000","last_publication_date":"2025-01-20T09:36:31+0000","slugs":["mayo-clinic-launches-two-new-companies"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches two new companies","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"DotMed: Mayo Clinic has launched two new companies to support its new technology initiative, the Remote Diagnostics and Management Platform. The solution applies artificial intelligence to derive insights from data and uses these findings to support human decision-making within existing clinical workflows. It supports “event-driven medicine” by aiming to provide insights in the right context at the right time.","spans":[]}],"date":"2021-04-18T18:30:00+0000","image":{"dimensions":{"width":1258,"height":834},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/b3368457-14a3-49a5-8a55-091bde35345d_iStock-536078501.jpeg?auto=compress,format","id":"YtechBAAACMADrti","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"53dbc569-9e4a-4b68-ab87-8f07b47e29c9","url":"https://www.dotmed.com/news/story/54546"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches two new companies","seoDescription":"DotMed: Mayo Clinic has launched two new companies to support its new technology initiative, the Remote Diagnostics and Management Platform. The solution applies artificial intelligence to derive insights from data and uses these findings to support human decision-making within existing clinical workflows. It supports “event-driven medicine” by aiming to provide insights in the right context at the right time.","socialImage":{}}},{"id":"Ytem8RAAACMADurV","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Ytem8RAAACMADurV%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:55:48+0000","last_publication_date":"2025-01-20T09:33:06+0000","slugs":["mayo-clinic-launches-two-companies-to-support-new-remote-monitoring-initiative"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic Launches Two Companies To Support New Remote Monitoring Initiative","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Medtech Insight: The Minnesota-based health care system announced the formation of Anumana Inc. to commercialize artificial intelligence-enabled algorithms and Lucem Health to curate data collected from remote monitoring devices.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1258,"height":834},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/b3368457-14a3-49a5-8a55-091bde35345d_iStock-536078501.jpeg?auto=compress,format","id":"YtechBAAACMADrti","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"c0e6df6d-93ce-420e-87be-ee430adb5aa8","url":"https://medtech.pharmaintelligence.informa.com/MT143786/Mayo-Clinic-Launches-Two-Companies-To-Support-New-Remote-Monitoring-Initiative"},"article":[],"slices":[],"seoTitle":"Mayo Clinic Launches Two Companies To Support New Remote Monitoring Initiative","seoDescription":"Medtech Insight: The Minnesota-based health care system announced the formation of Anumana Inc. to commercialize artificial intelligence-enabled algorithms and Lucem Health to curate data collected from remote monitoring devices.","socialImage":{}}},{"id":"YtejFxAAACIADtmY","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtejFxAAACIADtmY%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:39:22+0000","last_publication_date":"2025-01-20T09:32:44+0000","slugs":["startup-health-insights-virta--1doc3-close-rounds-over-1.4b-raised-this-week"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"StartUp Health Insights: Virta & 1Doc3 Close Rounds, Over $1.4B Raised This Week","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Health Transformer: Anumana, a startup designing neural network algorithms to enable early detection and accelerate treatment of heart disease, raised $25.7M led by founders nference and Mayo Clinic, with participation from Matrix Capital Management, Matrix Partners, and NTTVC. ","spans":[]}],"date":"2021-04-20T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/800d74b8-286d-4f01-a8be-62b4b6a3dbff_iStock-1327128846.jpeg?auto=compress,format","id":"YtejExAAACMADtmF","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"666c9e1a-2f83-40ea-97fe-c553c24fa1e5","url":"https://healthtransformer.co/startup-health-insights-virta-1doc3-close-rounds-over-1-4b-raised-this-week-week-4-21-2021-ca892c2add7f"},"article":[],"slices":[],"seoTitle":"StartUp Health Insights: Virta & 1Doc3 Close Rounds, Over $1.4B Raised This Week","seoDescription":"Health Transformer: Anumana, a startup designing neural network algorithms to enable early detection and accelerate treatment of heart disease, raised $25.7M led by founders nference and Mayo Clinic, with participation from Matrix Capital Management, Matrix Partners, and NTTVC.","socialImage":{}}},{"id":"YteQYhAAACMADoSc","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteQYhAAACMADoSc%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:19:34+0000","last_publication_date":"2025-01-20T09:36:57+0000","slugs":["fda-grants-breakthrough-device-designation-to-pulmonary-hypertension-early-detection-ai"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"FDA grants Breakthrough Device Designation to pulmonary hypertension early detection AI","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Pharma File: Anumana has announced the FDA had granted breakthrough Device Designation to its AI-enhanced ECG-based Pulmonary Hypertension (PH) Early Detection Algorithm. Breakthrough Device Designations recognise novel innovations demonstrating potential to provide more effective treatment, or diagnosis for life-threatening or irreversibly debilitating diseases. The designation helps to accelerate the regulatory process.","spans":[]}],"date":"2022-05-24T18:30:00+0000","image":{"dimensions":{"width":1355,"height":774},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/085e8fa4-0b8f-4dca-93a5-204d217847e9_iStock-1290220631.jpeg?auto=compress,format","id":"YteLlhAAACIADm8P","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"d1b682c9-fc17-4c26-877e-fb2c0f5be549","url":"http://www.pharmafile.com/news/647973/fda-grants-breakthrough-device-designation-pulmonary-hypertension-early-detection-ai"},"article":[],"slices":[],"seoTitle":"FDA grants Breakthrough Device Designation to pulmonary hypertension early detection AI","seoDescription":"Pharma File: Anumana has announced the FDA had granted breakthrough Device Designation to its AI-enhanced ECG-based Pulmonary Hypertension (PH) Early Detection Algorithm. Breakthrough Device Designations recognise novel innovations demonstrating potential to provide more effective treatment, or diagnosis for life-threatening or irreversibly debilitating diseases. The designation helps to accelerate the regulatory process.","socialImage":{}}},{"id":"YteoBxAAACEADu-7","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteoBxAAACEADu-7%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:00:25+0000","last_publication_date":"2025-01-20T09:33:17+0000","slugs":["mayo-clinic-finds-algorithm-helped-clinicians-detect-heart-disease-as-part-of-broader-ai-diagnostics-push"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic finds algorithm helped clinicians detect heart disease, as part of broader AI diagnostics push","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Med City News: Mayo Clinic shared results of a study showing that an AI tool developed by the system could be used to improve diagnosis of low ejection fraction, a type of heart disease. It's part of a broader push by Mayo Clinic to commercialize AI-based diagnostic tools, starting with spinout company Anumana.","spans":[]}],"date":"2021-05-08T18:30:00+0000","image":{"dimensions":{"width":1541,"height":680},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/024327d9-3c38-468c-b533-07d4f1b4aef6_iStock-1182622521.jpeg?auto=compress,format","id":"YteoBBAAACEADu-w","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"b2534b93-b0d8-422f-87a3-6a8221b143f3","url":"https://medcitynews.com/2021/05/mayo-clinic-finds-algorithm-helped-clinicians-detect-heart-disease-as-part-of-broader-ai-diagnostics-push/"},"article":[],"slices":[],"seoTitle":"Mayo Clinic finds algorithm helped clinicians detect heart disease, as part of broader AI diagnostics push","seoDescription":"Med City News: Mayo Clinic shared results of a study showing that an AI tool developed by the system could be used to improve diagnosis of low ejection fraction, a type of heart disease. It's part of a broader push by Mayo Clinic to commercialize AI-based diagnostic tools, starting with spinout company Anumana.","socialImage":{}}},{"id":"Yv0JChYAACcAFP4W","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Yv0JChYAACcAFP4W%22%29+%5D%5D","tags":[],"first_publication_date":"2022-08-17T15:29:53+0000","last_publication_date":"2025-01-20T09:37:13+0000","slugs":["migraine-with-aura-identified-as-independent-risk-factor-for-a-fib"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Migraine with aura identified as independent risk factor for A-fib","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Medical Xpress: Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online June 8 in Headache. The study used Mayo Clinic developed algorithm for detecting atrial fibrillation, which is now licensed to Anumana. ","spans":[{"start":255,"end":263,"type":"em"}]}],"date":"2022-08-03T18:30:00+0000","image":{"dimensions":{"width":1357,"height":772},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a76dd04e-4aa9-416d-881c-4f7b1eea49e7_iStock-864472226.jpeg?auto=compress,format","id":"YteZkRAAACAADq4Z","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"6ce124d9-2910-423a-bd0d-1377765d219a","url":"https://medicalxpress.com/news/2022-08-migraine-aura-independent-factor-a-fib.html"},"article":[],"slices":[],"seoTitle":"Migraine with aura identified as independent risk factor for A-fib","seoDescription":"Medical Xpress: Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online June 8 in Headache. The study used Mayo Clinic developed algorithm for detecting atrial fibrillation, which is now licensed to Anumana.","socialImage":{}}},{"id":"YteVLRAAACIADppg","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteVLRAAACIADppg%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:40:00+0000","last_publication_date":"2025-01-20T09:37:07+0000","slugs":["anumanas-ecg-pulmonary-hypertension-ai-algorithm-gains-breakthrough-status"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana's ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Medical Product Outsourcing: Artificial intelligence (AI)-driven healthtech company, Anumana has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its AI-enhanced, ECG-based pulmonary hypertension (PH) early detection algorithm. The precise and non-invasive screening tool supports earlier PH diagnosis, which may otherwise not be noticed until the disease has advanced, delaying treatment and limiting efficacy while adversely impacting outcomes.","spans":[]}],"date":"2022-05-23T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/b4a3c218-4795-49b1-bc73-0ccb0698564f_iStock-1298626492.jpeg?auto=compress,format","id":"YteVKBAAACMADppM","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"fad12c64-99cc-40bd-b588-0689bda2acb6","url":"https://www.mpo-mag.com/contents/view_breaking-news/2022-05-24/anumanas-ecg-pulmonary-hypertension-ai-algorithm-gains-breakthrough-status/"},"article":[],"slices":[],"seoTitle":"Anumana's ECG Pulmonary Hypertension AI Algorithm Gains Breakthrough Status","seoDescription":"Medical Product Outsourcing: Artificial intelligence (AI)-driven healthtech company, Anumana has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its AI-enhanced, ECG-based pulmonary hypertension (PH) early detection algorithm. The precise and non-invasive screening tool supports earlier PH diagnosis, which may otherwise not be noticed until the disease has advanced, delaying treatment and limiting efficacy while adversely impacting outcomes.","socialImage":{}}},{"id":"YtefyxAAACAADsqP","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtefyxAAACAADsqP%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:25:18+0000","last_publication_date":"2025-01-20T09:36:50+0000","slugs":["mayo-clinic-helps-launch-two-new-companies-for-improved-diagnostics"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic helps launch two new companies for improved diagnostics","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Mass Device: Mayo Clinic announced that it is introducing a new technology platform to support two new companies it has launched. Rochester, Minn.–based Mayo Clinic’s Remote Diagnostics & Management Platform (RDMP) is designed to connect data with new AI algorithms and augment human decision-making within existing clinical workflows, according to a news release.","spans":[]}],"date":"2021-04-14T18:30:00+0000","image":{"dimensions":{"width":1355,"height":774},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/085e8fa4-0b8f-4dca-93a5-204d217847e9_iStock-1290220631.jpeg?auto=compress,format","id":"YteLlhAAACIADm8P","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"f30bc69d-7904-44dc-886a-2cae94f6fab7","url":"https://www.massdevice.com/mayo-clinic-helps-launch-two-new-companies-for-improved-diagnostics/"},"article":[],"slices":[],"seoTitle":"Mayo Clinic helps launch two new companies for improved diagnostics","seoDescription":"Mass Device: Mayo Clinic announced that it is introducing a new technology platform to support two new companies it has launched. Rochester, Minn.–based Mayo Clinic’s Remote Diagnostics & Management Platform (RDMP) is designed to connect data with new AI algorithms and augment human decision-making within existing clinical workflows, according to a news release.","socialImage":{}}},{"id":"YteovxAAACIADvKf","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteovxAAACIADvKf%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:03:30+0000","last_publication_date":"2025-01-20T09:36:46+0000","slugs":["new-ventures-to-use-ai-to-target-heart-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"New Ventures To Use AI To Target Heart Disease","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Innovator News: Mayo Clinic announced a new technology platform and launched two new companies April 14 that promise to improve doctors’ ability to spot disease early by connecting data from remote medical devices with AI-enabled algorithms. The first target is the heart.","spans":[]}],"date":"2021-04-24T18:30:00+0000","image":{"dimensions":{"width":1277,"height":822},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a0bf0dd9-77fe-4cdf-ba56-ac79c3717b49_iStock-1367729537.jpeg?auto=compress,format","id":"YteJrBAAACMADmaJ","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"7e5f3aaa-2ffd-4372-bbe9-8a6797ffb64c","url":"https://innovator.news/new-ventures-to-use-ai-to-target-heart-disease-6401b68dd94b"},"article":[],"slices":[],"seoTitle":"New Ventures To Use AI To Target Heart Disease","seoDescription":"Innovator News: Mayo Clinic announced a new technology platform and launched two new companies April 14 that promise to improve doctors’ ability to spot disease early by connecting data from remote medical devices with AI-enabled algorithms. The first target is the heart.","socialImage":{}}},{"id":"Y2q-GRQAACUAvBhP","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y2q-GRQAACUAvBhP%22%29+%5D%5D","tags":[],"first_publication_date":"2022-11-08T20:39:27+0000","last_publication_date":"2025-01-20T09:37:01+0000","slugs":["mayo-clinic-spinout-anumana-acquires-neutrace-to-develop-cardiac-procedure-ai"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic spinout Anumana acquires NeuTrace to develop cardiac procedure AI","spans":[]}],"published":"NeuTrace Acquistion","summary":[{"type":"paragraph","text":"FIERCE Biotech: Mayo Clinic’s artificial intelligence spinout Anumana is taking a deeper dive into analyzing the pulsing electrical signals of the heart with a new acquisition aimed at developing software used during cardiac procedures.","spans":[]}],"date":"2022-11-08T19:30:00+0000","image":{"dimensions":{"width":1357,"height":772},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a76dd04e-4aa9-416d-881c-4f7b1eea49e7_iStock-864472226.jpeg?auto=compress,format","id":"YteZkRAAACAADq4Z","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"813e7862-cdbb-4f47-9f02-f5efc747bf6d","url":"https://www.fiercebiotech.com/medtech/mayo-clinic-spinout-anumana-acquires-neutrace-develop-cardiac-procedure-ai"},"article":[],"slices":[],"seoTitle":"Mayo Clinic spinout Anumana acquires NeuTrace to develop cardiac procedure AI","seoDescription":"FIERCE Biotech: Mayo Clinic’s artificial intelligence spinout Anumana is taking a deeper dive into analyzing the pulsing electrical signals of the heart with a new acquisition aimed at developing software used during cardiac procedures.","socialImage":{}}},{"id":"YtemMBAAACEADudw","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtemMBAAACEADudw%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:52:47+0000","last_publication_date":"2025-01-20T09:32:49+0000","slugs":["midwest-providers-eye-new-financial-opportunities"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Midwest providers eye new financial opportunities","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Modern Healthcare: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide truly continuous care to patients. The Remote Diagnostics and Management Platform (RDMP) connects data with innovative new artificial intelligence (AI) algorithms and augments human decision-making within existing clinical workflows. RDMP enables \"event-driven medicine,\" providing insights in the right context, at the right time.","spans":[]}],"date":"2021-04-18T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/800d74b8-286d-4f01-a8be-62b4b6a3dbff_iStock-1327128846.jpeg?auto=compress,format","id":"YtejExAAACMADtmF","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"6fe5adb5-d1a5-4e69-8914-2bb3f68a62dd","url":"https://www.pressreader.com/usa/modern-healthcare/20210419/281741272249826"},"article":[],"slices":[],"seoTitle":"Midwest providers eye new financial opportunities","seoDescription":"Modern Healthcare: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide truly continuous care to patients. The Remote Diagnostics and Management Platform (RDMP) connects data with innovative new artificial intelligence (AI) algorithms and augments human decision-making within existing clinical workflows. RDMP enables \"event-driven medicine,\" providing insights in the right context, at the right time.","socialImage":{}}},{"id":"Y5otrRcAACkAg7NW","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5otrRcAACkAg7NW%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-15T11:57:03+0000","last_publication_date":"2025-01-20T09:37:26+0000","slugs":["anumana-and-pfizer-partner-to-enable-early-detection-of-underdiagnosed-cardiovascular-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis","spans":[]}],"date":"2022-12-15T12:00:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis","spans":[{"start":0,"end":152,"type":"em"}]},{"type":"paragraph","text":"CAMBRIDGE, Mass. – Dec. 15, 2022 – Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has entered into a multi-year agreement with Pfizer, Inc. for Anumana to develop an artificial intelligence electrocardiogram algorithm (AI-ECG) designed to enable the early suspicion of cardiac amyloidosis. Anumana will conduct a clinical validation trial and pursue De Novo classification for the algorithm as a Software-as-a-Medical-Device (SaMD) and aims to gain regulatory approval for the algorithm as an SaMD for the detection of cardiac amyloidosis in the U.S., Europe and Japan. ","spans":[{"start":0,"end":32,"type":"strong"},{"start":35,"end":48,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.anumana.ai%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Anumana%2C+Inc.&index=1&md5=020f103ef23664bf196fbc5c0944f7e5","target":"_blank"}},{"start":114,"end":122,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/"}}]},{"type":"paragraph","text":"Cardiac amyloidosis is a serious, progressive, and underdiagnosed rare disease that leads to heart failure.1 In patients with cardiac amyloidosis, the heart walls become stiff, making it difficult for the left ventricle to properly relax and fill with blood, while at the same time hampering its ability to squeeze and pump blood out of the heart. Symptoms and comorbidities associated with cardiac amyloidosis, such as shortness of breath, knee pain, bilateral carpal tunnel syndrome, kidney disease, and gastrointestinal issues, can vary and seem unrelated, making diagnosis difficult.2,3 ","spans":[{"start":107,"end":108,"type":"label","data":{"label":"superscript"}},{"start":587,"end":591,"type":"label","data":{"label":"superscript"}}]},{"type":"paragraph","text":"“The challenge in diagnosing cardiac amyloidosis can prevent patients from getting treatment while the disease continues to progress,” said David McMullin, chief business officer of Anumana. “We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.”","spans":[]},{"type":"paragraph","text":"The research agreement with Pfizer will help deepen Anumana’s efforts to implement AI-enabled early detection software that can reveal signals from ECGs that humans cannot interpret. The ubiquitous nature of the painless, non-invasive 100-year-old ECG test gives AI-ECG algorithms the potential to reach a larger number of patients earlier. ","spans":[]},{"type":"paragraph","text":"“AI-ECG solutions alert clinicians to humanly imperceptible patterns in ECG signals, providing an early warning for serious occult or impending disease,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “This stands to improve the lives of people with cardiac amyloidosis by improving the speed of triage and care of this group.”","spans":[]},{"type":"paragraph","text":"Anumana was founded in 2021 in collaboration with the Mayo Clinic Platform. Anumana has licensed Mayo Clinic AI-ECG algorithms for low ejection fraction, pulmonary hypertension, and hyperkalemia, all of which have received Breakthrough Device Designation from the U.S. FDA. These algorithms have been validated by over 75 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021, and another first of its kind batch enrolled prospective clinical impact study that demonstrated the effectiveness of AI-ECG to screen for undetected atrial fibrillation in normal sinus rhythm that was published in The Lancet in 2022.","spans":[{"start":54,"end":74,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.mayoclinicplatform.org/"}},{"start":473,"end":488,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.nature.com/articles/s41591-021-01335-4"}},{"start":473,"end":488,"type":"em"},{"start":713,"end":723,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01637-3/fulltext"}},{"start":713,"end":724,"type":"em"}]},{"type":"paragraph","text":"","spans":[]},{"type":"paragraph","text":"About Anumana","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Anumana, an AI-driven health technology company and portfolio company of nference, is harnessing industry-leading AI and translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using AI-ECG algorithms and to enhance and improve interventional procedures through real-time AI techniques. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point of care to reduce costs and enhance quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance. For more information, visit anumana.ai and follow Anumana on LinkedIn and Twitter.","spans":[{"start":73,"end":81,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nference.com%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=nference&index=5&md5=a0f9300b3092d80a5263a979c50853a8","target":"_blank"}},{"start":930,"end":940,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.anumana.ai%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=anumana.ai&index=6&md5=fa195867fefb37c7ccf35a5a2184e240","target":"_blank"}},{"start":963,"end":971,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d","target":"_blank"}},{"start":976,"end":983,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83","target":"_blank"}}]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"References\n1.     Rapezzi C, Lorenzini M, Longhi S et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev. 2015;20(2):117-124.\n2.     Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357-1377.\n3.     Ash S, Shorer E, Ramgobin D, Vo M, Gibbons J, Golamari R, Jain R, Jain R. Cardiac amyloidosis-A review of current literature for the practicing physician. Clin Cardiol. 2021 Mar;44(3):322-331.","spans":[]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"Media Contact:\nSam Choinski\nPazanga Health Communications for Anumana\nschoinski@pazangahealth.com\n(860) 301-5058","spans":[{"start":0,"end":15,"type":"strong"},{"start":70,"end":97,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:schoinski@pazangahealth.com"}}]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"  ","spans":[]}],"slices":[],"seoTitle":"Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease","seoDescription":"Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis","socialImage":{}}},{"id":"Y6M5NxcAACJwmL1-","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y6M5NxcAACJwmL1-%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-21T16:51:13+0000","last_publication_date":"2025-01-20T09:38:26+0000","slugs":["anumana-pfizer-collaborate-on-ai-based-detection-of-cardiovascular-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana, Pfizer collaborate on AI-based detection of cardiovascular disease","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"NS Medical Devices: The research agreement with Pfizer will aid Anumana to develop an AI-enabled ECG algorithm to help detect patients who may be at risk of cardiac amyloidosis","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1541,"height":680},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/024327d9-3c38-468c-b533-07d4f1b4aef6_iStock-1182622521.jpeg?auto=compress,format","id":"YteoBBAAACEADu-w","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"8809ffe5-1a4d-4093-bf14-f542524cd56a","url":"https://www.nsmedicaldevices.com/news/anumana-pfizer-collaborate-ai-based-detection-cardiovascular-disease/"},"article":[],"slices":[],"seoTitle":"Anumana, Pfizer collaborate on AI-based detection of cardiovascular disease","seoDescription":"NS Medical Devices: The research agreement with Pfizer will aid Anumana to develop an AI-enabled ECG algorithm to help detect patients who may be at risk of cardiac amyloidosis","socialImage":{}}},{"id":"Y5yePxcAACoAjn-N","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5yePxcAACoAjn-N%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-16T16:43:53+0000","last_publication_date":"2025-01-20T09:37:34+0000","slugs":["anumana-and-pfizer-partner-for-cardiovascular-disease-detection"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana and Pfizer partner for cardiovascular disease detection","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Medical Device Network: Health technology company Anumana and Pfizer have signed a multi-year agreement to develop an artificial intelligence electrocardiogram (AI-ECG) algorithm for the early detection of cardiac amyloidosis. Under the deal, Anumana will carry out a clinical validation trial and seek De Novo classification for the new AI-ECG algorithm as a Software-as-a-Medical-Device (SaMD).","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1357,"height":772},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a76dd04e-4aa9-416d-881c-4f7b1eea49e7_iStock-864472226.jpeg?auto=compress,format","id":"YteZkRAAACAADq4Z","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"a238c36c-e012-4da2-971c-f3feb5f5fe1f","url":"https://www.medicaldevice-network.com/news/anumana-pfizer-cardiovascular-disease/"},"article":[],"slices":[],"seoTitle":"Anumana and Pfizer partner for cardiovascular disease detection","seoDescription":"Medical Device Network: Health technology company Anumana and Pfizer have signed a multi-year agreement to develop an artificial intelligence electrocardiogram (AI-ECG) algorithm for the early detection of cardiac amyloidosis. Under the deal, Anumana will carry out a clinical validation trial and seek De Novo classification for the new AI-ECG algorithm as a Software-as-a-Medical-Device (SaMD).","socialImage":{}}},{"id":"Y5ydfBcAAHL-jn4a","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5ydfBcAAHL-jn4a%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-16T16:34:36+0000","last_publication_date":"2025-01-20T09:38:16+0000","slugs":["pfizer-links-up-with-heart-disease-ai-developer-anumana-to-build-cardiac-amyloidosis-diagnostics"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"FIERCE Biotech: The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help diagnose cases of cardiac amyloidosis, where misfolded proteins build up around the tissue. ","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1357,"height":772},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a76dd04e-4aa9-416d-881c-4f7b1eea49e7_iStock-864472226.jpeg?auto=compress,format","id":"YteZkRAAACAADq4Z","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"38b07152-56ac-4c47-8e3a-dce55084b871","url":"https://www.fiercebiotech.com/medtech/pfizer-links-heart-disease-ai-developer-anumana-build-cardiac-amyloidosis-diagnostics"},"article":[],"slices":[],"seoTitle":"Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics","seoDescription":"FIERCE Biotech: The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfizer. They plan to develop programs that can help diagnose cases of cardiac amyloidosis, where misfolded proteins build up around the tissue.","socialImage":{}}},{"id":"YteiOxAAACMADtW5","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteiOxAAACMADtW5%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:35:42+0000","last_publication_date":"2025-01-20T09:32:34+0000","slugs":["mayo-clinic-launches-two-companies-to-improve-ai-diagnostic-and-preventative-care"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic Launches Two Companies To Improve AI Diagnostic And Preventative Care","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Healthcare Technology Report: Artificial Intelligence (AI) continues to improve the healthcare industry. Capitalizing on AI’s many applications, Mayo Clinic is currently launching two new ventures, Anumana and Lucem Health, in order to utilize AI capabilities for preventative and diagnostic care. ","spans":[]}],"date":"2021-04-28T18:30:00+0000","image":{"dimensions":{"width":1297,"height":809},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/6065a2ef-be32-416c-a0d0-47f09f11e803_iStock-1365534802.jpeg?auto=compress,format","id":"YtekgBAAACIADt_k","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"7e3a60fd-aba0-4ef5-b580-76b07a56ae55","url":"https://thehealthcaretechnologyreport.com/mayo-clinic-launches-two-companies-to-improve-ai-diagnostic-and-preventative-care/"},"article":[],"slices":[],"seoTitle":"Mayo Clinic Launches Two Companies To Improve AI Diagnostic And Preventative Care","seoDescription":"Healthcare Technology Report: Artificial Intelligence (AI) continues to improve the healthcare industry. Capitalizing on AI’s many applications, Mayo Clinic is currently launching two new ventures, Anumana and Lucem Health, in order to utilize AI capabilities for preventative and diagnostic care.","socialImage":{}}},{"id":"Y2u7ZRQAACUAwHly","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y2u7ZRQAACUAwHly%22%29+%5D%5D","tags":[],"first_publication_date":"2022-11-09T14:39:47+0000","last_publication_date":"2025-01-20T09:37:44+0000","slugs":["mayo-clinic-platform-portfolio-company-buys-ai-electrophysiology-startup"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic Platform portfolio company buys AI electrophysiology startup","spans":[]}],"published":"NeuTrace Acquistion","summary":[{"type":"paragraph","text":"Becker's Hospital Review: Anumana, a portfolio company of Mayo Clinic Platform, has acquired NeuTrace, a medtech startup that applies artificial intelligence to electrophysiology. Anumana can now integrate a patient's entire EHR with corresponding electrocardiograms and cardiac electrograms.","spans":[]}],"date":"2022-11-08T19:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/deb3bd27-d5d3-4033-970e-c4eeb36e00a9_iStock-1273839908.jpeg?auto=compress,format","id":"Ytea4RAAACIADrQE","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"96a31db7-9d7d-4fa6-93ef-33c91d5a9400","url":"https://www.beckershospitalreview.com/innovation/mayo-clinic-platform-portfolio-company-buys-ai-electrophysiology-startup.html"},"article":[],"slices":[],"seoTitle":"Mayo Clinic Platform portfolio company buys AI electrophysiology startup","seoDescription":"Becker's Hospital Review: Anumana, a portfolio company of Mayo Clinic Platform, has acquired NeuTrace, a medtech startup that applies artificial intelligence to electrophysiology. Anumana can now integrate a patient's entire EHR with corresponding electrocardiograms and cardiac electrograms.","socialImage":{}}},{"id":"ZBhU0RAAACIAZrtg","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZBhU0RAAACIAZrtg%22%29+%5D%5D","tags":[],"first_publication_date":"2023-03-20T12:45:11+0000","last_publication_date":"2025-01-20T09:38:57+0000","slugs":["fierce-medtechs-2022-fierce-15"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Fierce Medtech's 2022 Fierce 15","spans":[]}],"published":"Awards","summary":[{"type":"paragraph","text":"Fierce Medtech: Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of both the tech and healthcare industries but also making real progress toward their lofty goals. The companies on this year’s list—which kicks off the second decade of Fierce Medtech’s Fierce 15—are setting the bar even higher. Anumana, a joint venture between Nference and the Mayo Clinic, is using artificial intelligence to dig into the peaks and valleys of standard electrocardiograms to pull out not-so-standard analyses.","spans":[]}],"date":"2023-03-20T18:30:00+0000","image":{"dimensions":{"width":850,"height":478},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a97e714e-096f-48e4-9eb4-1b8b74fe40e4_Fierce+15+Logo.jpg?auto=compress,format","id":"ZBhU5hAAACMAZruJ","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"05c26695-885d-4163-8ad8-739cc29afa30","url":"https://www.fiercebiotech.com/medtech/fierce-medtechs-2022-fierce-15"},"article":[],"slices":[],"seoTitle":"Fierce Medtech's 2022 Fierce 15","seoDescription":"Fierce Medtech: Since its humble beginnings back in 2012, the Fierce 15 has made a point of spotlighting the most exciting startups in medtech—those not only challenging the limits of both the tech and healthcare industries but also making real progress toward their lofty goals. The companies on this year’s list—which kicks off the second decade of Fierce Medtech’s Fierce 15—are setting the bar even higher. Anumana, a joint venture between Nference and the Mayo Clinic, is using artificial intelligence to dig into the peaks and valleys of standard electrocardiograms to pull out not-so-standard analyses.","socialImage":{}}},{"id":"Y2rTEBQAAGXOvHdW","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y2rTEBQAAGXOvHdW%22%29+%5D%5D","tags":[],"first_publication_date":"2022-11-08T22:08:20+0000","last_publication_date":"2025-01-20T09:37:30+0000","slugs":["anumana-acquires-neutrace-establishing-a-comprehensive-electrophysiology-deep-learning-development-platform-and-product-pipeline"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline","spans":[]}],"published":"NeuTrace Acquistion","summary":[{"type":"paragraph","text":"AI Thority: Anumana, an AI-driven health technology company and portfolio company of nference, announced it has acquired NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP). The acquisition includes the NeuTrace EP Data Biome platform and a portfolio of AI-enabled EP software applications in development. As part of the transaction, nference acquired rights to the Data Biome platform for uses outside of the cardiovascular field.","spans":[]}],"date":"2022-11-08T19:30:00+0000","image":{"dimensions":{"width":1541,"height":680},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/024327d9-3c38-468c-b533-07d4f1b4aef6_iStock-1182622521.jpeg?auto=compress,format","id":"YteoBBAAACEADu-w","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"77d41e0c-88b3-4d2e-a004-3bc4450b86c3","url":"https://aithority.com/machine-learning/anumana-acquires-neutrace-establishing-a-comprehensive-electrophysiology-deep-learning-development-platform-and-product-pipeline/?utm_source=hootsuite&utm_medium=linkedin&utm_term=aithority.com&utm_content=aea6e086-62a5-4de8-8fc2-0d3909ef6031&utm_campaign=Organic"},"article":[],"slices":[],"seoTitle":"Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline","seoDescription":"AI Thority: Anumana, an AI-driven health technology company and portfolio company of nference, announced it has acquired NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP). The acquisition includes the NeuTrace EP Data Biome platform and a portfolio of AI-enabled EP software applications in development. As part of the transaction, nference acquired rights to the Data Biome platform for uses outside of the cardiovascular field.","socialImage":{}}},{"id":"Y2hEMhQAALOqsOie","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y2hEMhQAALOqsOie%22%29+%5D%5D","tags":[],"first_publication_date":"2022-11-07T19:32:12+0000","last_publication_date":"2025-01-20T09:36:54+0000","slugs":["anumana-acquires-neutrace-establishing-a-comprehensive-electrophysiology-deep-learning-development-platform-and-product-pipeline"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP) ","spans":[{"start":0,"end":128,"type":"em"}]}],"date":"2022-11-07T19:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for Electrophysiology (EP) ","spans":[{"start":0,"end":128,"type":"em"}]},{"type":"paragraph","text":"CAMBRIDGE, Mass., Nov. 7, 2022 – Anumana, an AI-driven health technology company and portfolio company of nference, announced today it has acquired NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP). The acquisition includes the NeuTrace EP Data Biome platform and a portfolio of AI-enabled EP software applications in development. As part of the transaction, nference acquired rights to the Data Biome platform for uses outside of the cardiovascular field.","spans":[{"start":0,"end":33,"type":"strong"},{"start":33,"end":40,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai"}},{"start":106,"end":114,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.nference.com/"}}]},{"type":"paragraph","text":"The acquisition positions Anumana as a leader in AI medical software development for cardiac electrophysiology, with a combined development capability - powered by nference’s nSights real world evidence generation platform - that can integrate a patient’s entire electronic medical record (EMR) with corresponding electrocardiograms (ECG) taken from the surface of the body and cardiac electrograms (EGM) taken from within the heart.","spans":[{"start":175,"end":182,"type":"hyperlink","data":{"link_type":"Web","url":"https://nference.com/nsights"}}]},{"type":"paragraph","text":"Rooted in deep data science and covered by more than 35 pending and registered patents, the NeuTrace EP Data Biome is a proprietary and device-agnostic platform for holistic in-procedure data integration and novel real-time AI applications. A portfolio of EP applications is under development with the potential to increase procedure accuracy, reduce procedure time, and improve patient safety and outcomes. Advanced deep learning techniques on in-procedure EGM and ECG data feeds, combined with pre- and post-procedure ECG and EMR data records, will enable new and improved ECG-AI based diagnostic and pre-diagnostic algorithms for early disease detection and treatment.","spans":[]},{"type":"paragraph","text":"“Anumana is pioneering new ground in cardiology AI software solutions that span the entire patient journey,” said David McMullin, chief business officer of Anumana. “With its deep learning models detecting patterns too subtle for the human eye to see, from undiagnosed disease in routine ECGs to real-time EGM signals during critical EP procedures, Anumana is on a mission to improve patient care by unlocking the electrical language of the heart as never before.”","spans":[]},{"type":"paragraph","text":"“We’ve been impressed by the complementary depth, breadth, and strength of the Anumana and nference teams and are excited by the transformative potential of the combined organizations,” said Srijoy Mahapatra, M.D., president and chief operating officer of NeuTrace. “Combining the power of NeuTrace’s EP Data Biome with EMR and other data modalities of nference’s nSights platform has the potential to unlock game-changing AI applications in early cardiovascular disease detection, rhythm management, and EP procedure safety, efficacy, and effectiveness, for improved long-term outcomes.”","spans":[]},{"type":"paragraph","text":"\"NeuTrace promises to significantly improve care through applied AI in both expert and non-expert EP labs,” said Pierre Jais, M.D., LYRC-Bordeaux and NeuTrace medical advisor. “As new tools come on-line in the EP lab, we will need artificial intelligence more than ever. By pairing these intraprocedural data with ECGs and full medical records, Anumana has the opportunity for AI-tailored recommendations patient-by-patient, which would be true precision medicine.”","spans":[]},{"type":"paragraph","text":"\"Electrophysiology and other cardiology procedures are extremely rich in data that has largely remained untapped when it comes to machine learning and deep learning techniques,” said K. Shivkumar, M.D., Ph.D., Director of UCLA Cardiac Arrhythmia Center & Interventional Cardiovascular Programs.* “The techniques and products that Anumana and nference are developing, especially when integrated with NeuTrace’s in-procedure technology, are groundbreaking not only in cardiology, but also when applied to other organs such as the brain and kidney. I look forward to the next-gen technologies that Anumana and nference’s combination with NeuTrace will produce.”","spans":[]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"About NeuTrace","spans":[{"start":0,"end":14,"type":"strong"}]},{"type":"paragraph","text":"NeuTrace was founded by Dr. K.Shivkumar and his colleagues, and molded with the business vision and guidance from Raghu Mendu and NC Murthy, along with leading AI/ML and Data technology experts. NeuTrace’s mission is to democratize clinical practice, starting with cardiac electrophysiology, by applying its agnostic technology platform and AI in clinical procedures, to greatly improve the efficiency, effectiveness, and safety of patient care and outcomes.","spans":[]},{"type":"paragraph","text":"About Anumana","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Anumana, an AI-driven health technology company and portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to unlock the electrical language of the heart as never before. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and other leading institutions to detect hidden diseases using ECG-AI and enhance and improve EP procedures through real-time AI techniques. Multiple Anumana algorithms have received FDA Breakthrough Device Designation and are currently undergoing rigorous clinical trial validation. Anumana software devices are designed for real-world physician use, integrating into existing workflows at the point-of-care, thereby reducing costs and enhancing quality of life. Anumana algorithms are investigational medical devices and have not yet received regulatory approval or clearance. For more information, visit anumana.ai and follow Anumana on LinkedIn and Twitter.","spans":[{"start":73,"end":81,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nference.com%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=nference&index=5&md5=a0f9300b3092d80a5263a979c50853a8","target":"_blank"}},{"start":939,"end":949,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.anumana.ai%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=anumana.ai&index=6&md5=fa195867fefb37c7ccf35a5a2184e240","target":"_blank"}},{"start":972,"end":980,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fanumana-inc%2F&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=LinkedIn&index=7&md5=f7fce1290dd50e60cf8dcc4239941b1d","target":"_blank"}},{"start":985,"end":992,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.twitter.com%2Fanumanainc&esheet=52777932&newsitemid=20220713005033&lan=en-US&anchor=Twitter&index=8&md5=a39169251f201b96e74b018a3dc96a83","target":"_blank"}}]},{"type":"paragraph","text":"About nference","spans":[{"start":0,"end":14,"type":"strong"}]},{"type":"paragraph","text":"Through its powerful technology platform and software, nference is transforming health care by making biomedical knowledge computable. Its partnership with Mayo Clinic and other renowned academic medical centers has given nference an opportunity to synthesize decades of institutional knowledge, producing real-world evidence in real-time by converting large amounts of de-identified data into deep insights to advance discovery and development of diagnostics and therapeutics. Its proprietary AI-enabled software platform, nSights, has been used to accelerate life sciences research, development, and clinical care in significant ways, including biomarker discovery and validation, real-world evidence generation leveraging real-world data, early disease detection, public health policy generation and validation, and more. For more information, visit www.nference.com and follow nference on LinkedIn and Twitter.","spans":[{"start":853,"end":869,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.nference.com"}}]},{"type":"paragraph","text":" ","spans":[]},{"type":"paragraph","text":"*Dr. Shivkumar is a founder of NeuTrace, and the views expressed by him are his own and do not represent the views of UCLA.","spans":[{"start":0,"end":123,"type":"em"}]},{"type":"paragraph","text":"  ","spans":[]},{"type":"paragraph","text":"Media Contact","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Sam Choinski","spans":[]},{"type":"paragraph","text":"Pazanga Health for Anumana","spans":[]},{"type":"paragraph","text":"(860) 301-5058","spans":[]},{"type":"paragraph","text":"schoinski@pazangahealth.com","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:schoinski@pazangahealth.com"}}]},{"type":"paragraph","text":" ","spans":[]}],"slices":[],"seoTitle":"Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline","seoDescription":"Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP)","socialImage":{}}},{"id":"Y6M5qRcAACgAmL5E","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y6M5qRcAACgAmL5E%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-21T16:52:40+0000","last_publication_date":"2025-01-20T09:38:41+0000","slugs":["pfizer-and-anumana-ink-multi-year-ai-electrocardiogram-algorithm-deal"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Pfizer and Anumana Ink Multi-Year AI Electrocardiogram Algorithm Deal","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"FDA News: Pfizer has entered into a multi-year deal with Anumana — a joint venture between the Mayo Clinic and nference, an electronic health record data company — to develop software for early detection of cardiac amyloidosis.","spans":[]}],"date":"2022-12-20T19:30:00+0000","image":{"dimensions":{"width":1297,"height":809},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/6065a2ef-be32-416c-a0d0-47f09f11e803_iStock-1365534802.jpeg?auto=compress,format","id":"YtekgBAAACIADt_k","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"ae7b883b-9b6d-46a5-8cff-829d62be8b90","url":"https://www.fdanews.com/articles/210536-pfizer-and-anumana-ink-multi-year-ai-electrocardiogram-algorithm-deal?v=preview"},"article":[],"slices":[],"seoTitle":"Pfizer and Anumana Ink Multi-Year AI Electrocardiogram Algorithm Deal","seoDescription":"FDA News: Pfizer has entered into a multi-year deal with Anumana — a joint venture between the Mayo Clinic and nference, an electronic health record data company — to develop software for early detection of cardiac amyloidosis.","socialImage":{}}},{"id":"ZzyVPhkAAEIAvU39","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZzyVPhkAAEIAvU39%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2024-11-19T13:43:15+0000","last_publication_date":"2025-01-20T09:33:55+0000","slugs":["anumana-named-to-fast-companys-2024-next-big-things-in-tech-awards"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Named to Fast Company’s 2024 Next Big Things in Tech Awards","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[{"type":"paragraph","text":"Award recognizes Anumana’s innovative AI-driven cardiovascular disease detection technology","spans":[{"start":0,"end":91,"type":"em"}],"direction":"ltr"}],"date":"2024-11-19T12:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – Nov. 19, 2024 – Anumana, a leading AI-driven health technology company, has been named to Fast Company’s 2024 Next Big Things in Tech list in the Health category. This distinction highlights Anumana’s work leveraging artificial intelligence (AI) to transform routine electrocardiograms (ECG) into tools that enable earlier diagnosis and treatment.","spans":[{"start":0,"end":42,"type":"strong"},{"start":35,"end":42,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":129,"end":152,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.fastcompany.com/next-big-things-in-tech/list","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"\"We’re honored to be recognized by Fast Company for our work in advancing cardiovascular care through our ECG-AI algorithms,” said Maulik Nanavaty, CEO of Anumana. “This award reflects our leadership in developing evidence-based AI algorithms that empower physicians to detect diseases and intervene earlier. We believe that innovation like our ECG-AI low ejection fraction algorithm, trained, validated, and studied across more than 150,000 patients, is changing the landscape of heart health and setting new standards for patient care.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Heart failure remains a leading cause of death and hospitalization globally, affecting nearly 6.7 million adults in the U.S. alone. Anumana’s FDA-cleared ECG-AI™ Low Ejection Fraction (LEF) algorithm uncovers insights from standard 12-lead ECG readings, enabling clinicians to diagnose and treat patients sooner. Currently available and recognized by the Centers for Medicare & Medicaid Services (CMS), the algorithm detects LEF—a key indicator of heart failure—without the onset of clear symptoms or conventionally identified ECG abnormalities.","spans":[{"start":0,"end":13,"type":"hyperlink","data":{"link_type":"Web","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10864030/#:~:text=Approximately%206.7%20million%20Americans%20over,develop%20HF%20in%20their%20lifetime.","target":"_blank"}},{"start":154,"end":189,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}},{"start":355,"end":395,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZyqGmhoAAEEA4fhJ","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"The company’s expansive pipeline includes dozens of first-in-class algorithms, including FDA Breakthrough Device-Designated ECG-AI algorithms for detecting pulmonary hypertension, cardiac amyloidosis, and hyperkalemia. Anumana plans to bring numerous algorithms to the market next year in the U.S. and Europe. ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“The Next Big Things in Tech provides a fascinating glimpse at near- and long-term technological breakthroughs across a variety of sectors,” said Brendan Vaughan, editor-in-chief of Fast Company. “Spanning everything from semiconductors to agricultural gene editing, the companies featured in this year’s list are tackling some of the world’s most pressing and vexing problems.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Fast Company’s Next Big Things in Tech highlights new technology breakthroughs that promise to help define the future of the industries they serve. This year, 138 technologies developed by established companies, startups, or research teams are featured for their potential to revolutionize the lives of consumers, businesses, and society overall. Click here to see the final list.","spans":[{"start":352,"end":357,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.fastcompany.com/next-big-things-in-tech/list","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"About Anumana ","spans":[{"start":0,"end":14,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Anumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. Anumana’s award-winning lead algorithm, ECG-AI™ LEF, is now available in the U.S. To learn more about how the algorithm can help clinicians identify LEF earlier and schedule a demo, visit us at ECG-AI LEF. For more information, visit www.anumana.ai or follow us on LinkedIn and X.","spans":[{"start":880,"end":890,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}},{"start":920,"end":934,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai/","target":"_blank"}},{"start":951,"end":959,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.linkedin.com/company/anumana-inc/","target":"_blank"}},{"start":964,"end":965,"type":"hyperlink","data":{"link_type":"Web","url":"https://x.com/anumanainc","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"About Fast Company","spans":[{"start":0,"end":18,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. The editor-in-chief is Brendan Vaughan. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication, Inc., and can be found online at fastcompany.com.","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana Media Contact","spans":[{"start":0,"end":21,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Andrea Sampson","spans":[],"direction":"ltr"},{"type":"paragraph","text":"President/CEO, Sampson Public Relations Group","spans":[],"direction":"ltr"},{"type":"paragraph","text":"asampson@sampsonprgroup.com ","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:asampson@sampsonprgroup.com","target":"_blank"}}],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana Named to Fast Company’s 2024 Next Big Things in Tech Awards","seoDescription":"Award recognizes Anumana’s innovative AI-driven cardiovascular disease detection technology","socialImage":{}}},{"id":"YtenmxAAACAADu3W","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtenmxAAACAADu3W%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:58:37+0000","last_publication_date":"2025-01-20T09:33:14+0000","slugs":["trial-demonstrates-early-ai-guided-detection-of-heart-disease-in-routine-practice"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Trial demonstrates early AI-guided detection of heart disease in routine practice","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Science Daily: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early stages when treatment would be most effective. The ECG AI-Guided Screening for Low Ejection Fraction, or EAGLE, trial set out to determine whether an artificial intelligence (AI) screening tool developed to detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.","spans":[{"start":542,"end":557,"type":"em"}]}],"date":"2021-05-05T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/11f5721e-e12a-4b3a-8092-765ae0bc1784_iStock-1307217457.jpeg?auto=compress,format","id":"YteNGxAAACIADnXD","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"d7c3dce6-3592-4495-8bf9-04daad592297","url":"https://www.sciencedaily.com/releases/2021/05/210506142116.htm"},"article":[],"slices":[],"seoTitle":"Trial demonstrates early AI-guided detection of heart disease in routine practice","seoDescription":"Science Daily: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early stages when treatment would be most effective. The ECG AI-Guided Screening for Low Ejection Fraction, or EAGLE, trial set out to determine whether an artificial intelligence (AI) screening tool developed to detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.","socialImage":{}}},{"id":"ZAD5BxAAACUAcrvv","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22ZAD5BxAAACUAcrvv%22%29+%5D%5D","tags":[],"first_publication_date":"2023-03-02T19:30:38+0000","last_publication_date":"2025-01-20T09:38:54+0000","slugs":["how-doctors-use-ai-to-help-diagnose-patients"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"How Doctors Use AI to Help Diagnose Patients","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially years before they might otherwise have been detected, said Dr. Paul Friedman, chair of the clinic’s cardiology department in Rochester, Minn.","spans":[]}],"date":"2023-02-28T19:30:00+0000","image":{"dimensions":{"width":1400,"height":932},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/5d3ee612-aef2-4500-ae0f-2e85b0dce544_dr+friedman.jpeg?auto=compress,format","id":"ZAD5SRAAAO-Vcr0j","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"6725cefd-ee95-47cb-b60e-35d93b660889","url":"https://www.wsj.com/articles/how-doctors-use-ai-to-help-diagnose-patients-ce4ad025"},"article":[],"slices":[],"seoTitle":"How Doctors Use AI to Help Diagnose Patients","seoDescription":"Wall Street Journal: At Mayo cardiology, an AI tool has helped doctors diagnose new cases of heart failure and cases of irregular heart rhythms, which are called atrial fibrillation, potentially years before they might otherwise have been detected, said Dr. Paul Friedman, chair of the clinic’s cardiology department in Rochester, Minn.","socialImage":{}}},{"id":"Y2q-lBQAAMDevBqP","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y2q-lBQAAMDevBqP%22%29+%5D%5D","tags":[],"first_publication_date":"2022-11-08T22:07:05+0000","last_publication_date":"2025-01-20T09:37:40+0000","slugs":["anumana-acquires-ai-medical-software-provider-neutrace"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana acquires AI medical software provider NeuTrace","spans":[]}],"published":"NeuTrace Acquistion","summary":[{"type":"paragraph","text":"NS Medical Devices: Anumana said that the acquisition strengthens its position as a developer of AI medical software for cardiac EP, powered by nference’s nSights real-world evidence platform.","spans":[]}],"date":"2022-11-08T19:30:00+0000","image":{"dimensions":{"width":1357,"height":772},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a76dd04e-4aa9-416d-881c-4f7b1eea49e7_iStock-864472226.jpeg?auto=compress,format","id":"YteZkRAAACAADq4Z","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"a9c99a44-4713-4f71-8e18-e04ff47eb22d","url":"https://www.nsmedicaldevices.com/news/anumana-acquires-neutrace/"},"article":[],"slices":[],"seoTitle":"Anumana acquires AI medical software provider NeuTrace","seoDescription":"NS Medical Devices: Anumana said that the acquisition strengthens its position as a developer of AI medical software for cardiac EP, powered by nference’s nSights real-world evidence platform.","socialImage":{}}},{"id":"YteqLRAAACIADvkg","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteqLRAAACIADvkg%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:09:36+0000","last_publication_date":"2025-01-20T09:34:45+0000","slugs":["tech-companies-aim-to-expand-use-of-data-analytics-in-healthcare"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Tech Companies Aim to Expand Use of Data Analytics in Healthcare","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Health IT Analytics: For years, data analytics in healthcare has been a frequent buzzword among industry leaders. The ability to leverage AI, machine learning, and other technologies to gain actionable insights from massive amounts of data is an exciting prospect, but one that has been notoriously difficult to realize. With the onset of the pandemic, healthcare was forced to come face-to-face with its many data challenges, from collection to accuracy and analysis. In response, the industry has ramped up its efforts to improve data analytics capabilities – with tech companies playing a major role. ","spans":[]}],"date":"2021-04-14T18:30:00+0000","image":{"dimensions":{"width":1192,"height":880},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/e824721d-aa63-42cc-b0bf-9559d7e7b3ff_iStock-1224500457.jpeg?auto=compress,format","id":"YteqHRAAACMADvjY","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"469b1281-08f5-476b-90a5-86e0e4530803","url":"https://healthitanalytics.com/news/tech-companies-aim-to-expand-use-of-data-analytics-in-healthcare"},"article":[],"slices":[],"seoTitle":"Tech Companies Aim to Expand Use of Data Analytics in Healthcare","seoDescription":"Health IT Analytics: For years, data analytics in healthcare has been a frequent buzzword among industry leaders. The ability to leverage AI, machine learning, and other technologies to gain actionable insights from massive amounts of data is an exciting prospect, but one that has been notoriously difficult to realize. With the onset of the pandemic, healthcare was forced to come face-to-face with its many data challenges, from collection to accuracy and analysis. In response, the industry has ramped up its efforts to improve data analytics capabilities – with tech companies playing a major role.","socialImage":{}}},{"id":"Y6M46hcAACgAmLz_","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y6M46hcAACgAmLz_%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-21T16:49:44+0000","last_publication_date":"2025-01-20T09:38:30+0000","slugs":["anumana-and-pfizer-partner-to-enable-early-detection-of-underdiagnosed-cardiovascular-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Diagnostic and Interventional Cardiology: Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis","spans":[]}],"date":"2022-12-20T19:30:00+0000","image":{"dimensions":{"width":880,"height":582},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/6619ee72-008c-4b61-9d12-be52b5ec8368_heart-2607178_1280.jpeg?auto=compress,format","id":"Ytec3RAAACIADrz3","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"4d92830e-0d7d-4f0a-b3d6-9e158e35e14e","url":"https://www.dicardiology.com/content/anumana-and-pfizer-partner-enable-early-detection-underdiagnosed-cardiovascular-disease"},"article":[],"slices":[],"seoTitle":"Anumana and Pfizer Partner to Enable Early Detection of Underdiagnosed Cardiovascular Disease","seoDescription":"Diagnostic and Interventional Cardiology: Companies initiate research agreement supporting development of new AI-ECG algorithm to help identify patients who may be at risk of cardiac amyloidosis","socialImage":{}}},{"id":"YtefXxAAACIADsir","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtefXxAAACIADsir%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:23:31+0000","last_publication_date":"2025-01-20T09:36:35+0000","slugs":["profile-of-a-founder-venky-soundarajan"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Profile of a Founder: Venky Soundarajan","spans":[]}],"published":"Features","summary":[{"type":"paragraph","text":"The Tech Tribune: An exclusive Tech Tribune Q&A with Venky Soundararajan (co-founder and CSO) of nference, which was honored in our: 2022, 2021, 2020 Best Tech Startups in Cambridge. ","spans":[]}],"date":"2021-04-14T18:30:00+0000","image":{"dimensions":{"width":304,"height":240},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/7f0b3f2e-81f5-46bf-b841-830c538a100f_Venky.png?auto=compress,format","id":"YtefXRAAACIADsie","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Web","key":"ba1c68ac-d94a-4bdb-8c86-0cf302452d9b","url":"https://thetechtribune.com/venky-soundararajan-of-nference/"},"article":[],"slices":[],"seoTitle":"Profile of a Founder: Venky Soundarajan","seoDescription":"The Tech Tribune: An exclusive Tech Tribune Q&A with Venky Soundararajan (co-founder and CSO) of nference, which was honored in our: 2022, 2021, 2020 Best Tech Startups in Cambridge.","socialImage":{}}},{"id":"YteqzhAAACAADvwC","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteqzhAAACAADvwC%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:12:16+0000","last_publication_date":"2025-01-20T09:36:16+0000","slugs":["mayo-clinic-launches-2-new-companies-to-use-patient-data-and-ai-to-advance-early-disease-detection"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches 2 new companies to use patient data and AI to advance early disease detection","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"FIERCE Healthcare: Mayo Clinic has launched a new initiative to collect and analyze patient data from remote monitoring devices and diagnostic tools and to use artificial intelligence to accelerate diagnoses and disease prediction. To support this effort, the hospital is launching two new companies, Anumana and Lucem Health, which are working with AI and medical algorithms that tap into the hospital's patient data.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/70024f3e-98f0-4d28-8ded-e109a1de8e65_iStock-1319855785.jpeg?auto=compress,format","id":"YteZBxAAACIADqut","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"5f24d801-d10e-4a7d-86a5-e2daf6fda756","url":"https://www.fiercehealthcare.com/tech/mayo-clinic-launches-two-new-companies-to-advance-early-disease-detection-using-ai"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches 2 new companies to use patient data and AI to advance early disease detection","seoDescription":"FIERCE Healthcare: Mayo Clinic has launched a new initiative to collect and analyze patient data from remote monitoring devices and diagnostic tools and to use artificial intelligence to accelerate diagnoses and disease prediction. To support this effort, the hospital is launching two new companies, Anumana and Lucem Health, which are working with AI and medical algorithms that tap into the hospital's patient data.","socialImage":{}}},{"id":"YteipBAAACIADteO","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteipBAAACIADteO%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:37:27+0000","last_publication_date":"2025-01-20T09:32:38+0000","slugs":["trial-demonstrates-early-ai-guided-detection-of-heart-disease-in-routine-practice"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Trial demonstrates early AI-guided detection of heart disease in routine practice","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Medical Xpress: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early stages when treatment would be most effective. The ECG AI-Guided Screening for Low Ejection Fraction, or EAGLE, trial set out to determine whether an artificial intelligence (AI) screening tool developed to detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.","spans":[{"start":543,"end":559,"type":"em"}]}],"date":"2021-05-15T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/b7e24b77-527e-4d38-98ff-dc2530e06e22_iStock-1330045892.jpeg?auto=compress,format","id":"YteikhAAACEADtc6","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"e812e49d-d45b-4ddb-a8c3-5faa458acd02","url":"https://medicalxpress.com/news/2021-05-trial-early-ai-guided-heart-disease.html"},"article":[],"slices":[],"seoTitle":"Trial demonstrates early AI-guided detection of heart disease in routine practice","seoDescription":"Medical Xpress: Heart disease can take a number of forms, but some types of heart disease, such as asymptomatic low ejection fraction, can be hard to recognize, especially in the early stages when treatment would be most effective. The ECG AI-Guided Screening for Low Ejection Fraction, or EAGLE, trial set out to determine whether an artificial intelligence (AI) screening tool developed to detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.","socialImage":{}}},{"id":"YteoZBAAACAADvD-","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteoZBAAACAADvD-%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:01:59+0000","last_publication_date":"2025-01-20T09:34:16+0000","slugs":["ai-guided-detection-of-heart-disease-in-routine-practice"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"AI-guided Detection of Heart Disease in Routine Practice","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Med India: Artificial intelligence (AI) screening helps detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.","spans":[]}],"date":"2021-05-08T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/deb3bd27-d5d3-4033-970e-c4eeb36e00a9_iStock-1273839908.jpeg?auto=compress,format","id":"Ytea4RAAACIADrQE","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"07648e73-6737-4a1b-9c1b-5609ac6c503f","url":"https://www.medindia.net/news/ai-guided-detection-of-heart-disease-in-routine-practice-201120-1.htm"},"article":[],"slices":[],"seoTitle":"AI-guided Detection of Heart Disease in Routine Practice","seoDescription":"Med India: Artificial intelligence (AI) screening helps detect low ejection fraction using data from an EKG could improve the diagnosis of this condition in routine practice. Study findings are published in Nature Medicine.","socialImage":{}}},{"id":"YtesHRAAACEADwBv","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtesHRAAACEADwBv%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:17:52+0000","last_publication_date":"2025-01-20T09:36:39+0000","slugs":["bostinnos-2021-inno-on-fire-meet-the-50-startups-and-individuals-setting-bostons-innovation-ecosystem-ablaze."],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"BOSTINNO'S 2021 INNO ON FIRE: Meet the 50 startups and individuals setting Boston's innovation ecosystem ablaze.","spans":[]}],"published":"Features","summary":[{"type":"paragraph","text":"Biz Journals: If 2020 was a strange year for Boston's startups, companies and nonprofits, 2021 was its equally weird sequel. But the continuing pandemic, global supply-chain shortages, economic turmoil and a remote work revolution haven't stopped them from innovating.","spans":[]}],"date":"2021-11-10T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/9b02b45b-45bd-4db3-ad1e-2364fdb9cc36_iStock-1340399193.jpeg?auto=compress,format","id":"YtesGRAAACEADwBc","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"cb0e1149-f990-40f8-87c8-78d003a22a9a","url":"https://www.bizjournals.com/boston/inno/stories/awards/2021/11/11/2021_inno_on_fire.html"},"article":[],"slices":[],"seoTitle":"BOSTINNO'S 2021 INNO ON FIRE: Meet the 50 startups and individuals setting Boston's innovation ecosystem ablaze.","seoDescription":"Biz Journals: If 2020 was a strange year for Boston's startups, companies and nonprofits, 2021 was its equally weird sequel. But the continuing pandemic, global supply-chain shortages, economic turmoil and a remote work revolution haven't stopped them from innovating.","socialImage":{}}},{"id":"Y5ypLhcAAHL-jpI5","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Y5ypLhcAAHL-jpI5%22%29+%5D%5D","tags":[],"first_publication_date":"2022-12-16T17:22:46+0000","last_publication_date":"2025-01-20T09:37:22+0000","slugs":["pfizer-partners-with-healthtech-company-on-ai-powered-cardiovascular-disease-detection"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Pfizer partners with healthtech company on AI-powered cardiovascular disease detection","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Becker's Hospital Review: Pharmaceutical giant Pfizer has partnered with digital health company Anumana, a company founded in 2021 in collaboration with the Mayo Clinic Platform, to develop an artificial intelligence electrocardiogram algorithm used for the detection of cardiac amyloidosis.","spans":[]}],"date":"2022-12-16T19:30:00+0000","image":{"dimensions":{"width":1366,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/abb32bff-de92-42a3-a980-60597b9c0924_iStock-1257645087.jpeg?auto=compress,format","id":"YteJURAAACMADmTt","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"8c03ae82-0152-49b6-bfc4-cc1bf72e3379","url":"https://www.beckershospitalreview.com/digital-health/pfizer-partners-with-healthtech-company-on-ai-powered-cardiovascular-disease-detection.html"},"article":[],"slices":[],"seoTitle":"Pfizer partners with healthtech company on AI-powered cardiovascular disease detection","seoDescription":"Becker's Hospital Review: Pharmaceutical giant Pfizer has partnered with digital health company Anumana, a company founded in 2021 in collaboration with the Mayo Clinic Platform, to develop an artificial intelligence electrocardiogram algorithm used for the detection of cardiac amyloidosis.","socialImage":{}}},{"id":"YterthAAACEADv6e","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YterthAAACEADv6e%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T07:16:09+0000","last_publication_date":"2025-01-20T09:36:24+0000","slugs":["ai-algorithm-aids-early-detection-of-low-ejection-fraction"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"AI Algorithm Aids Early Detection of Low Ejection Fraction","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Health Day: An artificial intelligence (AI) algorithm that uses data from electrocardiography can help increase the diagnosis of low ejection fraction (EF), according to a study published online May 6 in Nature Medicine.","spans":[{"start":204,"end":219,"type":"em"}]}],"date":"2021-05-27T18:30:00+0000","image":{"dimensions":{"width":1366,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/abb32bff-de92-42a3-a980-60597b9c0924_iStock-1257645087.jpeg?auto=compress,format","id":"YteJURAAACMADmTt","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"25636833-f666-4e56-8509-17795c18ff00","url":"https://consumer.healthday.com/artificial-intelligence-algorithm-ups-id-of-low-ejection-fraction-2652947185.html"},"article":[],"slices":[],"seoTitle":"AI Algorithm Aids Early Detection of Low Ejection Fraction","seoDescription":"Health Day: An artificial intelligence (AI) algorithm that uses data from electrocardiography can help increase the diagnosis of low ejection fraction (EF), according to a study published online May 6 in Nature Medicine.","socialImage":{}}},{"id":"YteZ9hAAACAADq_c","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteZ9hAAACAADq_c%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:00:25+0000","last_publication_date":"2025-01-20T09:32:15+0000","slugs":["fda-grants-breakthrough-device-designation-to-anumanas-ecg-pulmonary-hypertension-early-detection-ai-algorithm"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early Detection Algorithm. The algorithm is a precise, non-invasive screening tool that addresses an unmet need for earlier diagnosis of patients with pulmonary hypertension, which may otherwise go unnoticed until the disease has advanced, delaying treatment initiation, thereby limiting treatment efficacy and adversely impacting patient outcomes.","spans":[{"start":6,"end":19,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.anumana.ai%2F&esheet=52728706&newsitemid=20220524005374&lan=en-US&anchor=Anumana%2C+Inc.&index=1&md5=873288a5dfe6a7bc0766c9f3ed4f812a","target":"_blank"}},{"start":65,"end":79,"type":"hyperlink","data":{"link_type":"Web","url":"https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnference.com%2F&esheet=52728706&newsitemid=20220524005374&lan=en-US&anchor=nference%2C+Inc.&index=2&md5=ac638a4fc3eacf0e7af5b4e86f01868d","target":"_blank"}},{"start":194,"end":205,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.dicardiology.com/channel/artificial-intelligence","target":"_blank"}},{"start":216,"end":238,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.dicardiology.com/content/world-ph-day-raises-awareness-pulmonary-hypertensions-global-impact","target":"_blank"}}]}],"date":"2022-05-23T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/11f5721e-e12a-4b3a-8092-765ae0bc1784_iStock-1307217457.jpeg?auto=compress,format","id":"YteNGxAAACIADnXD","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"89d04393-09c3-46e9-89d4-ba705f8161a7","url":"https://www.dicardiology.com/content/fda-grants-breakthrough-device-designation-anumanas-ecg-pulmonary-hypertension-early"},"article":[],"slices":[],"seoTitle":"FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm","seoDescription":"DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early Detection Algorithm. The algorithm is a precise, non-invasive screening tool that addresses an unmet need for earlier diagnosis of patients with pulmonary hypertension, which may otherwise go unnoticed until the disease has advanced, delaying treatment initiation, thereby limiting treatment efficacy and adversely impacting patient outcomes.","socialImage":{}}},{"id":"YtegrhAAACIADs6T","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtegrhAAACIADs6T%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:29:08+0000","last_publication_date":"2025-01-20T09:31:54+0000","slugs":["mayo-clinic-launches-ai-focused-diagnostic-platform-ventures"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic Launches AI-Focused Diagnostic Platform Ventures","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"HC Innovation Group: Mayo Clinic announced a new technology platform initiative designed to deliver clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide continuous care to patients.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/1d8bbd56-972d-431d-aea8-c1752e772593_iStock-1211854748.jpeg?auto=compress,format","id":"YteKFRAAACEADmhe","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"7bc8b3c4-dc89-4f49-a228-01ab2d907fcf","url":"https://www.hcinnovationgroup.com/analytics-ai/artifical-intelligence-machine-learning/news/21218569/mayo-clinic-launches-aifocused-diagnostic-platform-ventures"},"article":[],"slices":[],"seoTitle":"Mayo Clinic Launches AI-Focused Diagnostic Platform Ventures","seoDescription":"HC Innovation Group: Mayo Clinic announced a new technology platform initiative designed to deliver clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster and more accurate diagnoses and provide continuous care to patients.","socialImage":{}}},{"id":"YteKGRAAACIADmh1","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteKGRAAACIADmh1%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T04:52:45+0000","last_publication_date":"2025-01-20T09:30:10+0000","slugs":["anumana-collaborates-with-novartis-pharmaceuticals-corporation"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Collaborates with Novartis Pharmaceuticals Corporation","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"AI TechPark: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.","spans":[]}],"date":"2022-07-13T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/1d8bbd56-972d-431d-aea8-c1752e772593_iStock-1211854748.jpeg?auto=compress,format","id":"YteKFRAAACEADmhe","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"c3be00e0-79e2-4120-bedb-03f62f7e6826","url":"https://ai-techpark.com/anumana-collaborates-with-novartis-pharmaceuticals-corporation/"},"article":[],"slices":[],"seoTitle":"Anumana Collaborates with Novartis Pharmaceuticals Corporation","seoDescription":"AI TechPark: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.","socialImage":{}}},{"id":"YtebohAAACIADrdu","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtebohAAACIADrdu%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:07:33+0000","last_publication_date":"2025-01-20T09:30:00+0000","slugs":["ai-researchers-at-mayo-clinic-use-the-apple-watch-to-detect-silent-weakening-heart-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"AI researchers at Mayo Clinic use the Apple Watch to detect silent, weakening heart disease","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"FIERCE Biotech: Using simplified ECG data taken from an Apple Watch, researchers at the Mayo Clinic were able to use an artificial intelligence algorithm to spot people whose hearts may be having trouble pumping blood out to the rest of the body. Previously, the algorithms for analyzing 12-lead ECGs—which have received a breakthrough designation from the FDA and an emergency authorization for use against COVID-19—were licensed by nference and Mayo Clinic to Anumana, an AI developer working on their commercialization.","spans":[]}],"date":"2022-05-02T18:30:00+0000","image":{"dimensions":{"width":1254,"height":837},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/707c5866-728d-4069-a6ca-a74bf2bdf027_iStock-1030755674.jpeg?auto=compress,format","id":"YtebnhAAACAADrdb","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"c7a4e3ee-6cf5-4bcc-bf25-ed96becd7f10","url":"https://www.fiercebiotech.com/medtech/ai-researchers-mayo-clinic-use-apple-watch-detect-silent-weakening-heart-disease"},"article":[],"slices":[],"seoTitle":"AI researchers at Mayo Clinic use the Apple Watch to detect silent, weakening heart disease","seoDescription":"FIERCE Biotech: Using simplified ECG data taken from an Apple Watch, researchers at the Mayo Clinic were able to use an artificial intelligence algorithm to spot people whose hearts may be having trouble pumping blood out to the rest of the body. Previously, the algorithms for analyzing 12-lead ECGs—which have received a breakthrough designation from the FDA and an emergency authorization for use against COVID-19—were licensed by nference and Mayo Clinic to Anumana, an AI developer working on their commercialization.","socialImage":{}}},{"id":"YteeChAAACMADsI3","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteeChAAACMADsI3%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:17:51+0000","last_publication_date":"2025-01-20T09:31:12+0000","slugs":["mayo-clinic-launches-two-tech-companies"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches two tech companies","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Modern Healthcare: One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/7f5d2277-a773-4c2f-8ab8-235d3012eb43_iStock-1304967852.jpeg?auto=compress,format","id":"YteOBxAAACAADnnm","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"3bf430db-18a7-47ab-a09c-ee88b245fef8","url":"https://www.modernhealthcare.com/patients/mayo-clinic-launches-two-tech-companies"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches two tech companies","seoDescription":"Modern Healthcare: One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.","socialImage":{}}},{"id":"YteU0BAAACIADpiz","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteU0BAAACIADpiz%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:38:27+0000","last_publication_date":"2025-01-20T09:29:34+0000","slugs":["anumanas-ai-tool-for-pulmonary-hypertension-gets-fda-breakthrough-status"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Medical Device Network: Anumana has received US Food and Drug Administration (FDA) Breakthrough Device Designation for its artificial intelligence (AI)-enhanced, electrocardiogram (ECG)-based Pulmonary Hypertension (PH) Early Detection Algorithm. The accurate, non-invasive screening tool aids in addressing an unmet need for early detection of PH in patients.","spans":[]}],"date":"2022-05-24T18:30:00+0000","image":{"dimensions":{"width":1277,"height":822},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a0bf0dd9-77fe-4cdf-ba56-ac79c3717b49_iStock-1367729537.jpeg?auto=compress,format","id":"YteJrBAAACMADmaJ","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"79a841ec-c8ee-49a4-95bd-fb21050321e4","url":"https://www.medicaldevice-network.com/news/anumana-pulmonary-hypertension-tool/"},"article":[],"slices":[],"seoTitle":"Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status","seoDescription":"Medical Device Network: Anumana has received US Food and Drug Administration (FDA) Breakthrough Device Designation for its artificial intelligence (AI)-enhanced, electrocardiogram (ECG)-based Pulmonary Hypertension (PH) Early Detection Algorithm. The accurate, non-invasive screening tool aids in addressing an unmet need for early detection of PH in patients.","socialImage":{}}},{"id":"YtehhBAAACAADtJv","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtehhBAAACAADtJv%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:32:39+0000","last_publication_date":"2025-01-20T09:28:44+0000","slugs":["how-a-new-ai-algorithm-could-help-in-the-early-detection-of-heart-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"How a New AI Algorithm Could Help in the Early Detection of Heart Disease","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Xtalks: An AI algorithm developed by researchers at the Mayo Clinic through its newly formed health technology company Anumana Inc., can assess for low ejection fraction through routine electrocardiograms (ECG, or also called EKG). The ECG-based AI-powered clinical decision support tool can enable diagnosis of low ejection fraction, especially in its earliest stages to facilitate more prompt diagnosis and treatment of the heart condition. In a clinical trial that evaluated the tool, the researchers found that it was able to detect an increased number of low ejection fraction cases in the earliest stages of the condition.","spans":[]}],"date":"2021-05-16T18:30:00+0000","image":{"dimensions":{"width":1357,"height":772},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a76dd04e-4aa9-416d-881c-4f7b1eea49e7_iStock-864472226.jpeg?auto=compress,format","id":"YteZkRAAACAADq4Z","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"4c1741db-1663-4710-9e50-cc4e8cbd74b5","url":"https://xtalks.com/how-a-new-ai-algorithm-could-help-in-the-early-detection-of-heart-disease-2703/"},"article":[],"slices":[],"seoTitle":"How a New AI Algorithm Could Help in the Early Detection of Heart Disease","seoDescription":"Xtalks: An AI algorithm developed by researchers at the Mayo Clinic through its newly formed health technology company Anumana Inc., can assess for low ejection fraction through routine electrocardiograms (ECG, or also called EKG). The ECG-based AI-powered clinical decision support tool can enable diagnosis of low ejection fraction, especially in its earliest stages to facilitate more prompt diagnosis and treatment of the heart condition. In a clinical trial that evaluated the tool, the researchers found that it was able to detect an increased number of low ejection fraction cases in the earliest stages of the condition.","socialImage":{}}},{"id":"YteOkxAAACIADnxs","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteOkxAAACIADnxs%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:11:50+0000","last_publication_date":"2025-01-20T09:29:06+0000","slugs":["novartis-links-up-with-mayo-clinic-spinout-anumana-to-develop-ecg-reading-ai"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Novartis links up with Mayo Clinic spinout Anumana to develop ECG-reading AI","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"FIERCE Biotech: Heart disease remains the leading cause of death around the world, but a flood of tech developers are hoping that artificial intelligence software might be the key to reducing that mortality rate. Latest to join the fray are Novartis and Anumana—a joint venture of the Mayo Clinic and Nference—which have teamed up to develop new AI algorithms. The collaboration is aimed at catching otherwise overlooked cases of life-threatening heart disease as early as possible, even before symptoms arise.","spans":[]}],"date":"2022-07-13T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/0b487497-acc8-4de9-bd1e-e1f19814ce53_iStock-1270372947.jpeg?auto=compress,format","id":"YteOjBAAACIADnxH","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"6f7a5b6a-5863-49ba-ac76-7ddc3612236b","url":"https://www.fiercebiotech.com/medtech/novartis-links-mayo-clinic-spinout-anumana-develop-ecg-reading-ai"},"article":[],"slices":[],"seoTitle":"Novartis links up with Mayo Clinic spinout Anumana to develop ECG-reading AI","seoDescription":"FIERCE Biotech: Heart disease remains the leading cause of death around the world, but a flood of tech developers are hoping that artificial intelligence software might be the key to reducing that mortality rate. Latest to join the fray are Novartis and Anumana—a joint venture of the Mayo Clinic and Nference—which have teamed up to develop new AI algorithms. The collaboration is aimed at catching otherwise overlooked cases of life-threatening heart disease as early as possible, even before symptoms arise.","socialImage":{}}},{"id":"YteK8xAAACAADmxB","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteK8xAAACAADmxB%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T04:56:23+0000","last_publication_date":"2025-01-20T09:28:51+0000","slugs":["anumana-and-novartis-partner-for-ai-based-heart-disease-detection"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana and Novartis partner for AI-based heart disease detection","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"NS Medical Devices: Health technology company Anumana has entered into a multi-year strategic collaboration with Novartis Pharmaceuticals to detect heart disease leveraging a series of artificial intelligence (AI)-powered software solutions. The partnership will advance the making and distribution of electrocardiogram (ECG) AI algorithms to assist doctors in quickly identifying and treating patients with life-threatening cardiac illnesses.","spans":[]}],"date":"2022-07-13T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/aa3a14be-0833-4103-a7fe-28f71358fe02_iStock-1330045892.jpeg?auto=compress,format","id":"YteK8BAAACAADmwu","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"29bd066d-92ee-4ff4-a318-c75355ee29fa","url":"https://www.nsmedicaldevices.com/news/anumana-and-novartis-partner-for-ai-based-heart-disease-detection/"},"article":[],"slices":[],"seoTitle":"Anumana and Novartis partner for AI-based heart disease detection","seoDescription":"NS Medical Devices: Health technology company Anumana has entered into a multi-year strategic collaboration with Novartis Pharmaceuticals to detect heart disease leveraging a series of artificial intelligence (AI)-powered software solutions. The partnership will advance the making and distribution of electrocardiogram (ECG) AI algorithms to assist doctors in quickly identifying and treating patients with life-threatening cardiac illnesses.","socialImage":{}}},{"id":"YteP8xAAACMADoKp","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteP8xAAACMADoKp%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:17:42+0000","last_publication_date":"2025-01-20T09:29:26+0000","slugs":["anumana-wins-fda-breakthrough-status-for-ai-algorithm-to-detect-ph"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana wins FDA breakthrough status for AI algorithm to detect PH","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"NS Medical Devices: AI-driven health technology company Anumana has received breakthrough device designation from the US Food & Drug Administration (FDA) for its ECG-based Pulmonary Hypertension (PH) algorithm. The AI-enhanced ECG-based early detection algorithm is a precise, non-invasive screening tool that is intended for the early diagnosis of patients with pulmonary hypertension. By using the availability of 12-lead ECGs in primary care, urgent care, and emergency room settings, Anumana’s ECG algorithm is designed to easily and safely detect PH at an early stage.","spans":[]}],"date":"2022-05-24T18:30:00+0000","image":{"dimensions":{"width":1366,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/abb32bff-de92-42a3-a980-60597b9c0924_iStock-1257645087.jpeg?auto=compress,format","id":"YteJURAAACMADmTt","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"f1eefd41-b500-4840-9f9c-5cf7f40508ca","url":"https://www.nsmedicaldevices.com/news/anumana-receives-fda-breakthrough-device-for-its-ecg-algorithm/"},"article":[],"slices":[],"seoTitle":"Anumana wins FDA breakthrough status for AI algorithm to detect PH","seoDescription":"NS Medical Devices: AI-driven health technology company Anumana has received breakthrough device designation from the US Food & Drug Administration (FDA) for its ECG-based Pulmonary Hypertension (PH) algorithm. The AI-enhanced ECG-based early detection algorithm is a precise, non-invasive screening tool that is intended for the early diagnosis of patients with pulmonary hypertension. By using the availability of 12-lead ECGs in primary care, urgent care, and emergency room settings, Anumana’s ECG algorithm is designed to easily and safely detect PH at an early stage.","socialImage":{}}},{"id":"YtePpxAAACEADoFR","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtePpxAAACEADoFR%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:16:26+0000","last_publication_date":"2025-01-20T08:33:30+0000","slugs":["anumana-collaborates-with-leading-global-health-care-company-to-detect-heart-disease-using-artificial-intelligence"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular disease","spans":[{"start":0,"end":162,"type":"em"}]}],"date":"2022-07-12T18:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular disease","spans":[{"start":0,"end":162,"type":"em"}]},{"type":"paragraph","text":"CAMBRIDGE, Mass., July 13, 2022 – Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.","spans":[{"start":0,"end":32,"type":"strong"},{"start":34,"end":47,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.anumana.ai/"}}]},{"type":"paragraph","text":"The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret. The collaboration will initially focus on cardiovascular diseases. Working with its expert partners from Mayo Clinic, Anumana will deploy novel solutions that use AI to analyze an ECG, a widely available, painless test that records the heart’s electrical signals to identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can lead to heart failure. The AI will also screen for atherosclerotic cardiovascular disease, which can lead to heart attack and stroke. In addition, an evidence-based, digital point-of-care solution will be developed to guide in optimizing guideline-directed medical therapies with the aim to lower risk for potentially avoidable hospitalizations and cardiovascular death. ","spans":[]},{"type":"paragraph","text":"“Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms,” said Murali Aravamudan, CEO of Anumana. “Bringing together premier global organizations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.”","spans":[]},{"type":"paragraph","text":"“Many heart diseases develop for years before signs and symptoms appear, but the first event may be life threatening,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “AI enables us to uncover hidden signals our bodies transmit to detect otherwise occult heart diseases, potentially years before symptoms appear. This collaboration has the potential to transform the use of an ubiquitous inexpensive test, the ECG, with the aim of democratizing disease detection and helping medical care teams to proactively manage heart disease ahead of time and prevent some clinical events from ever happening.”","spans":[]},{"type":"paragraph","text":"“Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care,” said Victor Bulto, President, Novartis Innovative Medicines US. \"Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population.”  ","spans":[]},{"type":"paragraph","text":"The Mayo Clinic Cardiology team, led by Dr. Friedman, pioneered the application of AI in cardiology and developed several algorithms based on millions of ECGs, including a low ejection fraction algorithm that received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Further validating the technology, a recent study presented by Mayo Clinic used a modified version of Anumana’s 12-lead ECG algorithm to detect left ventricular dysfunction with single-lead ECGs in smartwatches. These algorithms are licensed to Anumana for development of clinical solutions and have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for marketing authorization through an FDA DeNovo request.","spans":[{"start":353,"end":359,"type":"hyperlink","data":{"link_type":"Web","url":"https://newsnetwork.mayoclinic.org/discussion/mayo-researchers-use-ai-to-detect-weak-heart-pump-via-patients-apple-watch-ecgs/"}},{"start":656,"end":668,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.anumana.ai/publications"}},{"start":793,"end":808,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.nature.com/articles/s41591-021-01335-4"}},{"start":793,"end":809,"type":"em"}]},{"type":"paragraph","text":"About Anumana\nAnumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance. For more information, visit anumana.ai and follow Anumana on LinkedIn & Twitter.","spans":[{"start":0,"end":13,"type":"strong"},{"start":917,"end":927,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.anumana.ai/"}},{"start":950,"end":958,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.linkedin.com/company/anumana-inc/"}},{"start":961,"end":968,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.twitter.com/anumanainc"}}]},{"type":"paragraph","text":"Media Contact","spans":[{"start":0,"end":13,"type":"strong"}]},{"type":"paragraph","text":"Anumana \nAndrea Sampson, Sampson Public Relations Group\nasampson@sampsonprgroup.com\n562.304.0301","spans":[{"start":56,"end":83,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:asampson@sampsonprgroup.com"}}]}],"slices":[],"seoTitle":"Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence","seoDescription":"Novartis Pharmaceuticals Corporation to collaborate on development of new medical device software for earlier detection and intervention in cardiovascular disease","socialImage":{}}},{"id":"Z37w5BoAAEIAlQNV","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Z37w5BoAAEIAlQNV%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2025-01-09T12:30:41+0000","last_publication_date":"2025-01-20T06:00:45+0000","slugs":["anumana-appoints-dr.-simos-kedikoglou-as-president-and-chief-operating-officer"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Appoints Dr. Simos Kedikoglou as President and Chief Operating Officer  ","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[{"type":"paragraph","text":"Anumana appoints new President and COO","spans":[{"start":0,"end":38,"type":"em"}],"direction":"ltr"}],"date":"2025-01-09T12:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – Jan. 9, 2025 – Anumana, a leading AI-driven health technology company, announced the appointment of Dr. Simos Kedikoglou as President and Chief Operating Officer (COO), effective immediately.   ","spans":[{"start":0,"end":31,"type":"strong"},{"start":34,"end":42,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"Simos brings a distinguished track record in global healthcare strategy, medical device commercialization, and operational leadership to Anumana’s executive team. In his new role, he will lead Anumana’s commercial operations, drive strategic partnerships, and oversee the development and execution of growth initiatives to advance the company’s mission to transform healthcare through AI technology. ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"“Simos is a visionary leader with a deep understanding of the healthcare ecosystem and a proven track record of driving growth and innovation in the medtech space,” said Maulik Nanavaty, CEO of Anumana. “We are excited to welcome Simos to our team as we expand our impact in the healthcare industry. His extensive experience in medical device development and commercialization will help Anumana achieve its vision to deliver groundbreaking AI-powered solutions to improve patient outcomes.” ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Simos most recently served as CEO of Impulse Dynamics, where he led the global commercialization of the Optimizer®, the first active implantable device for heart failure treatment. During his tenure, Simos secured $350 million in funding and advanced multiple clinical trials, enrolling more than 5,000 patients. During COVID, he helped the company reach a $40 million revenue run rate and expanded its commercial team to over 150 members.  ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"He also played key roles as an Executive Board Member at MedAlliance, helping raise $150 million and facilitate its sale to Cordis. Previously, he was the Corporate Vice President of Business Development at Boston Scientific, managing global deals and acquisitions, and as an associate partner at McKinsey & Company, advising on $45 billion in healthcare transactions. ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"\"Anumana is at the forefront of an exciting transformation in healthcare, and it is an honor to join this innovative team,\" said Simos. \"The opportunity to harness AI's potential to transform cardiovascular care is inspiring and the potential is unlimited. I am eager to apply my experience in scaling medical technologies to help Anumana achieve its bold vision of improving patient outcomes and advancing healthcare globally.\" ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Simos holds a medical degree from the University of Athens, Greece, an MBA with distinction from Harvard Business School, a master’s in public health from Harvard University, and is a CFA charterholder. ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana  \nAnumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. Anumana’s award-winning 12-lead algorithm, ECG-AI™ LEF, is now available in the U.S. To learn more about how the algorithm can help clinicians identify LEF earlier and schedule a demo, visit us at ECG-AI LEF. For more information, visit www.anumana.ai or follow us on LinkedIn and X. ","spans":[{"start":0,"end":14,"type":"strong"},{"start":899,"end":909,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https:/anumana.ai/ecg-ai-lef___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6MThjZjpjNGE2YTA5ODRjZjJiNjlmYmY1ZTVmMTU0OTA3NWQ4Njc2Y2U5YjhkNDJhY2RlZGQzMTQyZjliOWJiMGYyM2MzOnA6VDpG","target":"_blank"}},{"start":939,"end":953,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___http:/www.anumana.ai___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6YTIwNTpkMDEwZjA1YjE0OWNkYmFjZDliZmI5ZjIwNTVhYzY2NjZlOTg3MDNlYzlkZTBlMTFkMzQ0MWUwNDk2Nzc4YTA3OnA6VDpG","target":"_blank"}},{"start":970,"end":978,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/anumana-inc/___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6Y2I1NzpmZmQ3MmUzYTZlMzc2NGIzYzViMzExMjU0NTliZGRlMmViNzllZjVkZWVhYWJkZWM1NGRjYjc4MjNiMDAyN2M3OnA6VDpG","target":"_blank"}},{"start":983,"end":984,"type":"hyperlink","data":{"link_type":"Web","url":"https://protect.checkpoint.com/v2/___https:/x.com/anumanainc___.YzJ1OmFjYzI6YzpvOmZhNzI3ZTk3YTUwMTQyZmY0MzNlZDVmMjJjZWZhZGJlOjY6ZDZiYzo4Y2MwYmE1MGI5YzhmOGI3MzZlNjlhZTk2MTUxNzYyYWIxMjEzNDU2OTNlOGY4YzI5ZmVkZjJhM2Q4NDk3NTY4OnA6VDpG","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"Media Contact ","spans":[{"start":0,"end":13,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Andrea Sampson ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Sampson Public Relations Group ","spans":[],"direction":"ltr"},{"type":"paragraph","text":"asampson@sampsonprgroup.com ","spans":[],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana Appoints Dr. Simos Kedikoglou as President and Chief Operating Officer  ","seoDescription":"Anumana appoints new President and COO","socialImage":{}}},{"id":"YteZHhAAACAADqwV","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteZHhAAACAADqwV%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:56:49+0000","last_publication_date":"2025-01-20T09:29:42+0000","slugs":["mayo-clinic-janssen-backed-venture-gets-fda-ok-for-pulmonary-hypertension-ai-algorithm"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic, Janssen-backed venture gets FDA OK for pulmonary hypertension AI algorithm","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Becker's Hospital Review: A Mayo Clinic and Janssen-backed venture has received FDA breakthrough designation for an algorithm designed to enable early detection of pulmonary hypertension. Anumana Inc. received the breakthrough device designation for its AI-enhanced, ECG-based algorithm screening tool that provides early diagnosis of patients with pulmonary hypertension, according to a May 24 press release.","spans":[]}],"date":"2022-05-23T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/70024f3e-98f0-4d28-8ded-e109a1de8e65_iStock-1319855785.jpeg?auto=compress,format","id":"YteZBxAAACIADqut","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"0b368d31-a73b-4815-b62d-28ea421cd792","url":"https://www.beckershospitalreview.com/innovation/mayo-clinic-janssen-backed-venture-gets-fda-ok-for-pulmonary-hypertension-ai-algorithm.html"},"article":[],"slices":[],"seoTitle":"Mayo Clinic, Janssen-backed venture gets FDA OK for pulmonary hypertension AI algorithm","seoDescription":"Becker's Hospital Review: A Mayo Clinic and Janssen-backed venture has received FDA breakthrough designation for an algorithm designed to enable early detection of pulmonary hypertension. Anumana Inc. received the breakthrough device designation for its AI-enhanced, ECG-based algorithm screening tool that provides early diagnosis of patients with pulmonary hypertension, according to a May 24 press release.","socialImage":{}}},{"id":"YteJVhAAACMADmUA","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteJVhAAACMADmUA%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T04:49:29+0000","last_publication_date":"2025-01-20T09:30:27+0000","slugs":["anumana-collaborates-with-leading-global-health-care-company-to-detect-heart-disease-using-artificial-intelligence"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Biospace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.","spans":[]}],"date":"2022-07-12T18:30:00+0000","image":{"dimensions":{"width":1366,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/abb32bff-de92-42a3-a980-60597b9c0924_iStock-1257645087.jpeg?auto=compress,format","id":"YteJURAAACMADmTt","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"32c61a4e-04f3-4dbc-b545-fc915a5c3112","url":"https://www.biospace.com/article/releases/anumana-collaborates-with-leading-global-health-care-company-to-detect-heart-disease-using-artificial-intelligence/"},"article":[],"slices":[],"seoTitle":"Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence","seoDescription":"Biospace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.","socialImage":{}}},{"id":"YteMeRAAACIADnL5","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteMeRAAACIADnL5%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:02:52+0000","last_publication_date":"2025-01-20T09:26:10+0000","slugs":["anumana-announces-issuance-of-new-american-medical-association-cpt-category-iii-codes-for-novel-ecg-ai-analysis-of-cardiac-dysfunction"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction","spans":[]}],"published":"Reimbursement Coding","summary":[{"type":"paragraph","text":"IT Business Net: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for novel assistive AI algorithmic electrocardiogram risk assessment for cardiac dysfunction, encompassing Anumana’s pipeline of AI-enhanced ECG-based algorithms currently in development for FDA regulatory clearance.","spans":[]}],"date":"2022-07-06T18:30:00+0000","image":{"dimensions":{"width":1312,"height":800},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/aa5e1021-0315-4d1d-8ea6-98c0c62ea44b_iStock-1327568875.jpeg?auto=compress,format","id":"YteMdRAAACMADnLi","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"c0b04e8f-5202-42bd-87aa-de6299592f7b","url":"https://itbusinessnet.com/2022/07/anumana-announces-issuance-of-new-american-medical-association-cpt-category-iii-codes-for-novel-ecg-ai-analysis-of-cardiac-dysfunction/"},"article":[],"slices":[],"seoTitle":"Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction","seoDescription":"IT Business Net: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for novel assistive AI algorithmic electrocardiogram risk assessment for cardiac dysfunction, encompassing Anumana’s pipeline of AI-enhanced ECG-based algorithms currently in development for FDA regulatory clearance.","socialImage":{}}},{"id":"YtePahAAACAADoA-","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtePahAAACAADoA-%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:15:25+0000","last_publication_date":"2025-01-20T09:25:57+0000","slugs":["anumana-announces-issuance-of-new-american-medical-association-cpt-category-iii-codes-for-novel-ecg-ai-analysis-of-cardiac-dysfunction"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Announces Issuance of New American Medical Association CPT® Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction","spans":[]}],"published":"Press Release","summary":[{"type":"paragraph","text":"Ground-breaking codes will facilitate the use, adoption, and pathway for potential reimbursement of AI-enhanced ECG-based algorithms, including Anumana’s pipeline of AI- enhanced ECG-based algorithms ","spans":[{"start":0,"end":200,"type":"em"}]}],"date":"2022-07-05T18:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"Ground-breaking codes will facilitate the use, adoption, and pathway for potential reimbursement of AI-enhanced ECG-based algorithms, including Anumana’s pipeline of AI- enhanced ECG-based algorithms ","spans":[{"start":0,"end":200,"type":"em"}]},{"type":"paragraph","text":"CAMBRIDGE, Mass., July 6, 2022 – Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT®) codes for novel assistive AI algorithmic electrocardiogram risk assessment for cardiac dysfunction, encompassing Anumana’s pipeline of AI-enhanced ECG-based algorithms currently in development for FDA regulatory clearance. ","spans":[{"start":0,"end":31,"type":"strong"}]},{"type":"paragraph","text":"This ground-breaking approval is a major milestone for AI in cardiology, recognizing Anumana’s AI-enhanced ECG-based algorithms as innovative technology necessitating the creation of a new procedure category. CPT Category III codes are designed to facilitate the use, adoption, and potential reimbursement of emerging technologies. The newly approved AMA CPT Category III codes were published on July 1, 2022, and will be effective on January 1, 2023. ","spans":[]},{"type":"paragraph","text":"“We are delighted that the American Medical Association has approved our application for a new category of CPT codes covering our AI-enhanced ECG algorithm pipeline,” said David McMullin, Chief Business Officer at Anumana. “The new AMA codes mark a significant milestone for Anumana, validating the potential impact of our innovative technology and establishing a pathway for widespread adoption and reimbursement.” ","spans":[]},{"type":"paragraph","text":"Anumana’s robust pipeline of novel algorithms has been validated by over 50 peer-reviewed publications, and are currently in development as medical devices. Anumana’s pulmonary hypertension algorithm received FDA Breakthrough Device Designation earlier this year, and its low ejection fraction algorithm received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. ","spans":[]},{"type":"paragraph","text":"About Anumana ","spans":[{"start":0,"end":14,"type":"strong"}]},{"type":"paragraph","text":"Anumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance. For more information, visit anumana.ai and follow Anumana on LinkedIn & Twitter. ","spans":[{"start":936,"end":944,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.linkedin.com/company/anumana-inc/"}},{"start":947,"end":954,"type":"hyperlink","data":{"link_type":"Web","url":"https://mobile.twitter.com/anumanainc"}}]},{"type":"paragraph","text":"","spans":[]},{"type":"paragraph","text":"Media Contact ","spans":[{"start":0,"end":14,"type":"strong"}]},{"type":"paragraph","text":"Anumana\n Andrea Sampson\n Sampson Public Relations Group asampson@sampsonprgroup.com 562.304.0301 ","spans":[]}],"slices":[],"seoTitle":"Anumana Announces Issuance of New American Medical Association CPT® Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction","seoDescription":"Ground-breaking codes will facilitate the use, adoption, and pathway for potential reimbursement of AI-enhanced ECG-based algorithms, including Anumana’s pipeline of AI- enhanced ECG-based algorithms","socialImage":{}}},{"id":"YtefEBAAACMADscr","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtefEBAAACMADscr%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:22:11+0000","last_publication_date":"2025-01-20T09:31:34+0000","slugs":["mayo-clinic-launches-two-companies-to-tap-patient-data-for-ai-tools"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches two companies to tap patient data for AI tools","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"STAT News: Mayo Clinic is launching two new companies as part of its bid to harness patient data and use it to deliver AI-guided care.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/0b487497-acc8-4de9-bd1e-e1f19814ce53_iStock-1270372947.jpeg?auto=compress,format","id":"YteOjBAAACIADnxH","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"a31ec6cc-bc96-4478-9cf2-c7d683447b0c","url":"https://www.statnews.com/2021/04/14/mayo-clinic-artificial-intelligence-anumana/"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches two companies to tap patient data for AI tools","seoDescription":"STAT News: Mayo Clinic is launching two new companies as part of its bid to harness patient data and use it to deliver AI-guided care.","socialImage":{}}},{"id":"Yteb5RAAACAADrih","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Yteb5RAAACAADrih%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:08:40+0000","last_publication_date":"2025-01-20T09:27:56+0000","slugs":["how-mayo-clinic-is-using-ai-to-spot-hidden-heart-conditions"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"How Mayo Clinic is using AI to spot hidden heart conditions","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Advisory Board: Mayo Clinic last month released a study suggesting that an artificial intelligence (AI) algorithm could be used to better diagnose a certain heart condition called low ejection fraction—one step in the Clinic's effort to incorporate AI into cardiac care more broadly.","spans":[]}],"date":"2021-05-31T18:30:00+0000","image":{"dimensions":{"width":1355,"height":774},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/085e8fa4-0b8f-4dca-93a5-204d217847e9_iStock-1290220631.jpeg?auto=compress,format","id":"YteLlhAAACIADm8P","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"722d12bf-a9b3-4662-867b-c799de03201b","url":"https://www.advisory.com/daily-briefing/2021/06/01/ai-cardiac-care"},"article":[],"slices":[],"seoTitle":"How Mayo Clinic is using AI to spot hidden heart conditions","seoDescription":"Advisory Board: Mayo Clinic last month released a study suggesting that an artificial intelligence (AI) algorithm could be used to better diagnose a certain heart condition called low ejection fraction—one step in the Clinic's effort to incorporate AI into cardiac care more broadly.","socialImage":{}}},{"id":"YtehPRAAACIADtEx","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtehPRAAACIADtEx%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:31:28+0000","last_publication_date":"2025-01-20T09:32:04+0000","slugs":["mayo-clinic-launches-two-joint-ventures-to-build-commercialize-diagnostic-ai-tools"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches two joint ventures to build, commercialize diagnostic AI tools","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Med City News: Mayo Clinic struck two joint ventures to develop and commercialize AI diagnostic tools. The idea was to develop algorithms to support clinicians’ decisions, starting with a suite of cardiology tools. The news comes a little over a month after Mayo Clinic announced it plans to create an “AI factory” as it expands its partnership with Google.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1359,"height":771},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/cb216372-203a-4332-993d-e007a78681a6_iStock-1127069581.jpeg?auto=compress,format","id":"YtehMhAAACMADtD-","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"2c4c5332-9382-4d72-a7c8-f999b045affb","url":"https://medcitynews.com/2021/04/mayo-clinic-launches-two-joint-ventures-to-build-commercialize-diagnostic-ai-tools/"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches two joint ventures to build, commercialize diagnostic AI tools","seoDescription":"Med City News: Mayo Clinic struck two joint ventures to develop and commercialize AI diagnostic tools. The idea was to develop algorithms to support clinicians’ decisions, starting with a suite of cardiology tools. The news comes a little over a month after Mayo Clinic announced it plans to create an “AI factory” as it expands its partnership with Google.","socialImage":{}}},{"id":"YtebPBAAACAADrWi","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtebPBAAACAADrWi%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:05:51+0000","last_publication_date":"2025-01-20T09:27:06+0000","slugs":["single-lead-ecg-tracings-from-an-apple-watch-effectively-identifies-patients-with-a-weak-heart-pump"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Single-Lead ECG Tracings from an Apple Watch Effectively Identifies Patients with a Weak Heart Pump","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"AZO Robotics: Patients with a weak heart pump were identified using single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic. Researchers modified an existing 12-lead algorithm for low ventricular ejection fraction — the weak heart pump — that is licensed to Anumana Inc., an AI-driven health technology company, by nference and Mayo Clinic, to interpret ECG signals produced from the single lead on an Apple Watch.","spans":[]}],"date":"2022-05-01T18:30:00+0000","image":{"dimensions":{"width":1277,"height":822},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a0bf0dd9-77fe-4cdf-ba56-ac79c3717b49_iStock-1367729537.jpeg?auto=compress,format","id":"YteJrBAAACMADmaJ","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"5ea1e1b8-842a-4c76-bc09-02544a1cf62b","url":"https://www.azorobotics.com/News.aspx?newsID=12924"},"article":[],"slices":[],"seoTitle":"Single-Lead ECG Tracings from an Apple Watch Effectively Identifies Patients with a Weak Heart Pump","seoDescription":"AZO Robotics: Patients with a weak heart pump were identified using single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic. Researchers modified an existing 12-lead algorithm for low ventricular ejection fraction — the weak heart pump — that is licensed to Anumana Inc., an AI-driven health technology company, by nference and Mayo Clinic, to interpret ECG signals produced from the single lead on an Apple Watch.","socialImage":{}}},{"id":"YteNbRAAACIADncz","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteNbRAAACIADncz%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:06:55+0000","last_publication_date":"2025-01-20T09:29:14+0000","slugs":["way-of-diagnosing-ph-in-common-heart-test-gets-fda-support"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Way of Diagnosing PH in Common Heart Test Gets FDA Support","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Pulmonary Hypertension News: Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The technology could help with the significant unmet need for earlier PH diagnoses and treatment start, leading to better outcomes, the company reported in a press release.","spans":[]}],"date":"2022-05-26T18:30:00+0000","image":{"dimensions":{"width":1200,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/cba86a30-bad4-48d3-8000-8bf91c5e417a_FDA-Breakthrough.jpeg?auto=compress,format","id":"YteNahAAACMADncm","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"8d432f43-ec52-4ea5-9c5c-d1aca4418887","url":"https://pulmonaryhypertensionnews.com/news/algorithm-ph-diagnosis-with-commmon-heart-test-gets-fda-support/"},"article":[],"slices":[],"seoTitle":"Way of Diagnosing PH in Common Heart Test Gets FDA Support","seoDescription":"Pulmonary Hypertension News: Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The technology could help with the significant unmet need for earlier PH diagnoses and treatment start, leading to better outcomes, the company reported in a press release.","socialImage":{}}},{"id":"YteJvRAAACEADmbU","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteJvRAAACEADmbU%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T04:51:13+0000","last_publication_date":"2025-01-20T09:30:18+0000","slugs":["anumana-collaborates-with-leading-global-health-care-company-to-detect-heart-disease-using-artificial-intelligence"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"AI Thority: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.","spans":[]}],"date":"2022-07-12T18:30:00+0000","image":{"dimensions":{"width":1277,"height":822},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a0bf0dd9-77fe-4cdf-ba56-ac79c3717b49_iStock-1367729537.jpeg?auto=compress,format","id":"YteJrBAAACMADmaJ","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"36e94100-95ba-4171-9e73-4e3d84dac8dd","url":"https://aithority.com/machine-learning/anumana-collaborates-with-leading-global-health-care-company-to-detect-heart-disease-using-artificial-intelligence/"},"article":[],"slices":[],"seoTitle":"Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence","seoDescription":"AI Thority: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.","socialImage":{}}},{"id":"Z3wWLBoAAEgAkMd5","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Z3wWLBoAAEgAkMd5%22%29+%5D%5D","tags":["Press Release"],"first_publication_date":"2025-01-07T12:30:37+0000","last_publication_date":"2025-01-20T06:55:49+0000","slugs":["anumana-and-alivecor-collaborate-to-advance-ecg-ai-algorithms-for-early-detection-of-cardiac-diseases-on-kardia-devices"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana and AliveCor Collaborate to Advance ECG-AI Algorithms for Early Detection of Cardiac Diseases on Kardia Devices","spans":[],"direction":"ltr"}],"published":"Press Release","summary":[{"type":"paragraph","text":"Anumana announces collaboration with AliveCor","spans":[{"start":0,"end":45,"type":"em"}],"direction":"ltr"}],"date":"2025-01-07T12:30:00+0000","image":{"dimensions":{"width":1600,"height":1600},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/86d13a6a-af1c-4cce-b9eb-94351864b1fc_Frame+6838.png?auto=compress,format","id":"YtePCRAAACIADn6C","edit":{"x":0,"y":0,"zoom":1,"background":"transparent"}},"externalLink":{"link_type":"Any"},"article":[{"type":"paragraph","text":"CAMBRIDGE, Mass. – Jan. 7, 2025 – Anumana, a leading AI-driven health technology company, today announced a collaboration with AliveCor to develop Anumana’s advanced AI algorithms for early cardiac disease detection on AliveCor’s Kardia electrocardiogram (ECG) devices, starting with Anumana’s FDA-cleared algorithm, ECG-AI™ LEF.","spans":[{"start":0,"end":33,"type":"strong"},{"start":34,"end":42,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/","target":"_blank"}},{"start":127,"end":135,"type":"hyperlink","data":{"link_type":"Web","url":"https://alivecor.com/","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"“AliveCor is already at the forefront of AI in cardiology, transforming the industry with clinically validated solutions that disrupt traditional care pathways to create a more connected, holistic cardiac health ecosystem – like the recently FDA-cleared Kardia 12L ECG System,” said Sanjay Voleti, Chief Business Officer at AliveCor. “This collaboration with Anumana will further strengthen our leadership in AI by expanding our solutions' ability to facilitate more personalized and timely care across diverse healthcare settings.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Anumana’s ECG-AI platform includes a suite of algorithms designed to detect cardiovascular diseases that are challenging to detect without costly, invasive, or difficult-to-access clinical tests. The collaboration with AliveCor – the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, which recently launched the Kardia™ 12L ECG System for healthcare professionals – will leverage Anumana’s industry-leading ECG-AI algorithms to help identify cardiac conditions earlier in the patient’s journey and get them into clinical care sooner.","spans":[],"direction":"ltr"},{"type":"paragraph","text":"The ECG-AI LEF algorithm, which received U.S. FDA clearance in 2023, uses routine 12-lead ECG data to detect LEF – a commonly underdiagnosed indicator of heart failure. It was recently included in the Centers for Medicare & Medicaid Services (CMS) 2025 Hospital Outpatient Prospective Payment System final rule.","spans":[{"start":41,"end":59,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZRo9DhAAACYAxfsK","target":"_blank"}},{"start":115,"end":167,"type":"hyperlink","data":{"link_type":"Web","url":"https://doi.org/10.15420/ecr.2019.14","target":"_blank"}},{"start":247,"end":299,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/newsroom/ZyqGmhoAAEEA4fhJ","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":"“Together with AliveCor, we are reshaping the future of cardiac care by unlocking new possibilities for early detection and intervention,” said David McMullin, Chief Business Officer at Anumana. “This collaboration demonstrates Anumana’s commitment to harnessing the potential of AI to expand the utility of ECG technology, making traditional diagnostic tools more powerful for patients and clinicians.”","spans":[],"direction":"ltr"},{"type":"paragraph","text":"About Anumana  \nAnumana is a leading AI-driven health technology company leveraging cutting-edge AI and industry-leading translational science to unlock the electrical language of the heart as never before. The company was founded by nference in collaboration with Mayo Clinic to leverage the clinical and technical expertise of both organizations to develop innovative ECG-AI technology into a clinically meaningful, medical-grade, and easy-to-use tool for clinicians to advance patient care. Anumana’s software-as-a-medical device (SaMD) ECG-AI™ solutions aim to detect diseases earlier using standard-of-care ECG readings, enabling clinicians to enhance and improve care with real-time AI insights. Anumana’s award-winning lead algorithm, ECG-AI™ LEF, is available in the U.S. To learn more about how the algorithm can help clinicians identify LEF earlier and schedule a demo, visit us at ECG-AI LEF. For more information, visit www.anumana.ai or follow us on LinkedIn and X.","spans":[{"start":0,"end":13,"type":"strong"},{"start":892,"end":902,"type":"hyperlink","data":{"link_type":"Web","url":"https://anumana.ai/ecg-ai-lef","target":"_blank"}},{"start":932,"end":946,"type":"hyperlink","data":{"link_type":"Web","url":"http://www.anumana.ai","target":"_blank"}},{"start":963,"end":971,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.linkedin.com/company/anumana-inc/","target":"_blank"}},{"start":976,"end":977,"type":"hyperlink","data":{"link_type":"Web","url":"https://x.com/anumanainc","target":"_blank"}}],"direction":"ltr"},{"type":"paragraph","text":" ","spans":[{"start":0,"end":1,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Media Contact                                                                   ","spans":[{"start":0,"end":80,"type":"strong"}],"direction":"ltr"},{"type":"paragraph","text":"Andrea Sampson","spans":[],"direction":"ltr"},{"type":"paragraph","text":"Sampson Public Relations Group","spans":[],"direction":"ltr"},{"type":"paragraph","text":"asampson@sampsonprgroup.com","spans":[{"start":0,"end":27,"type":"hyperlink","data":{"link_type":"Web","url":"mailto:asampson@sampsonprgroup.com","target":"_blank"}}],"direction":"ltr"}],"slices":[],"seoTitle":"Anumana and AliveCor Collaborate to Advance ECG-AI Algorithms for Early Detection of Cardiac Diseases on Kardia Devices","seoDescription":"Anumana announces collaboration with AliveCor","socialImage":{}}},{"id":"YteaaxAAACEADrHy","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteaaxAAACEADrHy%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:02:25+0000","last_publication_date":"2025-01-20T09:26:04+0000","slugs":["researchers-use-ai-to-detect-weak-heart-pump-via-patients-apple-watch-ecgs"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Researchers use AI to detect weak heart pump via patients' Apple Watch ECGs","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Medical Xpress: Single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic effectively identified patients with a weak heart pump. To interpret ECG signals generated from the single lead on an Apple Watch, researchers modified an established 12-lead algorithm for low ventricular ejection fraction—the weak heart pump—that is licensed to Anumana Inc., an AI-driven health technology company, by nference and Mayo Clinic.","spans":[],"direction":"ltr"}],"date":"2022-05-01T18:30:00+0000","image":{"dimensions":{"width":1253,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/67866ecc-81c7-4da0-8d57-33a0c7bdfaf5_iStock-1347259240.jpeg?auto=compress,format","id":"YteaVxAAACMADrGV","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"84a1cab3-788a-4896-a257-f8b405c00d22","url":"https://medicalxpress.com/news/2022-05-ai-weak-heart-patients-apple.html"},"article":[],"slices":[],"seoTitle":"Researchers use AI to detect weak heart pump via patients' Apple Watch ECGs","seoDescription":"Medical Xpress: Single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic effectively identified patients with a weak heart pump. To interpret ECG signals generated from the single lead on an Apple Watch, researchers modified an established 12-lead algorithm for low ventricular ejection fraction—the weak heart pump—that is licensed to Anumana Inc., an AI-driven health technology company, by nference and Mayo Clinic.","socialImage":{}}},{"id":"Ytea4xAAACIADrQP","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Ytea4xAAACIADrQP%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:04:22+0000","last_publication_date":"2025-01-20T09:26:17+0000","slugs":["could-ai-and-an-apple-watch-ecg-improve-the-prognosis-for-heart-failure"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Could AI and an Apple Watch ECG improve the prognosis for heart failure?","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Med City News: Early detection and treatment of heart failure can greatly improve an otherwise poor prognosis. Research from Mayo Clinic suggests artificial intelligence could be used to detect the condition even when no symptoms are present. To interpret ECG signals generated from the single lead on an Apple Watch, researchers at Mayo Clinic modified an established 12-lead algorithm used to detect a weak heart pump. That algorithm is licensed to Anumana, an AI-driven health technology company, by nference, which develops software solutions, and Mayo Clinic.","spans":[]}],"date":"2022-05-11T18:30:00+0000","image":{"dimensions":{"width":1365,"height":768},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/deb3bd27-d5d3-4033-970e-c4eeb36e00a9_iStock-1273839908.jpeg?auto=compress,format","id":"Ytea4RAAACIADrQE","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"415304a1-54ef-4403-b881-4b3723645c4a","url":"https://medcitynews.com/2022/05/could-ai-and-an-apple-watch-ecg-improve-the-prognosis-for-heart-failure/"},"article":[],"slices":[],"seoTitle":"Could AI and an Apple Watch ECG improve the prognosis for heart failure?","seoDescription":"Med City News: Early detection and treatment of heart failure can greatly improve an otherwise poor prognosis. Research from Mayo Clinic suggests artificial intelligence could be used to detect the condition even when no symptoms are present. To interpret ECG signals generated from the single lead on an Apple Watch, researchers at Mayo Clinic modified an established 12-lead algorithm used to detect a weak heart pump. That algorithm is licensed to Anumana, an AI-driven health technology company, by nference, which develops software solutions, and Mayo Clinic.","socialImage":{}}},{"id":"YteemhAAACEADsS6","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteemhAAACEADsS6%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:20:14+0000","last_publication_date":"2025-01-20T09:31:20+0000","slugs":["mayo-clinic-launches-2-companies-in-support-of-new-health-analytics-platform-initiative"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches 2 companies in support of new health analytics platform initiative","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Becker's Hospital Review: Rochester, Minn.-based Mayo Clinic launched two new companies to support its newly developed Remote Diagnostics and Management Platform, which connects data with artificial intelligence technologies for clinical decision support.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/11f5721e-e12a-4b3a-8092-765ae0bc1784_iStock-1307217457.jpeg?auto=compress,format","id":"YteNGxAAACIADnXD","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"e8f1a055-42a5-43cd-bfb3-c5a47b5565ad","url":"https://www.beckershospitalreview.com/digital-transformation/mayo-clinic-launches-2-companies-in-support-of-new-health-analytics-platform-initiative.html"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches 2 companies in support of new health analytics platform initiative","seoDescription":"Becker's Hospital Review: Rochester, Minn.-based Mayo Clinic launched two new companies to support its newly developed Remote Diagnostics and Management Platform, which connects data with artificial intelligence technologies for clinical decision support.","socialImage":{}}},{"id":"YteNHxAAACMADnXW","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteNHxAAACMADnXW%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:05:38+0000","last_publication_date":"2025-01-20T09:26:56+0000","slugs":["anumana-announces-issuance-of-new-american-medical-association-cpt-category-iii-codes-for-novel-ecg-ai-analysis-of-cardiac-dysfunction"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction","spans":[]}],"published":"Reimbursement Coding","summary":[{"type":"paragraph","text":"DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for novel assistive AI algorithmic electrocardiogram risk assessment for cardiac dysfunction, encompassing Anumana’s pipeline of AI-enhanced ECG-based algorithms currently in development for FDA regulatory clearance.","spans":[]}],"date":"2022-07-06T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/11f5721e-e12a-4b3a-8092-765ae0bc1784_iStock-1307217457.jpeg?auto=compress,format","id":"YteNGxAAACIADnXD","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"b070d598-6859-47cb-ac66-2eba19c67b98","url":"https://www.dicardiology.com/content/anumana-announces-issuance-new-american-medical-association-cpt-category-iii-codes-novel"},"article":[],"slices":[],"seoTitle":"Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction","seoDescription":"DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for novel assistive AI algorithmic electrocardiogram risk assessment for cardiac dysfunction, encompassing Anumana’s pipeline of AI-enhanced ECG-based algorithms currently in development for FDA regulatory clearance.","socialImage":{}}},{"id":"YtedmhAAACEADsBG","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtedmhAAACEADsBG%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:15:57+0000","last_publication_date":"2025-01-20T09:28:17+0000","slugs":["mayo-developed-ai-detects-heart-condition-from-apple-watch-ecgs"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo-developed AI detects heart condition from Apple Watch ECGs","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"Modern Healthcare: An artificial-intelligence algorithm developed at Mayo Clinic could identify left ventricular dysfunction—or a weak heart pump—in most patients based on Apple Watch data, researchers shared at a conference Sunday.","spans":[]}],"date":"2022-04-30T18:30:00+0000","image":{"dimensions":{"width":1411,"height":744},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/2fe5214a-d32d-462c-9b04-c17fe4a3d9e3_iStock-1286099765.jpeg?auto=compress,format","id":"YtedlhAAACMADsAz","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"bead1009-485c-423d-9865-a5bea585cd82","url":"https://www.modernhealthcare.com/patients/mayo-study-ai-can-detect-heart-condition-apple-watch-ecgs"},"article":[],"slices":[],"seoTitle":"Mayo-developed AI detects heart condition from Apple Watch ECGs","seoDescription":"Modern Healthcare: An artificial-intelligence algorithm developed at Mayo Clinic could identify left ventricular dysfunction—or a weak heart pump—in most patients based on Apple Watch data, researchers shared at a conference Sunday.","socialImage":{}}},{"id":"Ytec4BAAACEADr0K","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Ytec4BAAACEADr0K%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:12:51+0000","last_publication_date":"2025-01-20T09:28:11+0000","slugs":["mayo-clinic-ai-algorithm-proves-effective-at-spotting-early-stage-heart-disease-in-routine-ekg-data"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic AI algorithm proves effective at spotting early-stage heart disease in routine EKG data","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"FIERCE Biotech: An algorithm developed by the Mayo Clinic can significantly increase the number of cases of low ejection fraction caught in its earliest stages, when it’s still most treatable, according to a study published this month in Nature Medicine.","spans":[]}],"date":"2022-05-09T18:30:00+0000","image":{"dimensions":{"width":880,"height":582},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/6619ee72-008c-4b61-9d12-be52b5ec8368_heart-2607178_1280.jpeg?auto=compress,format","id":"Ytec3RAAACIADrz3","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"2dc23a38-57ac-43f0-b214-3c63b30f9f23","url":"https://www.fiercebiotech.com/medtech/mayo-clinic-ai-algorithm-proves-effective-at-spotting-early-stage-heart-disease-routine-ekg"},"article":[],"slices":[],"seoTitle":"Mayo Clinic AI algorithm proves effective at spotting early-stage heart disease in routine EKG data","seoDescription":"FIERCE Biotech: An algorithm developed by the Mayo Clinic can significantly increase the number of cases of low ejection fraction caught in its earliest stages, when it’s still most treatable, according to a study published this month in Nature Medicine.","socialImage":{}}},{"id":"YteLmRAAACEADm8e","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteLmRAAACEADm8e%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T04:59:08+0000","last_publication_date":"2025-01-20T09:28:25+0000","slugs":["anumana-entered-into-a-multi-year-strategic-collaboration-with-novartis-to-develop-ecg-ai-algorithms-for-the-detection-of-heart-disease"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"PharmaShots: The companies collaborated to develop & deliver new medical device software i.e., ECG AI algorithms for earlier detection of heart disease. The AI will screen for atherosclerotic CV disease which can cause a heart attack or stroke.  An evidence-based, digital point-of-care system will be created in order to improve medical therapies & lower the risk of hospitalizations and CV death","spans":[]}],"date":"2022-07-13T18:30:00+0000","image":{"dimensions":{"width":1355,"height":774},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/085e8fa4-0b8f-4dca-93a5-204d217847e9_iStock-1290220631.jpeg?auto=compress,format","id":"YteLlhAAACIADm8P","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"1d619d5e-5a25-4256-838a-69ab68a36d88","url":"https://pharmashots.com/7780/anumana-entered-into-a-multi-year-strategic-collaboration-with-novartis-to-develop-ecg-ai-algorithms-for-the-detection-of-heart-disease"},"article":[],"slices":[],"seoTitle":"Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease","seoDescription":"PharmaShots: The companies collaborated to develop & deliver new medical device software i.e., ECG AI algorithms for earlier detection of heart disease. The AI will screen for atherosclerotic CV disease which can cause a heart attack or stroke.  An evidence-based, digital point-of-care system will be created in order to improve medical therapies & lower the risk of hospitalizations and CV death","socialImage":{}}},{"id":"YteZmRAAACAADq49","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteZmRAAACAADq49%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:58:52+0000","last_publication_date":"2025-01-20T09:31:04+0000","slugs":["anumana-wins-fda-breakthrough-nod-for-ai-algorithm-that-detects-pulmonary-hypertension"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension","spans":[]}],"published":"FDA Status","summary":[{"type":"paragraph","text":"Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in 2021, designed its AI-enhanced, electrocardiograph (ECG)-based PH early detection algorithm as a precise, non-invasive screening tool to provide earlier diagnosis for patients with PH that may otherwise go unnoticed until the disease has advanced.","spans":[{"start":13,"end":20,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.massdevice.com/tag/anumana/","target":"_blank"}},{"start":193,"end":248,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.massdevice.com/mayo-clinic-helps-launch-two-new-companies-for-improved-diagnostics/","target":"_blank"}}]}],"date":"2022-05-23T18:30:00+0000","image":{"dimensions":{"width":1357,"height":772},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/a76dd04e-4aa9-416d-881c-4f7b1eea49e7_iStock-864472226.jpeg?auto=compress,format","id":"YteZkRAAACAADq4Z","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"4c11093c-8b0c-42d4-a099-9ae87eb26ca6","url":"https://www.massdevice.com/anumana-fda-breakthrough-ai-pulmonary-hypertension/"},"article":[],"slices":[],"seoTitle":"Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension","seoDescription":"Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in 2021, designed its AI-enhanced, electrocardiograph (ECG)-based PH early detection algorithm as a precise, non-invasive screening tool to provide earlier diagnosis for patients with PH that may otherwise go unnoticed until the disease has advanced.","socialImage":{}}},{"id":"YteOChAAACAADnnw","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YteOChAAACAADnnw%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T05:09:33+0000","last_publication_date":"2025-01-20T09:28:35+0000","slugs":["anumana-partners-with-novartis-for-ai-driven-heart-disease-detection"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Anumana partners with Novartis for AI-driven heart disease detection","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Medical Device Network: Health technology company Anumana and Novartis Pharmaceuticals Corporation have entered a partnership to use artificial intelligence (AI) for the detection of heart diseases. Under the multi-year collaboration, the companies will seek to deploy multiple AI-powered software solutions that will be able to identify hidden cardiovascular conditions.","spans":[]}],"date":"2022-07-13T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/7f5d2277-a773-4c2f-8ab8-235d3012eb43_iStock-1304967852.jpeg?auto=compress,format","id":"YteOBxAAACAADnnm","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"57b5badb-0226-4354-bb0a-31cec2b22553","url":"https://www.medicaldevice-network.com/news/anumana-novartis-heart-disease-detection/"},"article":[],"slices":[],"seoTitle":"Anumana partners with Novartis for AI-driven heart disease detection","seoDescription":"Medical Device Network: Health technology company Anumana and Novartis Pharmaceuticals Corporation have entered a partnership to use artificial intelligence (AI) for the detection of heart diseases. Under the multi-year collaboration, the companies will seek to deploy multiple AI-powered software solutions that will be able to identify hidden cardiovascular conditions.","socialImage":{}}},{"id":"YtbpjxAAACMAC5ns","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtbpjxAAACMAC5ns%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-19T17:27:48+0000","last_publication_date":"2025-01-20T09:28:57+0000","slugs":["novartis-turns-to-algorithms-developer-anumana-to-apply-ai-to-cardio-conditions"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Novartis turns to algorithms developer Anumana to apply AI to cardio conditions","spans":[]}],"published":"Partnerships","summary":[{"type":"paragraph","text":"Med City News: Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.","spans":[]}],"date":"2022-07-14T18:30:00+0000","image":{"dimensions":{"width":1254,"height":836},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/82553824-12ac-40e8-846c-2e420fd87298_iStock-1304967852.jpeg?auto=compress,format","id":"YtbpjBAAACEAC5nd","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"bb853968-eac0-4577-9067-99493c9696cb","url":"https://medcitynews.com/2022/07/novartis-turns-to-algorithms-developer-anumana-to-apply-ai-to-cardio-conditions/"},"article":[],"slices":[],"seoTitle":"Novartis turns to algorithms developer Anumana to apply AI to cardio conditions","seoDescription":"Med City News: Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.","socialImage":{}}},{"id":"YtegORAAACEADsyC","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtegORAAACEADsyC%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:27:11+0000","last_publication_date":"2025-01-20T09:31:43+0000","slugs":["mayo-clinic-launches-remote-diagnostics-platform-forms-2-new-companies-to-support-it"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Mayo Clinic launches remote diagnostics platform, forms 2 new companies to support it","spans":[]}],"published":"Company Launch","summary":[{"type":"paragraph","text":"Healthcare IT News: Anumana will develop and market algorithms for early detection of disease. Lucem Health can collect device data and feed it into clinical workflows. Both spin-offs aim to capitalize on advances in AI and remote telemetry.","spans":[]}],"date":"2021-04-13T18:30:00+0000","image":{"dimensions":{"width":1312,"height":800},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/aa5e1021-0315-4d1d-8ea6-98c0c62ea44b_iStock-1327568875.jpeg?auto=compress,format","id":"YteMdRAAACMADnLi","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"cc65c03e-ba65-493f-b15f-a291b23e48bc","url":"https://www.healthcareitnews.com/news/mayo-clinic-launches-remote-diagnostics-platform-forms-2-new-companies-support-it"},"article":[],"slices":[],"seoTitle":"Mayo Clinic launches remote diagnostics platform, forms 2 new companies to support it","seoDescription":"Healthcare IT News: Anumana will develop and market algorithms for early detection of disease. Lucem Health can collect device data and feed it into clinical workflows. Both spin-offs aim to capitalize on advances in AI and remote telemetry.","socialImage":{}}},{"id":"YtecjBAAACAADruH","uid":null,"url":null,"type":"news","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YtecjBAAACAADruH%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-20T06:11:27+0000","last_publication_date":"2025-01-20T09:28:01+0000","slugs":["inside-mayo-clinics-ai-factory-how-mayo-clinic-is-looking-to-use-ai-to-enhance-patient-care-and-clinical-decision-making"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"title":[{"type":"heading1","text":"Inside Mayo Clinic’s AI Factory: How Mayo Clinic is looking to use AI to enhance patient care and clinical decision making","spans":[]}],"published":"Research","summary":[{"type":"paragraph","text":"AI Data & Analytics Network: One of the most consequential applications of artificial intelligence (AI) and machine learning (ML) is medicine. Though medical AI is still in its infancy, experts predict that within the next decade, AI-powered technology will enable healthcare providers to dramatically increase the speed, accuracy and quality of medical care from diagnosis to recovery. At the forefront of this endeavor is Mayo Clinic.","spans":[{"start":75,"end":98,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.aidataanalytics.network/data-science-ai/articles/applied-ai-enterprise-data-science"}},{"start":108,"end":125,"type":"hyperlink","data":{"link_type":"Web","url":"https://www.intelligentautomation.network/learning-ml/articles/a-basic-guide-to-ml"}}]}],"date":"2021-02-28T18:30:00+0000","image":{"dimensions":{"width":1258,"height":834},"alt":null,"copyright":null,"url":"https://images.prismic.io/anumana/b3368457-14a3-49a5-8a55-091bde35345d_iStock-536078501.jpeg?auto=compress,format","id":"YtechBAAACMADrti","edit":{"x":0,"y":0,"zoom":1,"background":"#fff"}},"externalLink":{"link_type":"Web","key":"be0e7ffa-728b-4e2a-b712-7794c0f49207","url":"https://www.aidataanalytics.network/data-science-ai/articles/inside-mayo-clinics-ai-factory"},"article":[],"slices":[],"seoTitle":"Inside Mayo Clinic’s AI Factory: How Mayo Clinic is looking to use AI to enhance patient care and clinical decision making","seoDescription":"AI Data & Analytics Network: One of the most consequential applications of artificial intelligence (AI) and machine learning (ML) is medicine. Though medical AI is still in its infancy, experts predict that within the next decade, AI-powered technology will enable healthcare providers to dramatically increase the speed, accuracy and quality of medical care from diagnosis to recovery. At the forefront of this endeavor is Mayo Clinic.","socialImage":{}}}],"theme":{"id":"Ysjy1BAAACIAWvti","uid":null,"url":null,"type":"theme","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Ysjy1BAAACIAWvti%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-09T03:15:35+0000","last_publication_date":"2022-11-18T03:39:07+0000","slugs":["theme"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"facebook":null,"twitter":"https://twitter.com/anumanainc","linkedIn":"https://www.linkedin.com/company/anumana-inc","YouTube":"https://www.youtube.com/channel/UCZlMq0PGtuZg3hLPJaVIetA"}},"mainMenu":{"id":"YsjzBRAAACMAWvxJ","uid":null,"url":null,"type":"main-menu","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22YsjzBRAAACMAWvxJ%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-09T03:16:24+0000","last_publication_date":"2024-03-19T03:14:00+0000","slugs":["main-menu"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"links":[{"link":{"id":"ZGExlxEAACIAobEi","type":"page","tags":[],"lang":"en-us","slug":"anumanas-platform","first_publication_date":"2023-05-15T01:37:44+0000","last_publication_date":"2024-02-05T19:17:13+0000","uid":"platform","link_type":"Document","key":"80d69979-6f72-4ebe-8f9a-f536e0120d1c","isBroken":false},"linkText":"Platform"},{"link":{"id":"ZQsZnxAAACcAgNBS","type":"page","tags":[],"lang":"en-us","slug":"-","first_publication_date":"2023-10-02T10:45:01+0000","last_publication_date":"2024-04-11T14:32:31+0000","uid":"ecg-ai-lef","link_type":"Document","key":"3ecaa596-4547-48c3-bab5-63ec6bdca46f","isBroken":false},"linkText":"ECG-AI™ LEF"},{"link":{"id":"Zffi1xIAAExWcRys","type":"submenu","tags":[],"lang":"en-us","slug":"publications","first_publication_date":"2024-03-18T06:47:24+0000","last_publication_date":"2024-03-19T03:31:41+0000","link_type":"Document","key":"b45dec86-c31d-4f05-a1af-1261b737598e","isBroken":false},"linkText":"Resources"},{"link":{"id":"YskDARAAACEAW0KU","type":"page","tags":[],"lang":"en-us","slug":"-","first_publication_date":"2022-07-09T04:24:35+0000","last_publication_date":"2024-04-19T15:58:27+0000","uid":"pipeline","link_type":"Document","key":"40956f31-6c2c-435e-8eaa-b54b0f639382","isBroken":false},"linkText":"Pipeline"},{"link":{"id":"YskDdxAAACEAW0Sm","type":"page","tags":[],"lang":"en-us","slug":"news","first_publication_date":"2022-07-09T04:26:35+0000","last_publication_date":"2022-07-09T04:26:35+0000","uid":"newsroom","link_type":"Document","key":"bc7a7aa7-4c55-4554-9d63-3599e302a82d","isBroken":false},"linkText":"News"},{"link":{"id":"YskDyBAAACEAW0YV","type":"page","tags":[],"lang":"en-us","slug":"about-us","first_publication_date":"2022-07-09T04:27:55+0000","last_publication_date":"2025-01-09T12:30:08+0000","uid":"about-us","link_type":"Document","key":"f6dd034e-c444-4caf-8b91-2acd97eb08e8","isBroken":false},"linkText":"Team"}]}},"footer":{"id":"Ysjy9xAAACIAWvwC","uid":null,"url":null,"type":"footer","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Ysjy9xAAACIAWvwC%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-09T03:16:10+0000","last_publication_date":"2023-10-02T10:45:01+0000","slugs":["footer"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"leadFormTitle":[{"type":"heading2","text":"Download Our One-Pager","spans":[]}],"leadFormDescription":[{"type":"paragraph","text":"Featuring key corporate highlights and an overview of Anumana's technology","spans":[]}],"leadFormButtonText":"Submit and Download","onePager":{"link_type":"Media","key":"6ccf064b-2683-4f37-b180-4258f65c5d66","kind":"file","id":"ZRpIYhAAACUAxgsk","url":"https://anumana.cdn.prismic.io/anumana/2c68fa77-c554-4f8e-8119-90bf7b422c79_2023-10-01_Corporate+One-Pager_Q4.pdf","name":"2023-10-01_Corporate One-Pager_Q4.pdf","size":"2679929"},"menu1":[{"link":{"id":"YskEBhAAACMAW0cm","type":"page","tags":[],"lang":"en-us","slug":"privacy-policy","first_publication_date":"2022-07-09T04:28:57+0000","last_publication_date":"2022-07-09T04:43:54+0000","uid":"privacy-policy","link_type":"Document","key":"2a5fb934-2546-4d17-b00f-be1ec9274bcd","isBroken":false},"linkText":"Privacy Policy"},{"link":{"id":"YskEOBAAACAAW0gL","type":"page","tags":[],"lang":"en-us","slug":"terms-of-use","first_publication_date":"2022-07-09T04:29:47+0000","last_publication_date":"2022-07-09T04:45:11+0000","uid":"terms-of-use","link_type":"Document","key":"9fd60b73-cbc5-4cd0-9579-4efe9c170262","isBroken":false},"linkText":"Terms of Use"},{"link":{"id":"ZLFTQRIAACIAb_6E","type":"page","tags":[],"lang":"en-us","slug":"vulnerability-disclosure","first_publication_date":"2023-07-14T13:59:36+0000","last_publication_date":"2023-07-14T15:21:42+0000","uid":"vulnerability-disclosure","link_type":"Document","key":"7773945b-04e9-4743-8cbb-7f03668ddcb9","isBroken":false},"linkText":"Vulnerability Disclosure"}],"menu2":[{"link":{"id":"YskDARAAACEAW0KU","type":"page","tags":[],"lang":"en-us","slug":"-","first_publication_date":"2022-07-09T04:24:35+0000","last_publication_date":"2024-04-19T15:58:27+0000","uid":"pipeline","link_type":"Document","key":"d51ff104-662e-4c36-a559-64bbf5b1529c","isBroken":false},"linkText":"Pipeline"},{"link":{"id":"YskDMBAAACAAW0Np","type":"page","tags":[],"lang":"en-us","slug":"publications","first_publication_date":"2022-07-09T04:25:32+0000","last_publication_date":"2022-07-09T04:26:57+0000","uid":"publications","link_type":"Document","key":"cdb3cec4-506e-4bf4-b717-2c56b9ed5f28","isBroken":false},"linkText":"Publications"},{"link":{"id":"YskDdxAAACEAW0Sm","type":"page","tags":[],"lang":"en-us","slug":"news","first_publication_date":"2022-07-09T04:26:35+0000","last_publication_date":"2022-07-09T04:26:35+0000","uid":"newsroom","link_type":"Document","key":"7cc49992-294b-4af7-b7ae-f15d33560f49","isBroken":false},"linkText":"News"},{"link":{"id":"YskDyBAAACEAW0YV","type":"page","tags":[],"lang":"en-us","slug":"about-us","first_publication_date":"2022-07-09T04:27:55+0000","last_publication_date":"2025-01-09T12:30:08+0000","uid":"about-us","link_type":"Document","key":"71456c5d-d9e6-4343-b9f1-a51648c11354","isBroken":false},"linkText":"Team"},{"link":{"id":"YzHf7BMAALxVR7ms","type":"page","tags":[],"lang":"en-us","slug":"careers","first_publication_date":"2022-09-26T20:53:05+0000","last_publication_date":"2023-03-15T19:42:14+0000","uid":"careers","link_type":"Document","key":"19ff7044-c0e3-42ba-b767-38946f9813d8","isBroken":false},"linkText":"Careers"}]}},"banner":{"id":"Ysjy6BAAACAAWvu_","uid":null,"url":null,"type":"announcement-banner","href":"https://anumana.cdn.prismic.io/api/v2/documents/search?ref=Z5IFKhkAAEYA5duG&q=%5B%5B%3Ad+%3D+at%28document.id%2C+%22Ysjy6BAAACAAWvu_%22%29+%5D%5D","tags":[],"first_publication_date":"2022-07-09T03:15:55+0000","last_publication_date":"2025-01-07T12:34:13+0000","slugs":["announcement-banner"],"linked_documents":[],"lang":"en-us","alternate_languages":[],"data":{"enabled":true,"message":[{"type":"paragraph","text":"Anumana and AliveCor Collaborate to Advance AI for Cardiology","spans":[],"direction":"ltr"}],"buttonText":"See Release","buttonLink":{"link_type":"Web","key":"fb77a92c-4212-491a-85f6-0cb8a5584175","url":"https://anumana.ai/newsroom/Z3wWLBoAAEgAkMd5"}}}},"__N_SSG":true}